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ABSTRACT 
 
 Despite the efforts in malaria eradication and elimination, malaria still poses a global challenge 
to health that, through the spread of antimalarial resistance, highlights an urgent need for new 
approaches for malaria treatment. Heparin and sulphated glycosaminoglycans (GAGs) have 
been reported to have inhibition activity against intraerythrocytic stages of P.falciparum in vitro 
by (i) disrupting rosette formation, (ii) reversing cytoadhesion to human endothelial cell lines 
and (iii) blocking merozoite invasion. The extracellular form merozoites are the target of 
sulphated GAG inhibitors and, given relative ease of access to this stage and its essential activity 
in propagating an infection, an attractive target of drug development. However, due to the 
anticoagulation property and potential risk of heparin-induced thrombocytopaenia, heparin’s 
development as a potential adjunct therapy was halted.  
A rapid and scalable in vitro evaluation of the inhibitory activity of sulphated GAGs is a 
challenge using standard fluorescent assays of parasite growth as the dyes interact with the large 
negatively charged sulphated GAGs. In this study, we report the development of a robust and 
scalable luciferase-based assay, including the preparation of a new transgenic P.falciparum 
parasite strain, to determine whether sulphated GAGs have potential growth inhibition activity. 
Two distinct P.flaciparum strains (Dd2luc & NF54luc) were also used to explore the staging of 
the inhibition activity during the reinvasion process. This study uses GAGs from a range of 
sources; chemically modified heparins, low molecular weight heparins, and GAGs from animal, 
plant, marine and microbial sources. 
Sulphated GAGs inhibitors with good invasion-blocking potency (EC50 ranging between 2-
10µg/ml) have been identified and their anticoagulation activity was shown to be reduced 
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compared with unfractionated heparin. The staging of the effect of these compounds shows that 
they appear to have a profound effect on merozoite egress from an infected erythrocyte- 
inducing what is called here a clustered merozoite phenotype. This inhibitory effect hasn’t been 
recognized in previous studies for these GAGs, with only one other report of merozoite egress 
inhibition by unfractionated heparin available. This thesis highlight routes forward towards 
developing potent GAG inhibitors of merozoite release and the potential of a number of GAGs 
identified in this study as chemical tools to study the biology of merozoite egress from the 
erythrocyte. This study also discusses the implications in developing heparin mimetic with low 
or no anticoagulation activity, to be used as an adjunct therapy for the treatment of severe 
malaria.   
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Chapter one: General Introduction 
 
 
1.1 The burden of malaria 
Malaria is one of the most impactful infectious diseases that has shaped human life. It is a 
parasitic protozoan vector-transmitted disease that belongs to the Apicomplexan phylum, 
transmitted by Anopheles mosquitos to a vertebrate host (White et al., 2014). Malaria is endemic 
in over 87 countries worldwide, with some 219 million cases causing 435,000 deaths in 2017 
(WHO 2018). The geography of malaria disease extends from  the tropical areas of South 
American countries to South-east Asia with 90% of malaria cases reported in Sub-Saharan 
Africa; 85% of deaths are in the same  endemic area, mostly involving children under five years 
old (White et al., 2014) (Figures 1.1 and 1.2). To control malaria infection and decrease the 
mortality rate, novel approaches are needed such as the development of more active antimalarial 
drugs that address the increase in drug resistance, effective insecticides and the development of 
an effective vaccine (Hill., 2011). Five major parasite species cause malaria infection; P. 
falciparum, P. vivax, P. malaria, P.ovale, and P. knowlesi (Kantele & Jokiranta., 2011). P. 
falciparum presents the most virulent parasite among the rest of the Plasmodium species, it is 
responsible for the majority of malaria deaths and the main cause of severe malaria which is a 
multi-organ infection that leads to complicated consequences such as cerebral malaria, severe 
anaemia, jaundice, acidosis, pulmonary oedema, renal dysfunction/kidney injuries and low 
birth weight in pregnant women.  
P.falciparum distribution intersects with P.vivax geographically in endemic areas where the 
infection spreads. P.vivax, however, is not typically found in West Africa due to inability to 
infect Duffy-Blood-Group negative reticulocyte where this trait is predominant in this area  
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(Mandal., 2014). It is estimated that 25% of reported cases outside Africa caused by P.vivax 
(Price et al., 2007). That makes P. vivax widely spread geographically although being less lethal 
than P.falciparum (Guerra, Snow, & Hay, 2006). P. falciparum  is responsible for 80% of 
malaria deaths (severe malaria) with the majority occurring in children under five years 
worldwide (WHO, 2018).  
 
 
Figure 1.1 Map illustrating the endemic areas of P.vivax and P.falciparum (Source: 
Feachem et al., 2010). 
 
Malaria is also a travel-associated disease, imported from endemic areas to non-endemic areas 
and carried through the tourist, non-government aid or armed forces personnel (Genton et al., 
2008). The severity of the disease depends on factors such as age and immune status. (Mandal, 
2014).  
The main vector of malaria infection is mosquitoes of Anopheles genus. There are over 400 
Anopheles spp. although only 25 of them have been found to be good vectors of malaria (Sinka 
et al., 2012). Anopheles gambiae in Africa is an excellent example of a vector for malaria 
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transmission to humans and are characterised as tolerant to habitat changes having longevity, 
surviving in highly dense tropical areas and reproducing rapidly (White et al., 2014).   
 
 
Figure 1.2 Map illustrating the distribution of malaria around the world (Source: Cotter 
et al., 2013). 
 
1.2  P. falciparum life cycle  
The life cycle of P. falciparum requires a vertebrate host and mosquito vector to survive and to 
complete its cycle (White et al., 2014). The journey of the parasite (illustrated in Figure 1.3) 
starts as a sporozoite transmitted from the mosquito bite to human skin, with a few hundred 
sporozoites injected into the bloodstream where they migrate to infect hepatocytes and to start 
the first part of the asexual stages of infection. At the pre-erythrocytic (intrahepatic) stage no 
clinical symptoms occur, making early diagnosis of the disease challenging (Arama & Troye-
Blomberg., 2014).  
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Figure 1.3 Asexual and Sexual life cycles of Plasmodium falciparum in mosquito and the 
human host. (A) Parasite life cycle begin when motile sporozoite injected into human skin 
during mosquito of anophelines blood meal. (B) sporozoites seek their way to the liver and each 
sporozoite infect hepatocyte, multiply and stay in the liver for one week with no obvious sign 
of disease. (C) Hepatocyte schizonts rupture and release thousands of merozoites into blood 
circulation, starting asexual life cycle (blood-stage life cycle), illness symptoms occur at blood-
stage and develop later to severe disease if not been treated. Blood stage takes roughly 48 hrs 
to be completed, where parasite multiplies and develop into different forms (ring, trophozoite 
and schizont. (D) Some parasites develop into gametocyte (a sexual form of the parasite), taken 
by anopheline mosquito during blood-feeding, and replicate sexually to produce a zygote, then 
develop into, Ookinete and Oocyst. Oocyte rupture, releasing sporozoites which migrate to 
mosquito salivary gland, waiting for next mosquito blood-feeding to be inoculated into a new 
human host. The entire life cycle of P.flaciparum takes approximately one month to be 
completed. (source: white et al., 2014). 
 
A few hundred of sporozoite parasites will invade hepatic cells after their injection into blood 
circulation. But one study found that P.falciparum does not inject from a mosquito of anopheles 
directly into the blood circulation but into the dermis first (Hafalla, Silvie, & Matuschewski., 
2011). Sporozoites usually take from between 15 minutes to a few hours before invading 
hepatocytes. Sporozoites travel to the liver through their continuous gliding movement from 
the skin to arrive in the blood circulation to penetrate and traverse many of the defensive hepatic 
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macrophages (Küpfer cells) (White et al., 2014). The mobility of parasites is powered by the 
actomyosin motor and mediated by a group of proteins TRAP (thrombospondin-related 
anonymous protein), that enable the parasite to invade both salivary glands of the mosquito and 
human host. Ultimately, the invasive sporozoites grow, feed and multiply in the new host‘s liver 
cells to form thousands of merozoites; roughly 10000 to 30000 merozoites will be produced 
within 5 to 7 days. Eventually the  merozoites burst from the liver hepatocytes into bloodstream 
the and invade erythrocytes (Greenwood et al., 2008) . 
On completion of up to 14 days of intrahepatic growth and multiplication, merozoites are 
released (Figure 1.4) from the hepatocytes through merosomes that bud off from infected 
hepatocytes (Graewe et al., 2011). Merozoites released within the blood circulation are 
available to infect an erythrocyte, which starts next step of infection termed the 
(intra)erythrocyte stage or blood-stage (Figure 1.5) which includes the commonly described 
ring, trophozoite and schizont morphological stages (Weatherall et al., 2002). The invasion of 
erythrocytes is a multi-step process that takes minutes only to invade the red blood cells by 
merozoite, without lysing them, due to the presence of specialised organelles that prevent lysis 
(White et al., 2014). Three membrane-bound granules that play a vital role in the attachment 
process of the parasite are rhoptries, micronemes and dense granules that help the parasite to 
attach on the surface of red blood cells. 
During erythrocyte invasion, the merozoite reorients to bring the apical end into contact with 
the RBC cell membrane to form an irreversible close-junction between the parasite and blood 
cell. The merozoites release the contents of their membrane bound vesicles which include a 
range of adhesive proteins. After entry, the parasite starts a new life cycle consists of three 
stages: ring, trophozoite, and schizont.  P.falciparum and like other Plasmodium spp. utilises 
haemoglobin as a source of amino acids for anabolism (Weatherall et al., 2002). 
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Figure 1.4 Illustration of a P.flaciparum merozoite (Source: Bannister et al., 2003). 
 
 
After 48 hours of the invasion, schizonts form and release up to 30 to 40 daughter merozoites 
to invade a new erythrocyte as apart of its blood life cycle. The merozoite invasion to 
erythrocyte is a multi-step process and it is crucial when merozoite distinguish between 
erythrocytes and other cell types and for parasite survival (Bannister & Sherman 2009). 
Merozoite invasion is very rapid, it takes 15 seconds to complete the invasion, and that because 
merozoite is the only extracellular form of parasite blood stage life cycle and become a target 
to immune cells (Boyle et al., 2013). 
The early attachment of merozoite to erythrocyte is likely to be supported by MSPs (Merozoite 
Surface Proteins) which cover the merozoite surface. Moreover, the interaction of merozoite 
adhesive proteins such as reticulocyte-binding homologue (PfRh) and erythrocyte binding 
ligands (EBLs) also play important roles in parasite-host interaction (Satchwell., 2016). After 
attachment, the merozoite reorients so that the apical tip become in direct contact with the 
erythrocyte membrane. The merozoite then forms a tight junction between the parasite and 
erythrocyte (Cowman & Crabb., 2006). The parasitophorous vacuole is formed 
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Figure 1.5 Schematic illustration of P.falciparum intraerythrocytic lifecycle. Merozoite 
invades erythrocyte and subsequently develop through three distinct stages, ring, trophozoite 
and schizont where parasite divided into roughly 30 merozoites then rupture to invade a fresh 
erythrocyte.  Full blood stage life cycle takes approximately 48 hrs. (Source Tilley et al., 2011). 
 
now and an actin-myosin motor drives the inward mobility of merozoite. Rhoptries and 
micronemes release proteins which are associated with and form a tight junction which moves 
around merozoite surface powered by this actin-myosin motor. Finally, the parasite seals 
parasitophorous vacuole, discharge denes granules and transform into a ring stage (Figure1.6). 
The growing parasite inside the erythrocyte catabolizes the haemoglobin, reduces the 
deformability of the host cell by changing the actin-spectrin skeleton that changes the 
morphology of red cells as well as increases the permeability to support import of nutrients and 
expel waste products (Arama & Troye-Blomberg, 2014). 
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Figure1.6: Schematic representing the invasion steps of the P.falciparum merozoite into 
an erythrocyte. (1) parasite establish attachment with erythrocyte surface, MSPs mediated the 
first contact followed by attachment proteins such as (PfRh) and (EBL). (2) Parasite re-orient 
and proteins released from micronemes and rhoptries which leading to form a tight junction. 
(3) Actin-myosin power-driven merozoite to invade erythrocytes. (4) invasion lead in loss of 
merozoite surface protein and develop intraerythrocytic development cycle (Boyle et al., 2013).  
 
In a suspected adult infected person, the parasite population can reach more than 100 million 
in the blood circulation. The asexual blood-stage takes approximately 48 hours in P.falciparum, 
P.vivax, and P. ovale. While it takes 72 hours in P.malariae and 24 hours in  P.knowlesi (Arama 
& Troye-Blomberg., 2014). The blood cycle is associated with all of the signs and symptoms 
of the disease, including a range of general features such as fever, fatigue, muscle and joint 
pain, vomiting and abdominal pain. Infection with P.falciparum shows further complications 
associated with unique aspects of pathological development based on its cytoadhesive 
properties, with cerebral malaria as a particular example of this (Cowman, Berry, & Baum., 
2012). 
After the blood-stage cycle, gametocytes are formed that can be transmitted to a mosquito 
vector during a blood meal event- within the midgut, these gametocytes undergo their final 
maturation. The male gametocyte divides into many flagellated microgametes which are then 
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available to fertilize female macrogametes. Fertilization forms a zygote and further 
development takes place to form an ookinete within 18 hours from a blood meal. The slowly 
motile ookinete penetrates the midgut wall to form an oocyst. Within this structure, meiosis 
occurs to generate large numbers of haploid sporozoites (Marreelli & Castelli., 1999). The 
sporozoites are released from oocysts and travel through the haemocoel to infect the mosquito 
salivary gland be available to reinitiate and infection in a new human host. 
 
1.3 Clinical features of malaria 
The clinical symptoms of malaria disease are associated with blood-stage infection, however, 
uncomplicated malaria is usually asymptomatic. Often, the common signs of malaria disease 
are unspecific and may be shared with other diseases, although a laboratory investigation with 
a suspected person in an endemic area will confirm whether malaria infections are present. The 
initial symptoms include fever, headache, fatigue, muscle weakness, nausea, vomiting and 
abdominal pain (Weatherall et al., 2002). Most patients with uncomplicated malaria infection 
show signs of anaemia and in children, the liver can become larger after several days of 
infection. Meanwhile, jaundice is very clear in adults infected with malaria (White et al., 2014). 
The majority cases of uncomplicated malaria symptoms present with nonspecific signs and they 
are common among most Plasmodium spp, including fever, jaundice, nausea, diarrhoea, 
hyperventilation and vomiting. Signs occur in three stages (cold, hot and sweating), that will 
repeat every 36 or 48 hours. Uncomplicated malaria means that the patient circulating parasites 
with no  symptoms (Bartoloni & Zammarchi., 2012). Most infected persons with uncomplicated 
malaria have few physical findings, mild anaemia and liver enlargement (after several days of 
incubation epically in children). Uncomplicated malaria infection may lead to severe malaria 
that threatens human life if the disease is not treated (White et al., 2014). Many factors influence 
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on the duration of malaria infection such as antimalarial drugs, immune status of the host, the 
way of transmission and the species of parasite (Bartoloni & Zammarchi., 2012). In 
uncomplicated malaria, the incubation period of P.malaria and P.vivax may take up to two 
weeks while a more variable incubation period for  P.falciparum (between 9 to 30 days) may 
be expected (Bartoloni & Zammarchi., 2012). 
Severe malaria is defined as a dysfunction of one or more multiple vital organs of the host due 
to infection with the malaria parasite (WHO, 2012). The majority of cases of severe malaria 
results from infection with P.falciparum and rarely with P.vivax or P.ovale. The features of 
severe malaria may include renal failure, pulmonary oedema, cerebral malaria, severe anaemia, 
and metabolic acidosis; these complications of severe malaria may lead to death if not treated 
as soon as possible (Gachot & Ringwald., 1998). Severe malaria could increase death cases due 
to two pathways: first, severe anaemia leading to hypoxia and cardiac failure and second 
cerebral malaria (Menendez, Fleming, & Alonso., 2000). Severe malaria is a consequence of 
complications from the progression of malaria infection. In severe malaria, the immune system 
of the host fails to keep the infection under control. The clinical manifestations of severe malaria 
depend on the age and the clinical status of the patient, severe anaemia and hypoglycaemia are 
common in children, meanwhile, kidney injury and jaundice are more common in adults 
(Gachot & Ringwald., 1998). Severe malaria leads to serious medical conditions which include 
many pathological changes:  
(i) Pulmonary oedema: acute lung injuries can occur a few days after infection with severe 
P.falciparum, and they may develop after a short time of treatment. Acute respiratory distress 
syndrome is a feature complication in adults with severe malaria (White et al., 2014).  The first 
sign of pulmonary oedema is an increase in respiratory rate, however, this indication is similar 
to many diseases making diagnosis difficult without appropriate facilities, moreover, acidosis 
and pulmonary oedema may occur together during the infection course with severe malaria 
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(Trampuz et al., 2003).  The pathogenesis is not fully understood and parasite sequestration in 
pulmonary vascular is unclear but the endothelial damage which is inflammation-mediated 
might have a role in pathogenesis (White et al., 2014). 
(ii) Renal dysfunction/kidney injury: severe malaria may cause kidney injury and can occur at 
any age, but it is common particularly in adults. Acute kidney injury is pathologically similar 
to tubular necrosis and is associated with dysfunction with other vital organs (Brabin et al., 
2015). The majority of cases of malarial renal failure caused by P.falciparum and rarely P. 
vivax and affected usually children aged from four to eight years (Barsoum., 2000). In acute 
renal failure, due to infection with P.falciparum, the serum creatinine concentration can become 
higher than 265mM. The mortality rate of patients with renal dysfunction is higher compared 
with patients with no kidney failure (Gachot & Ringwald, 1998). Following kidney injury, 60-
70% of severe malaria cases with an initial elevated concentration of serum creatinine return 
into normal within 17 days (Nguansangiam et al., 2007).  
Haemodialysis should provide treatment that will improve the outcomes of patients. Renal 
syndromes associated with renal dysfunction due to infection with severe malaria can be 
categorised into two groups: chronic glomerulopathy that mainly occurs in African children and 
acute renal failure associated with P.falciparum in southeast Asia, India and Sub-Saharan 
Africa (Barsoum, 2000). Jaundice is the most common complication to occur with acute renal 
with more than 75% cases resulting from excessive haemolysis  (Tangpukdee et al., 2006). Both 
thrombocytopenia and anaemia are found in 70% of cases associated with malarial acute renal 
failure. 
 (iii) Cerebral malaria; is considered one of the acute neurological disorder of severe malaria 
complication and may lead to coma (WHO., 2018). Rosette phenomenon and cytoadhesion are 
the main features of CM, where rosette is the adherence of IE to non-IE and cytoadhesion is the 
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IE binding to the endothelium and other cells in the brain microvasculature (Udomsangpetch et 
al., 1989). Both of cytoadhesion and rosette lead sequestration of IE and non-IE (Leitgeb et al., 
2011) cause obstruction of blood flow in the microvasculature (MacKintosh, Beeson & Marsh, 
2004). P.falciparum erythrocyte membrane Protein 1(PfEMP1) is the main mediator of IE 
cytoadherence to endothelium cells, which are expressed on the surface of IE and bind to a 
range of host receptors such as ICAM1, CD36 and endothelial protein C receptor (EPCR) 
(Hviid & Jensen., 2015).  The mortality of cerebral malaria ranges from 10% to 50% (Trampuz 
et al., 2003). Many pathological changes occur during brain infection for both adults and 
children including retinopathy with haemorrhage and rising of blood lactate–pyruvate level 
(White et al., 2014). Post-mortem studies of pationts with cerebral malaria shows no clear 
evidence of cerebral oedema in adults while it is clear in African children (Potchen et al., 2012). 
Artemisinin and quinine are used to treat cerebral malaria with artemisinin usually acting on 
early and late stages of parasite development while quinine act only on the late stages of parasite 
infection (Newton & Krishna., 1998; Idro, Jenkins, & Newton, 2005).  
(iv) Severe anaemia is considered the main feature of severe malaria in children and pregnant 
women. The prevalence of anaemia in endemic areas of Africa varies between 31% to 90% in 
children (Premji et al., 1995) and between 60% to 80% in pregnant women (Menendez et al., 
2000). Thrombocytopenia also occurs and it is common even in uncomplicated malaria (White 
et al., 2014). In patients with uncomplicated severe P.falciparum , the Hb level is usually within 
the normal range in the first 24 hours, followed by fever, then followed by a significant decrease 
in the Hb (Wickramasinghe and Abdalla., 2000). Pathophysiology of severe anaemia disease 
act on two sides, that increase the destruction of erythrocytes and decrease the production of 
erythrocytes (Menendez et al., 2000). Blood transfusion could be very important to manage 
malaria severe anaemia and it is easy to administer and that can be life-saving, however, the 
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source of blood for transfusion is very important and variable in an endemic area with malaria 
that may carry HIV (Menendez et al., 2000). 
(v) Malarial acidosis is a common complication of severe malaria, defined as the increased 
production lactatic and keto acids (Allen, O’Donnell, Alexander, & Clegg., 1996). There are 
many factors that may be associated with severe malaria acidosis: fever, severe anaemia, 
hypervolemia (English, Muambi, Mithwani, & Marsh, 1997). Metabolic acidosis combined 
with cerebral malaria presents a strong signal for subsequent fatal outcomes. To manage 
acidosis sodium bicarbonate was used in past, but it failed to control the acidotic state. A N-
acetylcysteine inhibitor of tumour necrosis factor has been used also as an alternative to control 
acidosis but has failed to decrease the mortality rates (Watt, Jongsakul, & Ruangvirayuth, 
2002). Dichloroacetate is a cofactor used in the correction of glucose and lactate kinetics in 
children with severe acidosis malaria where it induces the activity of pyruvate dehydrogenase 
and accelerates the oxidative removal of lactate and consumption of glucose (Maitland & 
Newton, 2005).  
(vi) Severe malaria in pregnancy can cause abortion or death of pregnant women and their 
foetuse and is a major public health challenge in endemic areas (Dellicour et al., 2010) (Figure 
1.7). There are many significant symptoms and complications of severe P.falciparum infection 
associated with malaria in pregnancy lsuch as high parasitaemia, severe anaemia 
hypoglycaemia, acute pulmonary oedema and premature labour. Infection with severe malaria 
relies on many factors such as immunity levels in the pregnant and the current trimester. 
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Figure 1.7: Malaria risk map for P. falciparum and corresponding number of pregnancies 
in each continent in 2007. The number of pregnancies in three affected continents (with those 
at risk of malaria indicated in parentheses) (Source: Dellicour et al., 2010) 
 
One of the most significant pathophysiological disorders that may occur during pregnancy due 
to malaria infection is placental malaria which is an accumulation of infected red blood cells in 
intervillous space in the placenta. Congenital malaria occurs in approximately 5% of neonates 
but clears in 62% of cases (Falade et al., 2007). HIV-infected mothers are highly likely to infect 
with congenital malaria, that has affected negatively on birth weights of babies (Potchen et al., 
2012). The mortality rate of pregnant women infected with P.falciparum may reach 50%. For 
severe malaria in pregnancy, the treatment recommended by the WHO is the use of artesunate 
or quinine. For uncomplicated malaria, artemisinin-based combination therapy is the best 
option to treat such cases because it has proven efficacy and safety. Certain drugs are no longer 
recommended to avoid complications that may threaten pregnant life. Clindamycin and 
clindamycin -based combination therapies are now avoided because they cause hypoglycaemia 
in pregnant women, in addition, they may increase infection resistance towards treatment  
(Schantz-Dunn & Nour., 2009; Orton & Omari, 2008). 
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1.4 Malaria treatment 
For uncomplicated P.falciparum infection, artemisinin combination treatment (ACT) is 
recommended as the first line to treat uncomplicated P.falciparum malaria and other malaria 
species in regions with high multidrug resistance (Achan et al., 2011).The main challenge to 
supply ACT is the cost and its limited availability compared to quinine which is relatively cheap 
and widely available (Achan et al., 2011). For non-P. falciparum uncomplicated malaria, 
chloroquine is the first choice for treatment followed by primaquine to treat intrahepatic 
infections resulting from infection with P.ovale and P.vivax parasites (Walker, Nadjm, & 
Whitty, 2014). Quinine is an effective anti-malarial drug for non-P. falciparum malaria and has 
a rapid action against schizonts and gametocytes of P.vivax and P.malaria (Walker et al., 2014). 
Quinine is commonly prescribed intravenously at a dose of 10 mg/kg, three times a day, the 
recommended dose is given by slow infusion (Walker et al., 2014). In the case of treatment 
failure with quinine, WHO suggests a combination of quinine and doxycycline or tetracycline 
as the second-line therapy option for uncomplicated malaria infection and quinine plus 
clindamycin for pregnant women infected with malaria (Smith et al., 2008). The combination 
of quinine and azithromycin show high efficacy in multi-drug resistance malaria. The 
combination of quinine and doxycycline has proven effective in the treatment of chloroquine- 
and multi-drug resistant P. falciparum (Gaillard, Madamet, & Pradines, 2015). 
Artemisinin is an antimalarial drug that is now used widely to treat severe P.falciparum and has 
pharmacodynamic properties that offer advantages over other antimalarial drugs, such as; fast 
onset action and the inhibition of multiple stages of the parasite life cycle. It can be 
administrated orally or intravenously; it kills more rapidly and it is now one of the several anti-
malarial drugs used to treat malaria in areas with chloroquine resistance (Krishna, Uhlemann, 
& Haynes, 2004). One of the best properties of artemisinin is that it attacks and kills parasites 
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throughout the blood cycle stage whether is ring or in schizont form (Woodrow., 2005) and the 
action of the drug may extend to target gametocyte development.  
Anti-malarial drug resistance, especially in P.falciparum, is a significant problem facing the 
malaria eradication programme that may lead to an increase in malaria incidences (Achan et 
al., 2011). Most malaria-endemic areas, except Central America, have reported widespread 
resistance in P.falciparum to chloroquine. Moreover, mefloquine resistant P.falciparum has 
been reported in the western provinces of Cambodia and eastern provinces of Myanmar, 
although non-P. falciparum parasites are still sensitive to chloroquine. Resistance to artemisinin 
is rising in East Asia and can result in clinical failure to treat malaria patients (Walker et al., 
2014) although, drug resistance phenomenon is currently concentrated in South East Asia. The 
development of P. falciparum drug resistance has been documented in many areas of the world 
and sulfadoxine/pyrimethamine was one of the drugs that P.f alciparum has grown resistant in 
South Asia, Oceania, sub-Saharan Africa, South Asia and the Amazon basin. P.vivax 
chloroquine resistance was also reported in areas of Oceania, including Indonesia and Papua 
New Guinea.  
Genetic analysis of chloroquine drug resistance in P.falciparum shows a mutated gene termed 
pfcrt (P. falciparum chloroquine resistance transporter) is a key determinant, although other 
mutations may support the extent of the chloroquine resistance (Fidock et al., 2000). Resistance 
to amodiaquine appears to result from mutation of the pfpgh-1(P.falciparum p-glycoprotein 
homologues-1) (Reed, Saliba, Caruana, Kirk, & Cowman., 2000).  
The induction and then global spread of drug-resistance highlights the urgent need for new 
drugs with a new mechanism of action. Ideally, these drugs need to be effective against all 
species that infect human, be effective against current drug-resistant strains, ideally with 
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different components in a combination therapy targeting different targets of parasite life cycle 
to rapidly reduce parasitaemia and improve the clinical outcomes (Burrows et al., 2017).   
 
1.5 Prevention  
There is no effective vaccine that can fully protect against malaria and, until recently, there has 
been no licenced vaccine against P.falciparum (Hill., 2011). There are high demands for an 
effective vaccine that could save millions of lives and reduce malaria infection around the world 
especially in endemic areas (Drew & Beeson, 2015). The most recent candidate vaccine under 
development targets only one stage of the parasite life cycle, and that does not prevent or stop 
malaria infection completely. The multi-target vaccine is the required vaccine that involves 
more than one stage of the malaria life cycle and the pre-erythrocyte stage vaccine has been the 
most successful vaccine until now (Hill., 2011). Merozoite surface proteins (MSPs) are a 
potential target of vaccine designs because they are always under the attack of immune defence 
cell by the host. The essential purpose of vaccine is to stimulate the memory  T-cell  response 
and antibodies  to a few antigens  of malaria infection repeated, however, the main challenge 
that faces vaccine synthesis is the parasite life cycle itself, because the parasite changes 
morphologically during host life cycle and shows antigenic variation that enable parasite to 
escape from immune defensive cells (Arama & Troye-Blomberg., 2014). In addition, 
P.falciparum show significant genetic diversity, particularly of PfEMP1 (Plasmodium 
falciparum membrane protein) taken as an example as there are some 60 different var genes 
encoding for the production of this exported membrane-bound protein in a parasite genome 
(Gardner et al., 2002).  
To obtain a successful vaccine, three major elements should be taken into consideration  in 
vaccine development; first, the vaccine should contain multi immunogenicity that stimulates 
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multi-immune response; second, it should contain compounds that enhance the immune system 
to respond to malaria infection and work on many stages of infection including the liver stage 
and blood-stage; third, it should include multiple epitopes that are restricted to production by 
histocompatibility (MHC) complexes to defeat parasite genetic diversity and antigenic variation 
(Shi et al., 1999). 
 
 
Figure 1.8 Illustrate the development of P.falciparum vaccine. Different stages of parasite 
life cycle could be a potential target for vaccine development. Vaccine block parasite 
transmission to the human host, vaccine inhibit blood-stage cycle by blocking merozoite 
invasion into erythrocyte and vaccine inhibit sporozoite invasion into hepatocytes. (source 
Arama & Troye-Blomberg, 2014). 
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The RTS,S vaccine (commercially called Mosquitrix) is one of the most advanced vaccines and 
acts against P.falciparum circumsporozoite protein (CSP) and provides immunity during the 
pre-erythrocyte stage. The vaccine  acts specifically during the parasite journey from skin to 
liver or infected hepatocytes that stimulate antibodies of human acquired immunity to inhibit 
the invasion of sporozoites for hepatic cells  and its replication during liver stage infection and 
clear the parasite before going to infect the red blood cells (Arama & Troye-Blomberg., 2014) 
(Figure 1.8). RTS, S vaccine is considered the only advanced vaccine to provide efficacy in 
semi immunised adults, children and infants in endemic areas (Halbroth & Draper., 2015). 
RTS,S was developed by GSK in collaboration with the Walter Reed Army Institute of 
Research. The RTS,S  vaccine is a complex vaccine composed of several elements: T cells 
epitopes to CSP are fused with HBsAg, a hepatitis B virus antigen and together encoded in a  
recombinant hepatitis B virus vaccine developed by GSK (Halbroth & Draper., 2015) and 
assembled to Virus-Like Protein (VLP) with infused copies of HBsAg (Cohen, Nussenzweig, 
Vekemans, & Leach., 2010). The result of immunisation with RTS,S in infants aged  6 to 12 
weeks, given as a monthly dose for three months, presented moderate action and excellent 
safety, 30% real immunisation against clinical malaria and 26% against severe malaria (Clinical 
trial study published by The RTS,S Clinical Trials Partnership 2014). While 55% immunisation 
against all sorts of P.falciparum appeared in older children their ages between 5 to 17 months 
and 35% protection towards severe malaria during 14 months. The result of RTS,S trial phase 
III shows protection against malaria in children aged between 5-17 months and efficacy of the 
vaccine against severe malaria in ages between 6 to 12 weeks (Moorthy & Okwo-Bele, 2015). 
RTS,S/AS01 vaccine has been recommended by WHO for a pilot immunization programme, 
from the beginning of 2019, the vaccine  will deliver to three sub-Saharan countries and for 
selective areas to be provided to young children through immunisation routine (WHO, the 
malaria vaccine implementation programme (MVIP). 
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Chemoprophylaxis is an alternative option to protect or prevent individuals from catching 
malaria. Chemoprophylaxis is recommended for those who intend to travel or live in endemic 
areas. Atovaquone, doxycycline, proguanil, primaquine, and mefloquine are common 
prophylactic agents used in the prevention of malaria. In fact, there are no perfect reliable 
chemoprophylaxis agents and diagnosis should always present as a tool to detect malaria in any 
febrile patients who have come from infected areas (White et al., 2014). Chemoprophylaxis is 
recommended for pregnant women in endemic areas. A full course twice during pregnancy 
offers partial protection against malaria and sulfadoxine-pyrimethamine used for this purpose 
2013). Mefloquine is the only safe chemoprophylaxis prescribed to travelling pregnant women 
because no harmful effects have been shown in the second and third trimester of pregnancy 
(Schlagenhauf et al., 2012). For children, who are the most affected by infection with malaria, 
approximately 80% of cases. WHO recommended using Amodiaquine and Sulfadoxine-
pyrimethamine as prophylaxis for children aged between 3 to 29 months and to administer 
monthly not more than four doses in areas from the beginning of annual transmission 
season(WHO, 2012). Chloroquine is also an important prophylactic agent, in endemic areas 
where chloroquine resistance has not been reported, chloroquine should be recommended. 
 
1.6 Inhibition of P.falciparum merozoite invasion/egress by glycosaminoglycans (GAGs) 
and other inhibitors 
Most current antimalarial drugs have an intraerythrocytic effect by targeting different aspects 
of the blood-stage life cycle of P.falciparum. Examples include (i) chloroquine and artemisinin 
which target intercellular food vacuole (Fidock et al., 2000; Klonis et al., 2011), (ii) 
doxycycline, azithromycin and clindamycin that target apicoplast function and thus prevent 
schizonts to fully maturate (Dahl and Rosenthal 2007; Goodman, Su and McFadden 2007), (iii) 
pyrimethamine that inhibits DNA replication (Cowman et al. 1988) and (iv) atovaquone and 
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proguanil that targeting mitochondrial bc1 complex function (Fry and Pudney., 1992; Dick 
Dickerman et al., 2016). At the present, there is no licensed drug that targets the extracellular 
form of parasite merozoite, although azithromycin has shown merozoite invasion inhibition 
activity at very high concentrations (Wilson et al., 2015). However, the ease of bloodstream 
access to the extracellular merozoite and the multiplicity of targets available offers an attractive 
target for agents that inhibit merozoite reinvasion and thus reduce parasite proliferation and the 
associated disease burden. 
Recently many inhibitors have been proposed specifically to target merozoites by inhibition 
merozoite egress or invasion (Figure 1.9). These include; quinolylhydrazones that inhibit the 
subtilisin 1 serine protease which is required for merozoite egress (Gemma et al., 2012) and 
hydroxyethyl amine and aminohydantoins that target plasmepsin IX and X which are both 
essential for merozoite egress (Pino et al., 2017; Nasamu et al., 2017).  
Heparin, which is polysaccharides belonging to the glycosaminoglycans family, has been 
reported to inhibit parasite growth in vitro where the inhibition is reported to be through the 
blocking of the merozoite invasion process (Butcher, Parish and Cowden 1988; Boyle et al., 
2017). Many GAGs have been identified to block P.falciparum merozoite invasion, with these 
mainly being sulphated GAGs from a range of different sources, including; dextran sulphate 
(Butcher et al., 1988), curdlan sulphate (Havlik, Rovelli and Kaneko., 1994; Evans et al., 1998), 
carrageenan  from seaweed (Adams et al., 2005), fucosylated chondroitin sulphate (Bastos et 
al., 2014), sulphated cyclodextrins (Crandall et al., 2007), K5 polysaccharides (Boyle et al., 
2010), inulin sulphate, xylan sulphate, tragacanth sulfate and scleroglucan sulphate (Boyle et 
al., 2017). In addition to inhibiting erythrocyte invasion by P. falciparum, GAGs have also been 
reported to inhibit non-human malaria parasite. 
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Figure 1.9 Schematic illustrating the targets of P.falciparum merozoite inhibitors. (A) 
during merozoite development and egress from an erythrocyte and (B) during binding and 
invasion of a new host erythrocyte. (Source: Burn et al., 2019) 
 
 
 Heparin has been shown to inhibit the zoonotic P.knowlesi (Lyth et al., 2018), with this 
observation leading to a proposal that the inhibition of pan-species is potentially possible with 
sulphated GAGs. Whilst the exact mechanism of sulphated GAGs inhibition is not well 
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understood, several targets of inhibition have been proposed. Heparin is reported to inhibit early 
essential steps of merozoite invasion to erythrocyte by targeting MSP1 (Boyle et al., 2010), and 
interacting with rhoptry microneme proteins involved in the merozoite reorientation (Baum et 
al., 2009; Kobayashi et al., 2010; Kobayashi et al., 2013). Much more recently, heparin has also 
been reported to inhibit merozoite egress and dispersal (Glushakova et al.,  2017) - thus, heparin 
and other sulphated GAGs, seems to inhibit multiple merozoite invasive proteins. Therefore, it 
is unlikely that a parasite would develop resistance to these sulphated GAGs, in fact, the 
attempts to obtain a parasite-resistant to heparin was unsuccessful (Boyle et al., 2010). 
Sulphated GAGs have been evaluated in vivo in mice models and shown to block merozoite 
invasion as well as disrupting cytoadhesion (Xiao et al., 1996).  
The inhibition effect of heparin and other sulphated GAGs have been reported not only in 
targeting merozoite invasion but extended to include prevent cytoadhesion and disrupt rosette 
formation. These studies include the sulphated GAGs dextran and fucoidan sulphate (Rowe et 
al., 1994; Barragan et al., 1999), carrageenan (Adams et al., 2005), curdlan sulphate (Havlik et 
al., 2005; Helen M. Kyriacou et al., 2007) and fucosylated chondroitin sulphate (Bastos et al., 
2014). 
Heparin has been evaluated clinically as an adjunct therapy for P.facliaprum severe malaria  
(Smitskamp and Wolthuis., 1971; Munir et al., 1980; Rampengan., 1991), with curdlan sulphate 
also used to treat severe/cerebral malaria (Havlik et al., 2005). However, due to their 
anticoagulation properties, increasing the risk of haemorrhage, as well as the risk of heparin-
induced thrombocytopenia, heparin was not recommended to be used as an adjunct therapy to 
treat malaria.  
The idea of modified heparin or other heparin-like mimetics that exhibits low anticoagulation 
activity but may also affect either invasion or infected erythrocyte binding is attractive as a 
potential adjunct therapy. Various heparins have been employed in other clinical areas, for 
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example; a non-anticoagulant low molecular weight heparin (LMWH) was used as 
antiangiogenic in an animal model (Pisano et al., 2005) and similarly, reduced anticoagulant 
heparin show anti-cancer growth inhibition (Yu et al., 2010). In P.falciparum, LWMH and low 
anticoagulant sulphated GAGs have been reported in several studies, showing both anti-
cytoadhesion, rosette disruption and invasion blocking activity – and several with low 
anticoagulation activity. Curdlan sulphate has a ten-fold reduction in anticoagulation activity 
when tested in a clinical trial with severe P.flaciparum (Havlik et al., 2005), Low anticoagulant 
heparin disrupt rosettes in vitro (Carlson et al., 1992), and the low anticoagulant glycan inhibit 
merozoite invasion and disrupt rosettes (Vogt et al., 2006). A chemically modified LMWH 
derivative with low anticoagulation disrupts rosettes (Skidmore et al., 2008; Boyle et al.,2017), 
a semi-synthetic GAGs with low anti aPTT and PT (Skidmore et al., 2017) and a low 
anticoagulant, sulphated GAGs inhibit merozoite invasion in vitro (Boyle et al.,2017). Recently 
a low anticoagulant, LMWH sevuparin which is a negatively charged depolymerized heparin 
with MW ~8000 Daltons and very low anticoagulation activity, has been evaluated in phase 
I/IIa clinical trial as an adjunct therapy to treat uncomplicated P.falciparum malaria (Leitgeb et 
al., 2017). This trial showed sevuparin inhibits merozoite invasion with no anticoagulation 
effect at concentrations lower than 6 mg/kg. The phase I work showed the sevuparin was well-
tolerated and safe, however, the potency of sevuparin was relatively low as the effect of 
sevuparin and drug was very close to the control of using the drug alone. Chemical modification 
of heparin and other sulphated GAGs, however, may provide a start for the development a 
future adjunct therapy for malaria treatment, and offer an additional option to meet the 
challenge of treating patients with drug-resistant malaria.   
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1.7 Glycosaminoglycans  
Glycosaminoglycans (GAGs) are unbranched, linear polysaccharides, consisting of repeated 
disaccharides units linked by glycosidic bonds ( or β) between amino sugar and a uronic acid 
in the disaccharide unit to form a complex structure (Köwitsch et al., 2017). GAGs are present 
on the surface of most cells types as a key constituent of the extracellular matrix. Sulphated 
GAGs, except hyaluronan (HA), are synthesised enzymatically in the cell’s Golgi apparatus 
and then exported to the plasma membrane surface. Sulphated GAGS are typically present in 
cells as proteoglycans, where side chains are attached to a protein (Gabius., 2009). There are 
six key groups of GAGs:  heparin, heparin sulphate, chondroitin sulphate (CS), dermatan 
sulphate (DS), keratan sulphate (KS) and hyaluronic acid (HA) (Figure 1.10). 
 
 
Figure 1.10 Illustrates the major repeated disaccharides in six major glycosaminoglycans 
(source: Köwitsch et al., 2018) 
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1.7.1  Heparan and heparin sulphate 
Heparan sulphate (HS) and heparin are like all GAGs, linear polysaccharides made of repeated 
disaccharides subunits. They mainly consist of uronic acid (1-4) glucosamine, with different 
patterns of substitution of the disaccharides subunits, the substitution is N-sulphate, O-sulphate 
and N-acetyl groups, making both GAGs, structurally, the most complex polysaccharides when 
compared with other polysaccharides in the GAG family (Rabenstein, D. L., 2002). Heparin 
and HS are built from the identical monosaccharide structure blocks, the uronic acid of the 
uronic acid-(1 4)-D-glucosamine repeating disaccharides may be either α-L-iduronic (IdoA) or 
β-D-glucuronic acid (GlcA), mutually of which may be 2-O-sulfated (Ido(2S) and GlcA(2S)). 
The β-D-glucosamine (GlcN) may be either N-sulphated (GlcNS) or N-acetylated (GlcNAc), 
both of which may be 6-O-sulfated (GlcNS(6S) and GlcNAc(6S)) and the GlcNS and 
GlcNS(6S) may also be 3-O-sulphated (GlcNS(3S) and GlcNS(3,6S)) (Rabenstein., 2002). 
Heparin disaccharides are built of iduronic acid of which IdoA2-S and glucosamine N-S and 
additionally GlcA. By contrast, HS disaccharides predominantly consist of glucuronic acid and 
N-acetylated glucosamine (Köwitsch et al., 2017). Notably, heparin is highest negatively 
charged of all known biomolecules and the degree of sulphation in heparin is higher than that 
of HS (Nelson at el., 2008), and the distribution of sulphation over heparin is more equal than 
that in HS where there are alternating high sulphation and lower or non-sulphated sections 
(Powell et al., 2004). Both heparin and HS are produced as proteoglycans, Heparin is 
synthesised in connective tissues type mast cells and basophils, while HS is synthesised by all 
mammalian cells (Rabenstein., 2002; Varki., 1999).  
HS and heparin have distinct biological functions. Heparin inhibits a wide range of biological 
activities including complement activation, angiogenesis, tumour growth factor and viral entry. 
Heparin is a well-known anticoagulant and has been used for decades to treat different serious 
clinical conditions such as thromboembolism. The anticoagulation activity is the result of 
27 
 
heparin interaction with thrombin, a serine protease inhibitor that mediates the anticoagulant 
activity of heparin (Jin et al., 1997). Heparin inhibits antithrombin (AT) by binding AT with a 
specific and unique sequence of heparin polysaccharides where only one-third of heparin chains 
have this anticoagulation property (Rabenstein., 2002). HS instead plays a key role in biological 
functions where HS meditate the biological function by binding to proteins such as; inhibition 
of blood clotting (Marcum et al.,1986), cell adhesion (Lindahl et al.,1994), regulation of cell 
growth and proliferation (Perrimon et al., 2000), vital role in angiogenesis (Iozzo et al., 2001), 
tumor metastasis (Hulett et al., 1999) and in viral invasion by acting as receptors to for the virus 
invasive ligands (Shukla et al., 1999). 
 
I.7.2 Dermatan sulphate / Chondroitin sulphate 
Chondroitin sulphate (CS) is a linear polysaccharide, consist of repeated disaccharides units of 
N-acetyl galactosamine (GalNAc) or glucuronic acid (GlcA) linked by β1-4 or 1-3 linkage with 
sulphation group present C-4 GalNAc(Janet M et al., 2002). Dermatan sulphate (DS) is also 
known as chondroitin sulphate (CSB) where iduronic acid is present in DS which distinguishes 
it from CS. DS and CS vary in their MW and length, 5-70 kDs (Linhardt et al., 2006; Volpi., 
2007). Both DS and CS found to have different vital roles in many biological processes where 
found as proteoglycans as DSPG and CSPG, for instance in the regulation of fibrillogenesis 
(Dunkman et al., 2014), they also interact with neuron and neural cell adhesion molecules 
(Mauler et al., 1994), interact with growth factor of fibroblasts (Trowbridge and Gallo, 2002), 
act as regulator during inflammation, tumour development and wound healing by effect on the 
signalling course in the cell (Volpi., 2011). 
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1.7.3 Keratan sulphate (KS) 
Keratan sulphate is a polysaccharide consist of repeated disaccharides of which GlcNAc and 
galactose linked by β1-4 and 1-3 linkage, both may which sulphated at C6. The MW of KS 
diverges and array 5-25 kDa , dependent on the source of KS (Hopwood and Robinson., 1973)       
KS found naturally, highly concentrated in the cornea. KS classified into three classes, 
depending on KS O or N  connecting to amino acid core proteins: KS-I  KS  is N-linked via 
GlcNAc to asparagine, KS-II where O- linked through GalNAc to serine, KS-III is O-connected 
through mannose to serine (Uchimura at al., 2015). KS-I is distinguished from KS-II by its 
lower sulphation degree, and longer chain length,  where KS-II is highly sulphated and shorter, 
also, KS-II found in cartilages meanwhile KS-I found mainly in the cornea which is responsible 
for corneal transparency and tissue dehydration (Köwitsch et al., 2018). KS-III is found in 
proteoglycans of nervous tissue and brain (Uchimura., 2015). 
 
1.7.4 Hyaluronan (Hyaluronic acid) 
Hyaluronic acid (HA), unlike other GAGs, is not sulphated and non-linked to protein cores, 
synthesis by integral membrane protein and release to the extracellular space (Weigel and 
DeAngelis., 2007). HA structurally is unbranched polysaccharides, consist of repeated 
disaccharides of GlcA linked via β (1-4) to β (1-3) GlcNAc glycosidic linkage. HA is found in 
difference placed in human tissues, such as; synovial fluids, skin, umbilical cord and cartilage 
where found to be at high concentrations in these human tissues (Fraser et al., 1997). The MW 
of HA is varying and decrease with age (drop from 2000 kDa to 500kDa) (Holmes et al., 1988) 
which have a negative impact on its biological functionality. HMW HA has an 
immunosuppressive and anti-inflammatory, while the LMW HA has a reverse action, it exhibits 
angiogenic, immunostimulatory properties (Stern et al., 2006). 
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1.8 A role for GAGs in mediating P.falciparum pathogenicity 
Rosette formation and cytoadhesion both lead to serious consequences which may include; 
obstruction of microvasculature, tissue hypoxia and organ failure (for review see Von Itzstein 
et al., 2008).  Glycosaminoglycans such CSA and HS are recognised to have a role in 
P.falciparum cytoadhesion and merozoite invasion by facilitating host cell- IE interactions. For 
example, CSA which is expressed in many cell surfaces, erythrocyte and placenta during the 
pregnancy mediates parasite cytoadherence within the placenta. IE is concentrated within the 
intervillous blood space where CSA expressed on the syncytiotrophoblasts of the placenta act 
as a receptor for PfEMP1 on the surface of IE (Gill et al., 2009).  Heparan sulphate was observed 
to have high affinity and more frequent binding to IE in isolates from children with severe 
malaria compared with those with mild malaria, suggesting that HS could be one of the 
sequestration receptors that contribute to malaria severity (Heddini  et al., 2001). In addition to 
the roles of CSA and HS in rosetting and cytoadhesion, both were found to play a role in the 
regulation of placental inflammation a consequence of parasite adhesion. Heparin is also 
suggested to act as a receptor for merozoite invasive ligands during erythrocyte invasion, with 
heparin showing an ability to bind MSP1-41 and MSP1-33, suggesting that heparin or heparin-
like molecules are receptors for the merozoite invasion process (Boyle et al., 210). 
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1.9 Objectives of this study 
As outlined above, heparin and a range of GAGs used as heparin-mimetics have been evaluated 
in some P. falciparum strains for their ability to reverse cytoadhesion or disrupt resetting. There 
is less information on their effect on blocking the erythrocyte reinvasion pathway, few 
exploring the cross-strain activity and the use of either direct microscopic examination or a flow 
cytometry assay limits the scalability of these assays.  
These limitations were explored here through objective 1: the development and validation of a 
novel bioluminescent plate-based assay – utilising a neuraminidase sensitive strain NF54 to 
complement a neuraminidase insensitive Dd2 transgenic strain already available Panels of 
heparin medicines, low molecular weight heparins, and chemically modified heparins, 
sulphated complex carbohydrates from a range of sources as well as naturally sulphated GAGs 
from marine sources were tested in this novel assay. This material provided for objective 2: the 
screening and confirmation of hits from these libraries as concentration-dependent inhibitors of 
in vitro growth in two P. falciparum strains. 
Hits were taken forward for objective 3: To determine the relative anticoagulation activity of 
these hits and define the inhibitory action to merozoite egress and/or erythrocyte invasion. The 
results of these studies are discussed in the wider context as their potential for development as 
an adjunct therapy for severe malaria. 
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Chapter two: Materials and Methods 
 
 
2.1 Materials 
Plasticware were sourced, unless otherwise indicated, from Greiner Bio-one or Starlabs. All 
chemicals were provided by Sigma or VWR. Human blood that used for P.falciparum culture 
was provided to Paul Horrocks as an approved user by The National Blood and Transplant 
Service (account H064) and stored and disposed of under the HTA License 12349. All work in 
the Category III cell culture facility was done as described in the Health and Safety Executive 
approved Code of Practice for this facility. All glycosaminoglycans (GAGs) were kindly 
provided by the Skidmore Laboratory, School of Life Science, Keele University. All GAGs 
were diluted in water and final stock concentration of was 10mg/ml.  
 
2.2 Material stock (reagents)  
50X Malaria Sybr Green I fluorescence (MSF) lysis buffer  
 20 mM Tris-HCl,( Ph 7.4) 5 mM EDTA, 0.008% saponin and 0.08%  and 0.8% Triton X  
Cytomix buffer composition 
120 mM KCl; 0.15 mM CaCl2; 10mM K2HPO4/KH2PO4, pH 7.6; 25 mM Hepes, pH 7.6; 2 
mMEGTA, pH 7.6; 5mM MgCl2; pH adjusted with KOH) 
20X SSC (3.0M NaCl, 0.3M sodium citrate) 
175.3g NaCl and 88.2g sodium citrate were added to 800ml sdH2O, the pH of the solution 
adjusted to 7.0 by adding HCl and made up to 1 L with sdH2O. The solution was then 
autoclaved and stored at room temperature. 
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50X Tris-Acetate-EDTA (TAE) buffer 
242g of Tris-base, 57.1 ml of 100 % glacial acetic acid and 100 ml of 0.5 M EDTA (pH 8.0) 
were added to a total volume of 1 L of sdH2O. The solution autoclaved and stored at room 
temperature. 
Ethylene Diamine Tetra Acetic Acid (EDTA) 0.5M, pH8.0 
93.05g of disodium EDTA.2H20 was added to 400ml sterile distilled water (sdH20) and sited 
on a magnetic stirrer. 10g of NaOH pellets were added, the pH adjusted to 8.0 by adding (10N 
NaOH) and then made up to 500ml with sdH2O. The solution was then autoclaved to sterilise. 
Glucose solution (45%w/v) 
90 g of D-glucose was added to 200 ml of sdH2O and the solution mixed on a magnetic stirrer, 
filter sterilised and then stored at 4°C. 
Glycerolyte freezing solution  
 Freezing solution is composed of Glycerol 57 g; Potassium Chloride 30 mg; Sodium Lactate 
1.6 g; Sodium Phosphate Dibasic 124.2 mg; Sodium Phosphate Monobasic 51.7 mg per 100 ml 
dH2O; pH 6.8 adjusted with phosphoric acid.The solution was then stored at 4°C. 
Hypoxanthine solution (X1000) 
340 mg of hypoxanthine was added to 25 ml of 1N NaOH to achieve a 1000X stock 
concentration. This solution was stored at -20°C in 0.5mL aliquots. 
LB agar 
LB agar was purchased from Merck. 37.0 g of agar was suspended in 1 L of sdH2O and mixed 
on a magnetic stirrer. The agar then autoclaved and either used immediately or stored at 4°C. 
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LB broth 
LB broth purchased from Merck. 25.0 g was suspended in 1 L of sdH2O, mixed on a magnetic 
stirrer and then stored at 4°C until used. 
SOC medium  
To 950ml sdH20, 5 g of yeast extract, 20 g tryptone and 0.5 g of NaCl were added and 
homogenised on a magnetic stirrer. 10 ml of 250 mM of KCl was added to the solution and pH 
7.0 was achieved with 5 N NaOH and 5 ml of filter-sterilized 2M MgCl2 was. The final volume 
of a solution made up to 1L with sdH2O, autoclaved and stored at -20°C. 
WR99210 stock 
0.05 g of WR99210 (a gift from Jacobus Pharmaceuticals, Princeton, NJ) was added to 1 ml of 
DMSO to prepare a 25 mM stock for long-term storage at-20°C. For short-term use, a 25 μM 
stock was prepared by diluting 1μl of the 25 mM stock to 1 ml of complete medium (1/1000 
dilution). 100 μl of the 25μM short-term stock was added to 500 ml of P. falciparum culture 
medium to provide a final 5nM concentration required for drug pressure. 
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2.3 List of equipments 
1. GloMax®-Multi+ Microplate Multimode Reader with Instinct® (Promega, UK). 
2. Incubator 37 ˚C (Nuaire). 
3. Microbiology Safety Cabinet (ICN Flow). 
4. Centrifuge- U-320R (Boeco, Germany). 
5. CX21FS1 Microscope (Olympus). 
6. JB Aqua 5 Water Bath (Grant.) 
7. Shaker incubator (Certomate HK). 
8. Fluorescent microscope (Evos cell imaging system, Life technologies). 
9.Electroporator (Bio-Rad genpulser XCELL). 
10. Benchtop centrifuge (Sigma). 
11.Bacterial culture incubator (Scientific Laboratory Supplies). 
12.Gel document system (Syngene). 
13.Electrophoresis unit (Jencons). 
14.Autoclave (Tuhnauer). 
15.Real-time PCR (Applied Biosystems, Step One Plus). 
16. Conventional PCR (Eppendorf® Mastercycler). 
17. Thrombostat 1 (Behnk Elektonik GmH &co. KG) 
18.  Flow Cytometer (Guava® EasyCyte, Merck) 
19. Hybridization incubator (Techne, HB-1D hybridizer). 
20. Light microscope with camera (Dialux 20EB, infinity camera) 
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2.4 Cell culture materials 
2.4.1 Preparation of complete and incomplete P. falciparum cell culture medium 
Incomplete cell culture medium comprised 500 ml of RPMI (Roswell Park Memorial Institute)-
1640 medium (Sigma) with the following components added; 2.5 ml of 1N NaOH, 2 ml of 45% 
(w/v) glucose solution, 18.75 ml of 1M HEPES buffer solution (Sigma), 5ml of 200 mM 
glutamine solution (Sigma), 0.5 ml 1000x Hypoxanthine solution, 1.25 ml of 10 mg Gentamicin 
Sulphate (Sigma). To prepare complete cell culture medium, the following components were 
also added; 20 ml of human serum and 20 ml of 5% albumax -II.  
 
2.4.2 Preparation of human serum and erythrocytes 
Human fresh blood O Rh+ was supplied by National Blood and Transfusion Science (UK 
Bristol). All work was carried out in a Health and Safety Executive approved CAT-III facility 
according to standard operating procedures. On delivery, human blood was stored in labelled 
50 ml tubes and kept at 4oC for up to four weeks. To prepare a 50% of haematocrit stock for 
P.falciparum cell culture, the upper serum phase was removed and the red blood cells 
suspended with an equal volume of incomplete cell culture medium and then collected by 
centrifugation (8 min, room temperature, 4000 rpm). The upper phase was removed, and the 
red blood cells resuspended with an equal volume of incomplete medium, mixed and 
centrifuged (3500 rpm, 5min, at room temp). The washed red blood cells were suspended finally 
in an equal volume of incomplete medium, mixed and then stored at 4oC. Human serum was 
provided as a discrete product or was collected from blood deliveries.  Serum was complement 
inactivated by heating to 57oC for 30 min, then stored at-20 oC in 40 ml aliquots.  
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2.5 P.falciparm cell culture methods 
2.5.1 In vitro intraerythrocytic continuous culture of P.falciparum 
Parasite stocks were typically continuously cultured at a 2% haematocrit (HCT) and between a 
0.5 to 3% parasitaemia as originally described by (Trager and Jensen, 1976) and modified later 
by Freese et al, 1988. Cultures were maintained under 1% oxygen, 3% carbon dioxide and 96% 
nitrogen (BOC, special gases) and at 37oC. The growth of the parasite culture was controlled 
by diluting the culture with fresh complete media and replacement of infected red blood cells 
with fresh uninfected stock. The parasitaemia of the culture was regularly assessed by light 
microscopy of a 10% Giemsa-stained thin smear. A thin blood smear was dried and fixed with 
absolute methanol and dried again, the slide covered with 10% Giemsa stain and left to stain 
for 5 minutes. The stain was washed off with water and left to air dry. Parasitaemia and parasite 
life cycle staging was assessed by using a 100x oil immersion objective lens. 
Dd2Luc strain was developed by Wong et al., (2011) to temporally express luciferase in 
trophozoite stages under the control of a Pfpcna flanking sequence. This strain requires 5nM 
WR99210 of drug selection. The NF54 strain was provided by the Merrick laboratory and 
requires no selective drug pressure. In this study, a NF54Luc was developed, and like the Dd2 
strain above, temporally expresses luciferase and requires 5nM WR99210 of drug selection. 
 
2.5.2 Sorbitol-synchronisation of P. falciparum culture 
To obtain a homogenous single-stage population, parasites were synchronised with sorbitol as 
originally described by Lambros and Vanderberg (1979). Predominantly ring-stage parasite 
culture was collected by centrifugation at 3000rpm for 5 minutes (room temperature). The 
supernatant was removed and 5 pellet volumes of 37°C pre-warmed 5% sorbitol was added to 
the red blood cell pellet and incubated at 37°C for 10 minutes. The synchronised culture was 
collected by centrifugation (1800 rpm, room temperature, 5 mins). The supernatant was 
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removed, and the red blood cell pellet added to a culture flask with an appropriate volume of 
fresh blood and complete cell culture medium. 
 
2.5.3 Storage of P. falciparum culture 
Highly synchronized ring stage (~10% parasitaemia) parasite cultures are stored at -800C for 
future use. The red blood cells in a predominantly ring stage culture were collected by 
centrifugation for 5 minutes at room temperature at 1800rpm. The supernatant was removed, 
and the red cell pellet volume estimated. The final process requires addition of five volumes of 
glycerolyte freezing solution to the prepared three volumes of red blood cells. The first volume 
of glycerolyte freezing solution is added drop by drop and mixed continuously. After leaving 
this for five minutes the remaining four volumes of glycerolyte freezing solution are added 
gradually, again with continual mixing. 0.8 ml of samples were aliquoted into sterile freezing vials 
(NUNC) and stored at -80oC until required. 
To thaw a frozen sample, the vial of frozen P.falciparum was taken from -80 °C and moved to 
the water bath at 37°C for one minute and then transferred into a 50 ml centrifuge. A 1/5th 
volume of 12% NaCl was added slowly to the sample and left for 5 minutes. Ten pellet volumes 
of 1.8% NaCl were then carefully added, one volume at a time with continual mixing. Finally, 
10 volumes of 0.9% NaCl in 0.2% glucose were added in the same way. After this, the sample 
was centrifuged (1800rpm, 5 min, room temperature) and the final pellet resuspended in 
complete culture medium, gassed and placed at 37°C. 
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2.6 Transfection and monitoring of luciferase expression 
Transfection carried out by using Gene Pulser XcellTM Electroporation System (Biorad, UK) 
as described by Hasenkamp et al., (2013). In a 2mm cuvette (Bio-Rad), 180 µl of 1x cytomix, 
20-40 µl of plasmid DNA (delivering between 20-40µg of plasmid(s) and 200 µl of cytomix-
washed uninfected erythrocytes were all mixed gently and subjected to a standard 
electroporation condition [310V, 960μF and ∞Ω resistance]. The DNA-loaded erythrocytes 
were immediately transferred into a small flask containing 20ml of complete medium and 200µl 
of NF54 trophozoite-infected erythrocytes (at about 3-5% parasitaemia), gassed (1% O2, 3% 
CO2, and 96%N2) and placed in a 37oC incubator. Drug selection pressure was applied two 
days post-transfection using  2.5nm WR99120 which added to the parasite culture to maintain 
plasmid DNA episomally within the parasite. 
Two days post-transfection, Parasite growth and luciferase expression was monitored to 
confirm the transfection of the episomes with the luciferase reporter gene. A blood smear was 
made and examined under a light microscope to establish erythrocyte reinvasion. Luciferase 
expression was monitored using a standard luciferase assay. In a 96 multi-well tissue culture 
plate (Sarstedt, UK) 40 µl of resuspended transfected parasite culture was added to 10µl of 5x 
lysis buffer (Promega, UK) and 50 µl of luciferase buffer. The luciferase bioluminescence signal 
is reported in relative light units (RLU) using a Glomax Multi Detection System (Promega, 
UK). Data were transferred into an excel spreadsheet using the InstinctTM software (Promega).  
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2.7 Isolation of DNA from P.falciparum 
Total DNA, including any episomal plasmid materials, were isolated from transfected parasites 
using one of two methods. The first described is a standard phenol-chloroform extraction 
protocol, the second protocol was done using a QIAamp® DNA isolation kit from the blood.  
 
2.7.1 Phenol-chloroform DNA extraction method 
The erythrocyte pellet from at least 100ml of 2% HCT culture with a high (>5% trophozoite 
and schizont staging) was collected by centrifugation (1800rpm, 5 min, room temperature) and 
washed twice with 25ml of chilled 1xPBS. The pellet was then resuspended in 25ml of 
1xPBS/0.1% saponin. After two minutes, the released parasites were collected by centrifugation 
(4000rpm, 10 min, room temperature). The parasite pellet was resuspended in 1840 µl of DNA 
extraction buffer (1200µl sdH2O, 200µl TN9 [500mM Tris HCl pH9, 2M NaCl], 400µl 0.5M 
EDTA and 40µl 50mg/ml-1 Proteinase K) and gently mixed by pipetting several times. After 
this 200µl of 100% SDS was added and mixed gently in a sealed tube in rotating incubator at 
50C0 overnight. The following morning, 1ml of phenol/chloroform/isoamyl alcohol (25:24:1, 
Sigma) was added to the tubes and then taped to a microcentrifuge tube rotator for 60 min at 
room temperature. After this, the aqueous and phenol phases were separated by centrifugation 
(4000rpm, 10 min, room temperature). The upper aqueous phase was transferred to a clean 
microcentrifuge tube and the phenol/chloroform extraction repeated for 20 mins After 
collecting the aqueous phase again, this had a 1/30th volume of 3M sodium acetate pH5.5 added 
and mixed by inversion before 0.6 volume of isopropanol (Sigma) was added to the aqueous 
phase and mixed by inversion. DNA that precipitates after mixing in the isopropanol was 
collected by spooling the end of a bacterial streaking loop. This DNA was then suspended in a 
small volume (between 100-200µl) of T10E1  
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buffer (10mM Tris HCl, 1mM EDTA, pH8.0) to achieve a 1-2µg/µl concentration, then DNA 
pellet was stored at 4oC.  
 
2.7.2 QIAamp® DNA extraction method 
The total genetic material from parasite-infected erythrocytes was isolated and purified using 
the standard protocol provided by the manufacturer of the QIAamp® DNA Blood Kit (Qiagen). 
Briefly, 200 µl of iRBC (>5% trophozoite and schizont staging) was collected by centrifugation 
and an equal volume of ice-cold 1x PBS/0.3% saponin was added, mixed well and placed on 
ice for 5 min. The released parasites were then collected by centrifugation at 14000 rpm, 40C 
for 1 min. The supernatant was removed and the parasite pellet washed with an equal volume 
of ice-cold 1xPBS ensuring the pellet was completely resuspended. The parasites were again 
collected by centrifugation before being resuspended in 200µl of 1x PBS. 20 µl of the Qiagen-
supplied protease buffer was added and mixed well with the sample before 200µl of buffer Al 
was added to the sample, mixed using a vortex for 15s and incubated at 56°C for 10 min. The 
sample was then centrifuged briefly to collect the sample before 200 µl of absolute ethanol was 
added to the sample and mixed again using a vortex for 15 seconds. This solution was applied 
to a QIAamp Mini spin column (in 2 ml collection tube), centrifuged at 6000g for 1min and the 
filtrate discarded and the column (with the bound DNA) placed in a new 2 ml collection tube.  
500 µl of buffer AW1 was added to the Mini spin column, centrifuged at 6000g for 1min and 
the filtrate discarded. Next, 500µl of buffer AW2 was added to the column and centrifuged 
(14000 rpm room temp for 3 min at room temperature) and the filtrate discarded. The mini spin 
column then placed in a fresh 1.5 ml microcentrifuge tube and 30µl of elution (AE) buffer added 
then sample kept at room temp for 10 min, centrifuged at 8000 rpm for 1 min. The concentration 
of DNA in the eluted sample was determined using a Nanodrop before storage at 40C. 
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2.8 Assays of growth inhibition in intraerythrocytic P. falciparum  
Typically, growth inhibition assays were done using synchronized trophozoite stage parasites 
exposed to the compound/drug being evaluated for one cycle of intraerythrocytic growth (48 
hrs). Assessment of the growth inhibition, normalised to controls for 100% growth (no 
compound/drug) or 0% growth (typically a 10µM super lethal dose of chloroquine), was made 
using either plate-based assays or by flow cytometry. 
 
2.8.1 Multiwell plate-based assays of growth inhibition in P. falciparum. 
These growth inhibition assays were done using a 96-multiwell tissue culture plate (Sarsted, 
UK). 100 μl of complete medium was added to all test wells except for the first column where 
an appropriate volume of complete growth medium was added depending upon the dilution 
factor (typically this was 200 μl for a two-fold dilution series). This first column of the plate 
was supplied with an appropriate volume of the molecule of interest (Glycosaminoglycans 
GAGs or drugs) and mixed by repeated pipetting. Serial transfers of an appropriate volume 
(typically 100 μl in a two-fold dilution series) from each column provided for a serial dilution 
of the molecule of interest. After this GAG/drug dilution, 100 μl of a master mix of P. 
falciparum culture which consists of 2% synchronous trophozoite stage parasites at a 4% 
hematocrit in complete medium was added. This then provided for 200 μl assays at a 2% 
parasitaemia and 2% haematocrit.  
Whilst the starting parasitaemia would be varied depending on the growth inhibition assay, the 
haematocrit and total volume were constant. Positive controls for a 100% growth were provided 
by no drug control. The 0% growth was established with a 10 μM super lethal concentration of 
chloroquine. After the dilution was complete, 200 μl of incomplete growth medium was added 
to outermost wells on each plate to minimize edge effect evaporation. The plate was moved to 
a humidified box and gazed with keep incubation condition of 1% O2, 3% CO2 and 96% N2 at 
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37oC. For most experiments, a two-fold dilution series was used, with three technical repeats 
on each plate (a plate, therefore, being used to test two molecules of interest). Typically, three 
biological repeats were done for each molecule of interest. Data were extracted into an Excel 
sheet via InstinctTM software (Promega). Growth inhibition data from were normalised against 
the 100% and 0% controls. Here, normalised growth in the test well is defined as [signal in test 
well – mean signal at 0% growth]/ [mean signal at 100% growth – mean signal at 0% growth] 
X100. The mean and standard deviation of typically n=9 repeats, being plotted on a log 
concentration normalised response curve in GraphPad Prism v5.0 (GraphPad Software, Inc., 
San Diego, CA) to establish the 50% Effective concentration (EC50) and their 95% confidence 
intervals (95%CI). Assessment of parasite growth was made on a plate-based assay of Dd2luc 
and NF54luc using either a luciferase assay or a Malaria Sybr Green I fluorescence assay. 
 
2.8.2 Luciferase Assay 
The luciferase assay used is adapted and modified from that reported by Hasenkamp et al., 
(2012) and used here to explore the growth inhibition and invasion blocking effects of 
glycosaminoglycans on Dd2luc or NF54luc strains. The 96-microwell plates were incubated at 
37oC for either 6, 48 or 96 hours depending on the nature of the experiment. In 96-multiwell 
white plate (Greiner, UK), 40 μl of Dd2luc or NF54luc wells were transferred and 10 μl of 5X 
Passive Lysis Buffer (Promega, UK) was added and carefully mixed. 50 μl of the standard 
luciferase substrate (Promega, UK) was added. The plate was shaken gently and the 
bioluminescence signal, in relative light units (RLU), immediately measured on a Glomax 
Multi Detection System (Promega, UK). Bioluminescence provides variation in raw data, 
influenced by parasitamia, culture health and staging as well as substrate used, time for assay 
etc. However, like any robust assay system, normalization controls for these and has been 
demonstrated for our bioluminescent parasites in Hasenkamp et al., (2012). 
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2.8.3 Malaria Sybr Green I fluorescence (MSF) Assay 
This Protocol was described previously by Smilkstein et al. (2004). Sybr Green I (Invitrogen, 
UK supplied as a 5000X stock) was added to 1x MSF lysis buffer in 1:5000 ratio. This was then 
mixed and placed in the dark until use. For the assay, 100 μl of MSF/Sybr Green I buffer was 
added to a black 96-multiwell plate (Greiner, UK) and an equal volume of parasite culture from 
the growth inhibition assay was added and the plate shaked gently to homogenise the well 
contents. This plate was placed at room temperature in the dark place for 30-60 minutes. The 
fluorescent signal, in RLU, was then measured through the blue fluorescent module (excitation 
490nm: emission 510–570nm) of a Glomax Multi Detection System (Promega, UK).   
 
2.8.4 Flow cytometry-based assays of growth inhibition in P. falciparum. 
A flow cytometry approach to monitor the grow inhibition of different GAGs has been adapted 
here from the original report of Boyle et al. (2010). Synchronized Dd2luc or NF54luc trophozoites 
were cultured in the presence of the GAG of interest according to the standard 96-well plate 
protocol described above (section 2.8.1) The experiment was performed as at least three 
independent biological repeats (n=3) and the growth inhibition measured by flow cytometry 
after 48 and 96 hours of incubation. Parasite cultures were mixed to resuspend the monolayer 
and washed twice with 1x PBS (Sigma). The washed red blood cell pellet was collected by 
microcentrifugation (13000rpm, 30 sec, room temperature) and 5 μl of the red blood cell pellet 
suspended in 90 μl of complete medium (4% haematocrit) was mixed with the same volume of 
10% ethanol/1X PBS containing a 10X concentration of SYBR Green I dye (provided as a 
10,000X stock, Invitrogen) and incubated for 20 minutes in the dark.  
The collected data was analysed and plotted using Guava EasyCyteTM HT System and 
GuavaSoft 3.1.1 software (Millipore, USA). 
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To determine the parasitaemia in the culture, the population of red blood cells were determined 
by plotting the forward scatter (FSC) and side scatter (SSC) of each event (Figure 2.1A). This 
population was gated (Figure 2.1B) and for this population, the side scatter plotted against the 
fluorescence signal using the Yellow -Blue (YEL-B) filter as indicated for the use of the SYBR 
Green I dye (Figure 2.1C). 20,000 cells were analysed for each sample. To monitor the growth 
inhibitory effect of each GAGs at the concentration tested, the normalised growth was 
determined against an untreated control. In the example shown here, the untreated control is 
represented in panel C of figure 2.1 (3.63%), with the experiment represented in panel D. Here, 
the normalised growth in the experiment would be (0.46/3.63 x100) 12.7% of the untreated 
control. The mean and standard deviation of n=3 biological repeats were plotted using 
GraphPad Prism v5.0 (GraphPad Software, Inc., San Diego, CA).  
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                 A                                                   B                                             C 
 
 
              D                                                 E                                                  F 
 
Figure 2.1 Shows flow cytometry dot plot growth inhibition assay using SYBR Green I 
DNA stain method after 48 hours incubation.  
C, F represent parasitaemia of untreated sample (iRBC only), treated parasite with 100 µg/ml 
of Tinzaparin (LMWH) or with unfractionated heparin respectively. Infected and uninfected 
(20,000 cells) were gated and labelled as RBC (A, D) meanwhile unlabelled are components of 
dead parasite or debris. B, E represents gated RBC only. 
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2.9 Monitoring the time course of P.falciparum intraerythrocytic development in the 
presence of GAGs 
 
The experiment was carried out using the standard 96-microwell microplate condition (section 
2.8.1). Highly synchronized Dd2luc or NF54luc schizonts (34-40 hours post-infection) were 
treated with a fixed 100µg/ml concentration of GAG of interest and incubated at 37oC for 48hrs 
to complete one intraerythrocytic cycle. At 18, 24, 48 hours after the start of the experiment, 
the contents of the well were resuspended and 10 μl used to prepare a thin smear that was fixed 
and stained with 10% Giemsa. The slides were examined under a 100x oil immersion lens using 
a light microscope. For each experiment, and three biological repeats were done, 100 infected 
red blood cells were identified, and the morphological parasite stage recorded. Photographs 
were captured using the Dialux 20 EB microscope connected with a camera (InfinityX) and 
processed using the DPXview pro software.  
To more closely explore the phenomenon of merozoite clusters formed with some GAGs at 
high concentrations, synchronized Dd2luc and NF54luc schizonts (34-40 hours post-infection) 
were incubated for 48 hours with different concentration of GAGs. As described above, thin 
smears of the treated and untreated parasite cultures were examined by light microscopy and a 
count of different morphological forms done. The experiment was carried out using the standard 
96 microplate conditions and for three biological repeats (n=3).  
Where fluorescent imaging of infected erythrocytes were required, a method adapted from 
MacKenzie & Ruxton (2015) was used after some modifications. After 48 hours of incubation, 
GAG treated, and untreated parasite were resuspended, and a thin smear slide was prepared. 
These slides were stained with SYBR Green I (Invitrogen) diluted 1:1000 in 10% ethanol in the 
dark at room temperature for 20 minutes. After washing generously with water, slides were 
examined and photos taking using the EVOS cell imaging system (Life Technologies) under 100x 
oil emersion magnification using the GFP filter (emission 510nm) 
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2.10 Molecular Methods 
 
2.10.1 Plasmid DNA transformation of Escherichia coli 
 
Plasmid DNA was transformed into chemically competent E. coli (Bioline) according to the 
manufacturer’s instructions. Briefly, Up to 4 µl of a 10 ng plasmid DNA stock, or up to 10 µl 
of a ligation reaction, was added to the chemically-competent E.coli and kept on ice for 30 min 
and followed by heat shock (42°C, 30 sec). These cells were then placed on ice for 2 min. Then 
250 µl of SOC medium was added to the cells and these then placed in a shaking incubator at 
37°c for 45 min at 225 rpm. Three volumes of 10, 30, 100 µl of the transformed E. coli were 
spread over three pre-prepared Ampicillin selective plates (90mm LB agar plates supplemented 
with 100µg/ml ampicillin). These plates were inverted and kept at 37°C overnight. The next 
day, single colonies were picked and inoculated into 5 ml of LB medium containing 100µg/ml 
ampicillin and placed on a shaker incubator at 37°C at 225 rpm to grow overnight. 
 
2.10.2 Plasmid DNA minipreparation from E. coli  
Plasmid DNA was isolated and purified from E. coli according to manufacturer instructions of 
the GeneJET system (Thermo Scientific). A 1ml culture of overnight growth of E. coli was 
transferred to 1.5 ml Eppendorf tube and collected by centrifugation at 8000 rpm, room 
temperature for 2 min. The supernatant was discarded and the bacterial pellet resuspended in 
250 µl of the supplied resuspension solution. Cells were suspended completely through 
vortexing until clumps became homogenised and 250µl of the supplied lysis solution was added 
and mixed by inverting the tube 6-8 times. After this, 250 µl of neutralization buffer was added 
that precipitates the protein/lipid content on inversion. The lysate was cleared by centrifugation 
for 5 min at 12000g at room temperature and transferred to a Gene JET column and centrifuged 
for 1 min at 12000g at room temperature. The flow through was discarded and 500 µl of 
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supplied wash solution was added and centrifuged for 1 min at 12000g at room temperature. 
The flow through was discarded and the spin column placed in a sterile 1.5 ml Eppendorf tube. 
30 µl of supplied elution buffer was added to the centre of the column and kept for 10 min at 
room temperature before the eluting the DNA by centrifugation for 1 min at 12000g at room 
temperature. The quality and concentration of the purified plasmid DNA were checked using a 
Nanodrop device before the plasmid was stored at -20°C. 
 
2.10.3 Maxi plasmid DNA preparations from E. coli 
To prepare plasmid material for transfection of P. falciparum, a maxipreparation using a Qiagen 
Maxi Plasmid DNA preparation kit was used according to the manufacturer’s instructions. 
Bacterial culture (between 200 to 300ml in LB supplemented with 100µg/ml ampicillin) was 
grown whilst shaking overnight. The bacteria were harvested by centrifugation 6000g for 15 
min at 4°C and then fully resuspended in 10 ml of buffer P1 (50mM Tris-HCl pH8.0, 10mM 
EDTA, 100μg/ml RNase). Then 10ml of buffer P2 (200mM NaOH, 1% SDS) was added and 
mixed thoroughly by inverting 6-8 times to obtain a viscous appearance and kept 5 min at room 
temperature. Then 10ml of ice-chilled P3 buffer was added (3.0M sodium acetate pH5.5) and 
immediately mixed by inverting 6-8 times and incubated on ice for 20 minutes. At this time, a 
Qiagen Tip500 was equilibrated by adding 10ml of the supplied QBT buffer and allowed to 
empty by gravity flow. During the equilibration, the bacterial lysate was cleared by 
centrifugation at 20000g for 30 minutes at 4°C. The cleared lysate was added to the Tip500 and 
allowed to empty by gravity flow. The Tip500 with the now bound plasmid DNA was washed 
twice with 2 x 30ml of the supplied QC wash buffer. The plasmid DNA was finally eluted by 
adding 15 ml of the supplied QF buffer which was then mixed in a 50ml tube with 10.5 ml of 
room temperature isopropanol to precipitate the plasmid DNA. The DNA was collected by 
high-speed centrifugation at 15000g for 30 min at 4°C. The DNA pellet was washed with 5ml 
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of 70% ethanol and then centrifuged at 15000g for 10 min at 4°C. The supernatant was carefully 
discarded and DNA pellet air-dried for 10 min. The DNA pellet was redissolved in a suitable 
volume of water (200-300 µl) to provide an approximately 2µg/µl concentration as determined 
using a Nanodrop. 
 
2.10.4 Restriction digests  
All restriction endonucleases were sourced from Promega. Plasmid DNA or gDNA was 
restricted according to the manufacturer’s instructions. Typically for a plasmid restriction, 0.5µl 
of the restriction enzymes was used to restrict between 0.5 to 2µg of DNA in a 20µl volume of 
the appropriate 1x fast green buffer (diluted in sdH20 from a 10x stock). The restriction digest 
was incubated at 37°C in a heated block for 1 hour. The restricted DNA was size-fractionated 
on an agarose gel and the DNA stained with ethidium bromide visualized using a UV gel 
documentation system  (Syngene). 
 
2.10.5 Agarose gel electrophoresis and imaging  
Agarose gel electrophoresis for DNA size fractionation was used routinely to assess restrictions 
of plasmid DNA or genomic DNA fragments. The concentration of agarose gel ranged between 
0.8% to 2% with larger fragments separated on lower concentration gels. To prepare a 1% 
agarose gel, 1g of agarose powder (Invitrogen) is added to 100 ml of 1XTAE buffer (made from 
dilution from a 50XTAE stock). The mix was then heated in an 800W microwave oven for 1-2 
minutes, with regular checking and mixing, to dissolve the agarose and then cooled to 
approximately 45°C. To this cooled agarose solution,  3 µl of a 10 mg/ml EtBr solution was 
added before the liquid poured to set in a cast.  Typically a 50-100ml gel would require at least 
30 mins to become solid for use – at this time it was immersed in 1XTAE buffer in a gel tank 
and the comb for the wells removed at this time. For most gels, 5 µl of a standard DNA ladder 
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(Invitrogen) was added to the first well. Restriction digests or PCR reactions etc were then 
loaded, in 1X loading dye to the remaining wells. Electrophoresis was typically done between 
80-100V (8-10V/cm) for 45 minutes. The DNA in the gel was then visualized using the UV gel 
documentation system. 
 
2.10.6 Purification of DNA fragments from agarose gel 
Restricted DNA fragments were isolated and purified using the S.N.A.P. gel purification kit as 
supplied by the manufacturer (Invitrogen). DNA was size-fractionated in a maximum of a 1% 
agarose gel that was stained with ethidium bromide. Under a short exposure to low-intensity 
long-wave UV light, the desired DNA fragments were isolated and then transferred to clean 1.5 
ml Eppendorf tube containing the supplied binding solution (10ul per 10mg of gel slice). The 
sample was mixed by vortexing and incubated at 600C for 10 minutes until the gel slices 
dissolved completely. The gel mixture was transferred to a minicolumn assembly and incubated 
for 1 minute at room temp. The mixture then centrifuged at 14000rpm for 1 min at room 
temperature and washed twice using 700µl and then 500µl of the supplied wash buffer, each 
time using centrifugation at 14000rpm for 1 minute at room temperature. The column was 
finally transferred to clean 1.5ml microcentrifuge tube contain and 35µl of nuclease-free water 
added to the column, left for one minute and then eluted at 14000rpm for 1 min at room 
temperature. As well as using the Nanodrop to confirm the concentration of eluted DNA, 
typically 5 µl of the eluted DNA sample was size-fractionated and visualized on an agarose gel. 
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2.10.7 DNA ligations 
Both vector and insert DNA fragments used in this study provided complementary overlapping 
ends. As such as standard T4 ligase (Invitrogen)  reaction were done using the materials 
provided by the manufacturer in 10 µl reaction volumes. Ligations were prepared with between 
10-30 ng of vector sequence with different ligations using a 1:1 and a 1:3 vector: insert ratio. 
Reactions were incubated at room temperature for at least 5 hrs, and normally overnight. 
Ligations were then transformed into chemically competent E.coli cells as described above in 
section 2.10.1 
 
2.10.8 Polymerase chain reaction (PCR)  
PCR was performed using MyTaq™ Red Mix kit (Bioline) using the manufacturer’s 
instructions. The normal PCR reaction volume was 50 µl. This included; 2µl of DNA template 
(typically 10ng of plasmid or 100ng of genomic DNA), 1µl each of forward and reverse primers 
(20ng/µl), 25µl My Taq Red Mix and 22 µl of distilled water. PCR cycling conditions (using 
an Eppendorf Master cycler Personal thermocycler) were typically; 
 
(i) 95°C for 4 min,  
(ii) 95°C for 1 min (melting step)  
(iii) 53°C for 1min (hybridization step- adjusted based on the oligo annealing 
temperatures) 
(iv) 68°C for 1 min (extension step – adjusted for 1000bp product/min) 
(v) Repeat steps (ii) to (iv) for 30 cycles 
(vi) 68°C for 10 min (final extension) and hold at 18°C  
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PCR genotyping was deployed to distinguish between the transfected NF54Luc and laboratory 
strain Dd2Luc. MSP1, MSP2 and GLURP were the three loci selected for comparison of the PCR 
length polymorphisms (Ridzuan et al., 2016) between these two strains. See (Table  2.1) 
 
Table 2.1 shows primers used for PCR genotyping 
 
2.10.9 Quantitative real-time PCR (qRT-PCR) 
Total genomic DNA was isolated flowing DNA extraction method described previously (see 
2.7.2). SYBR Green master mix (Applied Biosystems) was used for all qPCR in this study and 
performed on a StepOnePlus real-time PCR system (Applied Biosystems). Primers were 
designed to amplify a fragment of the luciferase gene, approximately (350bp); forward primer 
5'-AATCCGGAAGCGACCAACGC-3', and reverse primer 5'-
CGCGTCGAAGATGTTGGGGT-3'. The PCR mix was prepared according to the 
manufacturer’s instructions, briefly, 1µl of gDNA (concentrations ranged between 30 to 83 
ng/µl for template used), 10 µl of SYBR Green buffer, 2µl each of the primers (20ng/µl) and 
6µl of H2O to provide a final total of 20µl. qPCR conditions were 95°C for 10 mins, followed 
by 40 cycles of 95°C for 15 s and 60°C for 60 s. Using the 2−ΔΔCt method for relative 
quantitation of copy number, the copy number of the luciferase gene in NF54luc (compared 
Gene/family Primer Sequence  
MSP-1 MI-OF 
MI-OR 
5’ CTAGAAGCTTTAGAAGATGCAGTATTG 3’ 
5’ CTTAAATAGTATTCTAATTCAAGTGGATCA 3’ 
GLURP G-OF 
G-OR 
5’ TGAATT GAAGATGTTCACACTGAAC 3' 
5' GTGGAATTGCTTTTTCTTCAACACTAA 3' 
MSP2 M2-OF  
M2-OR 
5' ATGAAGGTAATTAAAACATTGTCTATTATA 3'  
5' CTTTGTTACCATCGGTACATTCTT 3'   
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against Dd2luc defined here as 1 in the ratio analysis), and compared to standards using 
chromosomally-located control (housekeeping) genes, seryl-tRNA synthetase (s-tRNA syn) , 
aldolase and Actin (β-actin1) (Table 2.2). Each relative quantification experiment was 
performed in triplicate and three independent biological repeats were done. Data were analysed 
using Step-One (V2.3) software and plotted using GraphPad Prism v5.0 (GraphPad Software, 
Inc., San Diego, CA). 
 
Table 2.2 (housekeeping) genes primers used in q-PCR assay 
 
 
2.10.10 Probe preparation for southern blotting 
A 350bp PCR of the luciferase gene was used to prepare a probe for Southern blots analysis. 
The oligonucleotide primers used were Forward- 5´ GGCCCGGCGCCATTCTATCCGC 3´ 
and Reverse-5´GCCCATACTGTTGAGCAATTCAC3´. After the PCR was size-fractionated, 
the product was gel purified as described previously (See2.10.6).This product was used as a 
template in a PCR DIG Probe Synthesis Kit (Roche) protocol that incorporates DIG-dUTP into 
the PCR product Briefly, 2.5 µl (~26 ng) of DNA template added to 10 µl each of forward and 
reverse primers (20ng/µl), 5 µl 10xPCR DIG probe synthesis mix, 5 µl dNTP (40µM), and 0.75 
µl enzyme mix and distilled water up to 50 µl. The PCR amplification conditions were the same 
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as used in the example above. The amplified labelled probe was then used for hybridization to 
the Southern blot.  
2.10.11 Southern blotting  
Genomic DNA (10µg/lane) were restricted in 30µl volumes overnight and size-fractionated 
on a 15-20cm long 0.8% agarose gel in 1x TAE buffer. The control molecular weight marker 
was DIG-DNA molecular weight marker II (0.12-23.1kbp) (Roche) [5µg(500µl stock 
concertation)], 10 µl mixed with 2 µl of 5X loading dye .The DNA was size-fractionated 
slowly (maximum of 80V) for 4-6 hrs. After UV gel documentation, the agarose gel was 
soaked in 500 ml of depuration solution (0.2 N HCl) for 15 minutes with gentle agitation. 
This was replaced with 500 ml of denaturation solution (0.5 M NaOH, 1.5 M NaCl) for 45 
minutes with gentle agitation. Finally, the gel was washed twice in 500 ml neutralising 
solution (0.5 M Tris-HCl pH7.5, 1.5 M NaCl) for 20 minutes with gentle agitation with a 
final brief was in distilled water. Hybond N+ (GE Healthcare products) was pre-soaked in 
2x SSC and placed on top of the gel, followed by a paper towel stack (see Figure 2.2) in a 
DNA transfer apparatus. 
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Figure 2.2. Illustration of a southern blotting apparatus. The schematic shows the relative 
order of the Whatman 3M wick underneath the gel, with the Hybond N+ membrane on top of 
the gel and the 2XSSC drawn through the gel by capillary action to transfer the DNA from the 
gel onto the Hybond N+ membrane. 
 
After an overnight transfer, the Hybond N+ membrane was rinsed 2xSSC and exposed for three 
minutes to 302 nm UV (DNA side down). This membrane was pre-hybridized by incubating 
with 25 mL of pre-heated Easy-Hyb solution (GE Healthcare) for 4 hours whilst rotating in a 
42°C hybridisation oven. The DIG-labelled PCR probe (c 500ng to achieve 20 ng/ml) was heat-
denatured for 5 minutes at 95°C and snap cooled immediately on ice and added to the membrane 
in 25ml of pre-heated Easy-Hyb solution. TheDIG labelled probe was incubated overnight at 
42°C in the rotating hybridisation oven. After this, the membrane was washed twice with 2x 
SSC, 0.1% SDS (100 ml/wash) for 15 minutes at room temperature. The wash was repeated 
twice using 0.5x SSC, 0.1% SDS (50 ml/wash) for 15 minutes at 68°C in the hybridisation 
oven. The membrane was removed and rinsed for 5 minutes in 50 ml of 1x DIG washing buffer 
(Roche) and blocked with 50 ml 1x blocking solution for 30 minutes. The membrane then 
incubated with a diluted anti DIG in 1X blocking solution for 30 minutes at room temperature. 
The membrane was washed twice with 50 ml of 1x DIG washing buffer in a small tray and 
equilibrated for 5 minutes in 5 ml 1x detection solution and placed (DNA side up) on a plastic 
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film. 20 drops (~0.5 ml) of CDP-Star ready-to-use solution (chemiluminescent substrate for 
alkaline phosphatase) was added to the membrane and then sealed with saran wrap and 
incubated in the dark for 5 minutes at room temperature. The wrap was removed to remove 
excess solution, resealed with saran wrap and placed (DNA side up) in a FluorChem M imaging 
system to document the fluorescent signal. 
    
2.11 Prothrombin time (PT) assay 
This assay was utilized to evaluate the anticoagulation activity of GAGs for the extrinsic and 
common pathway. 50 µl ml of human plasma or (plasma control) was added in cuvette contain 
ball bearing followed by adding 50 µl of HPLC grade water (for control) or with two-fold 
dilution series (100µg/ml) heparin and incubated for 1 minute at 370C in.  After 1 minute 
exactly, 50 µl of pre-warmed thromborel S reagent was added. Coagulation time measured by 
using Thrombostat 1(Behnk Elektronik GmH &co. KG). 
 
2.12 Activated thromboplastin time (aPTT) assay 
To evaluate GAGs anticoagulation activity for the intrinsic and common pathway. In a cuvette 
containing a ball bearing, 50 µl of normal human or control plasma was added to 25 µl ml of 
HPLC grade water for control or with two-fold dilution series (100µg/ml) heparin followed by 
adding 50 µl of pathromtin SL regent and incubated for 2 minutes at 370C. 25 µl of pre-warmed 
CaCl (50 mM) was added to the solution immediately after 2 minutes of incubation. Clotting 
time was measured by using Thrombostat 1(Behnk Elektronik GmH &co. KG). 
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Chapter three: Generation and validation of NF54luc transgenic parasite 
strain expressing a trophozoite stage-specific luciferase reporter   
 
3.1 Introduction 
 Transgenic Plasmodium parasite strains provide valuable tools in the study of these parasites, 
supporting studies as diverse as investigating cell-host interaction to exploration and evaluation 
of new parasite inhibitors and vaccines (Othman et al., 2017). Genetic modification of 
Plasmodium falciparum  is currently limited to manipulation of the intraerythrocytic stages, 
maintained by continuous in vitro culture systems (Trager and Jensen, 1976), with this process 
made more challenging  as delivery of exogenous DNA to the parasite needs to cross four 
membrane barriers: (i) erythrocyte plasma membrane,(ii) parasitophorous vacuole membrane 
(iii) parasite plasma membrane and (iv) the nuclear membrane barrier (for review see Horrocks 
& Lanzer., 1998). In addition, the extreme bias in parasite DNA AT content – particularly in 
non-coding regions, makes subcloning these sequences within E.coli more challenging (Wu et 
al., 1995; Horrocks & Lanzer., 1998). However, these challenges have been overcome, with the 
first Plasmodium species manipulation achieved by Goodewardene et al., (1993), who 
described the transient expression of a luciferase reporter gene into the avian malaria parasite 
Plasmodium gallinaceum. This work was shortly followed by the successful transfection of P. 
falciparum by Wu et al., (1995). 
Generation of a P. falciparum transgenic parasite, using electroporation to introduce exogenous 
DNA into parasite cell, requires the use of plasmid DNA carrying different DNA elements 
which are all required for the transfection to succeed. Selection markers (often drug resistance 
genes) with an appropriate promoter and terminator sequences play an important role in plasmid 
DNA maintenance (replication and segregation) for both episomal maintenance or integration 
into the parasite genomic DNA (Goonewardene et al., 1993; van Dijk et al.,1997). Common  
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bacterial selectable markers include; neomycin phosphotransferase, blasticidin S deaminase 
(Botstein et al., 1999) , puromycin-N-acetyltransferase conferring resistance to blasticidin S, 
geneticin (G418) and puromycin, respectively (De Koning-Ward et al. 2001) or the use of 
human/parasite dihydrofolate reductase (DHFR) conferring resistance to the antifolates 
pyrimethamine or WR9921( McElwain et al., 2002). The plasmid construct also often has a 
fluorescent or luminescent reporter based on the proposed application of this marker gene 
(Marin-Mogollon et al., 2019). The first description of a bioluminescent based assay of parasite 
growth was by Cui et al., (2008). This assay was later further evaluated for antimalarial drug 
discovery (Wong et al., 2011; Hasenkamp et al., 2013) where a Dd2 strain containing a 
luciferase reporter gene (Dd2luc)  flanked by the 5`and 3` regulatory regions of the proliferating 
cell nuclear antigen (PCNA) gene providing a strong stage-specific expression of luciferase in 
trophozoites. This same GM parasite has demonstrated a range of uses in the investigation of 
epigenetic gene regulation, exploring transfection methods and their efficiencies as well as a 
new assay studying the pharmacodynamics of drug action (Wong et al., 2011; Hasenkamp et 
al., 2013; Ullah et al., 2017). 
We plan here to use the same reporter system (Wong et al., 2011) but instead introducing it into 
a different parasite strain - NF54. Dd2luc was developed using Bxb1 integrase system which 
mediates the integration of a sequence bearing an attp site into the genomic DNA at a previously 
integrated attB site (Adjalley et al., 2010; Nkrumah et al., 2006). With NF54attB strain being 
available this was the intended approach here. In other work described here, we achieve a stable 
transfection in the NF54 parasite using a plasmid construct bearing Rep20 sequences. Rep20 is 
a unique repeated, 21 bp sequence found in all subtelomeric of the 14 P. falciparum 
chromosomes and is not found in other eukaryotes (McElwain et al., 2002). It has previously 
been shown that plasmids bearing a rep20 sequence lead to an episomal maintained plasmid by 
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promoting plasmid segregation between daughter merozoites and by mediating plasmid 
tethering to the chromosomes (O’Donnell et al., 2002).  
We used these approaches to transfect NF54 parasite phenotype with the same luciferase 
construct we already have available in the Dd2luc strain.  The new genetically modified NF54luc 
parasite is required for our planned investigations of the invasion inhibition effect of heparin 
and other sulphated GAGs. Heparin and related sulphated GAGs have been reported in several 
previous studies to inhibit parasite growth, mainly by blocking merozoite invasion into the 
uninfected erythrocyte (Leitgeb et al., 2017; Boyle et al., 2017; Clark et al., 1997; Xiao et al. 
1996) and this inhibition is likely mediated by targeting key merozoite invasive proteins and 
inhibiting parasite –erythrocyte ligand interactions (Boyle et al., 2010). In addition to blocking 
processing of merozoite surface proteins (MSP), heparin has been found to mask the apical 
surface of merozoite by binding with various merozoite apical proteins, such as the erythrocyte-
binding antigen-175 (EBA-175) (Kobayashi et al., 2013). These ligands of merozoite-
erythrocyte interaction bind with a range of erythrocyte receptors (Sim et al., 1994; Cowman et 
al., 2017). There are three principle erythrocyte receptors localized on the erythrocyte cell 
surface important for merozoite invasion; glycophorin (gp) A or B and an unidentified trypsin 
sensitive molecule termed X. (Mitchell et al., 1986; Hadley at el., 1987; S.A. Dolan et al., 1994). 
For example, the merozoite ligand EBA-175 binds to sialic acid residues on gpA (sialic acid-
dependent) (Orlandi et al., 1992). Cloned parasite isolates have been shown to employ a range 
of alternative pathways to invade erythrocyte (Dolan et al., 1990; Dolan et al., 1994). 
Importantly, Dd2 has a neuraminidase-sensitive invasion phenotype, where merozoite invasion 
is dependent on sialic acid which is cleaved off by neuraminidase treatment (Binks & Conway, 
1999). However, the NF54 strain acts the same as its progeny 3D7 strain and has an alternative 
invasion pathway in that it is neuraminidase-resistant, i.e merozoite invasion of the erythrocyte 
is non-sialic acid dependant (Theron et al., 2010).  
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Here I describe the generation and then validation a NF54luc transgenic parasite strain that bears 
the same luciferase reporter system as the existing Dd2luc strain available in the laboratory. This 
line will then be available to use alongside Dd2luc in GAGs inhibition studies as a second 
independent strain, with an alternative invasion phenotype, to explore the potential for strain-
dependent invasion inhibition effects. 
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3.2 Results 
 
3.2.1 Comparison of plate-based fluorescence versus bioluminescence assays of 
intraerythrocytic growth inhibition using glycosaminoglycans 
 
Assays of inhibition of intraerythrocytic growth using microplate assays usually use the Malaria 
Sybr Green I Fluorescence (MSF) assay. This assay was originally developed by Smilkstein et 
al., (2004) and is based on the emitted fluorescence signal of Sybr Green I when intercalated 
into DNA – with the DNA content of the in vitro assay dependent on the growth and 
multiplication of a parasite culture over 48 hours. However, initial experiments using a plate-
based Sybr Green I assay to monitor the inhibitory effect of heparin over 48 hours on a starting 
2% trophozoite Dd2luc culture (Figure 3.1) showed that increasing concentrations of heparin 
did not lead to a decrease in fluorescence signal as the growth inhibitory effect increased, but 
rather led to an increase in fluorescence. Microscopic examining (data not shown) of cultures 
exposed to high concentrations of heparin did not show an increase in parasite numbers, with 
the opposite true when no parasites were observed. We concluded that there was a heparin-Sybr 
Green I affect that leads to an increase in fluorescence. This is also true for low molecular 
weight heparins and glycosaminoglycans isolated from marine sources (Figure3.1), these 
compounds reflecting materials assessed in Chapters 4 and 5 of this thesis.   
The Dd2luc strain used is a transgenic strain that expresses high levels of luciferase in the late 
trophozoite stage – with the expression linked to the S-phase of parasite growth (Wong et al., 
2011). This strain has also been evaluated to measure the growth inhibitory effects of 
compounds and determine their EC50 (Hasenkamp et al., 2013). Using a plate-based luciferase 
assay, concentration-dependent inhibition of parasite growth was observed for all the 
glycosaminoglycan compounds previously tested in the MSF assay (Figure 3.1). Based on this 
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data, it was determined that plate-based assays to determine growth inhibitory effects of 
glycosaminoglycans should use a luciferase assay. 
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Figure 3.1 Comparison of plate-based MSF vs. luciferase assays. The growth inhibition A 
of heparin, two low molecular weight heparins B, C (enoxaparin and reviparin) and two marine-
derived glycosaminoglycan fractions D, E (Crab fraction 4 and Prawn fraction 5) in a MSF 
fluorescence (red) and luciferase (blue) assay. The mean ± stdev of n=6 (technical triplicate 
with two biological repeats) are shown for each assay. 
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3.2.2 Generation the NF54luc transgenic parasite 
The development of the Dd2luc strain tested here is described in Wong et al. (2011). Here co-
transfection of a Dd2attB (developed by Nkrumah et al., 2006) with (i) a PΔ1 plasmid with an 
AttP site that also had a luciferase expression cassette and blasticidin C drug selection cassette 
(Blasticidin-S deaminase gene) and (ii) pINT plasmid (Nkrumah et al., 2006) that bears a 
neomycin drug selection cassette and the mycobacteriophage Bxb1 integrase that mediates 
chromosomal integration of PΔ1 by catalysing recombination between incoming attP and the 
chromosomal attB (chromosome 7). 
Also available from Professor Fidock (Columbia University, New York, USA) was a NF54attB 
strain. As well as NF54 having distinct drug resistance phenotypes to Dd2 (see Hasenkamp et 
al., 2013), it also has a distinct erythrocyte invasion phenotype as well. Dd2 is significantly 
dependant on sialic acid on glycophorins – and its invasion of erythrocytes is therefore 
neuraminidase-sensitive, unlike NF54 (Theron et al., 2010). Whilst erythrocyte invasion is 
trypsin sensitive in both strains, Dd2 invasion is not affected by chymotrypsin (Theron et al., 
2010). The NF54 strain offered a second, independent strain to use in assays to monitor invasion 
of erythrocytes by glycosaminoglycans. 
Using the pINT and PΔ1 plasmids, a co-transfection to produce DNA-loaded erythrocytes 
(Hasenkamp et al., 2013) to genetically modify NF54attB was done in duplicate. After three 
attempts, each with duplicate experiments, no recovery of parasites post-drug selection or any 
luciferase signal above background was seen. Also available in the laboratory was a standard 
NF54 strain. It was decided to generate a stable episome parasite NF54 strain by transfection 
using PΔ1 and blasticidin C drug selection alone. Again, using the same DNA preloading into 
erythrocytes transfection protocol, this was done three times, each experiment being done in 
duplicate. The same monitoring of Giemsa-stained thin blood smears and luciferase expression 
was done for at least 30 days in all experiments, but no genetic modification was shown. 
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A revised approach was decided on. It was decided to source the pDC2-CAM-GFP-NC-
hDHFR-rep20 plasmid from Professor Fidock. In this plasmid, there is (i) a green fluorescent 
protein (GFP) expression cassette, (ii) a WR99210 antifolate drug selection cassette (based on 
the human dihydrofolate reductase gene, hDHFR) and (iii) P. falciparum subtelomeric Rep20 
repeats. It has previously been shown that Rep20 play an important role in plasmid segregation 
between two daughters cells and in the maintenance of the episomal plasmid (O’Donnell et al. 
2002). The stage-specific luciferase cassette (pcna 5’UTR-luciferase- pcna 3’UTR) from PΔ1 
can be removed as a ApaI-PstI fragment and used to replace the GFP expression cassette in 
pDC2-CAM-GFP-NC-hDHFR-rep20 see (Figure 3.2). After the subcloning was completed, a 
plasmid (MH3) was identified in a restriction screen as containing the luciferase expression 
cassette in the new pC2 plasmid backbone (Figure 3.3).  
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Figure 3.2 Scheme describing the luciferase cassette subcloning strategy. The stage-specific 
luciferase expression cassette from (A) PΔ1 was removed as a ApaI-PstI fragment and used to 
replace the GFP cassette in (B) pDC2-CAM-GFP-NC-hDHFR-rep20 using the same restriction 
sites. BSD, blasticidin S deaminase; attP/attB are BxbI integrase sites; PCNA, proliferating cell 
nuclear antigen, a DNA replication protein; UTR, untranslated region; CAM, calmodulin 
5’UTR; HSP86, heat shock protein 86; hrp2, histidine-rich protein; hDHFR, human 
dihydrofolate; rep20, P. falciparum subtelomeric repeat 20. 
 
 
 
 
 
 
 
Replace GFP cassette with 
luciferase cassette 
A 
B 
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Figure 3.3 Restriction analysis of MH3. (A) Map of the MH3 plasmid illustrating the relative 
orientation and sizes of the components of this plasmid (PCNA, proliferating cell nuclear 
antigen; UTR, untranslated region; hrp2, histidine-rich protein; hDHFR, human dihydrofolate; 
PcDT, Plasmodium chabaudi DHFR-TS; rep20, P. falciparum subtelomeric repeat 20; AmpR, 
ampicillin resistance) (B) Size fractionated restrictions (see above) of MH3 plasmid to confirm 
the correct structure of the plasmid. The 1kb ladder was sourced from BioLines. 
 
 
 
A 
B 
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Transfection of NF54 with MH3 plasmid was done using the same plasmid-preloading of 
erythrocytes. This was done in duplicate, with a biological repeat of the duplicate approximately 
a week later. After two days, 2.5nM WR99210 selection was applied and monitoring of 
Giemsa-stained thin blood smears and luciferase expression started.  
A thin smear was taken every two days from the four transfections, monitoring for rings to 
show a new reinvasion event and measuring luciferase luminescence. In all four cultures 
(NF54luc1, NF54luc2, NF54luc3, NF54luc4) an increase in luciferase signal above background 
(typically above 200 counts with a background of 50 counts) was found after 23 days post-
transfection (Figure 3.4). Ring stage parasites were seen at the 24th, 25th-day post-transfection 
for NF54luc1 and NF54luc2 respectively. Meanwhile, NF54luc3 and NF54luc4 in the second 
biological repeat had ring-stage parasites observed on the 26th and 29th-day post-transfection, 
respectively (Figure 3.4). At this stage, NF54luc2 and NF54luc4 were stored in liquid nitrogen 
and not investigated any further. NF54luc1 and NF54luc3 were expanded, aliquots stored and 
taken forward to validate the transfectants. 
 
3.2.3 Validation of the NF54luc transgenic parasite 
A series of experiments were carried out to validate the production on a NF54luc transgenic line 
that expresses luciferase from an episomal MH3 plasmid. The first determination was that the 
same trophozoite stage-specific expression was produced from the MH3 plasmid. 
The Pfpcna gene from which the 5’ and 3’ UTR flanking sequences are used in MH3 is 
expressed strongly at the onset of DNA replication, corresponding to mature trophozoites and 
early schizonts (between 26-36 hours post-invasion) (Hasenkamp et al., 2012). There are low 
levels of luciferase expression in rings, early trophozoites and in late schizonts. 
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Figure 3.4. Monitoring of transfections. The luciferase expression level in the transfections 
in the two biological repeats (here A and B) post-transfection are shown. A positive result was 
considered above 200 counts. These all occurred before the first observation of ring stages (red 
symbol) on Giemsa-stained thin smears. 
 
 
 
To confirm the same stage-specific expression, NF54luc1, NF54luc3 and Dd2luc were tightly 
synchronized using sorbitol lysis. Stating with a ring stage culture (approximately 6-10 hours 
post-infection), samples of 2% haematocrit and 2% parasitaemia cultures were maintained at 
37°C with harvests done at early trophozoites (18-24 hours post-infection), mature 
trophozoites/early schizonts (26-36 hours post-infection) and in mature schizonts (after 36 
hours post-infection). Samples for luciferase assays (40µl of 10 ml cultures, done in technical 
triplicate) and Giemsa-stained thin smears (to confirm staging, see Figure 3.5A) were done. 
The experiment was repeated three times for NF54luc1 and NF54luc3 with Dd2luc only done the 
once as this has previously been published (Wong et al., 2011). 
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Figure 3.5 Monitoring stage-specific luciferase expression.  The intraerythrocytic developmentally-linked expression of luciferase was done on 
synchronised parasites (A) for Giemsa-stained images of named parasite stage and the relative light units (RLU) plotted in (B). The bars represent 
the mean signal with whiskers showing the stdev of n=9 measurements in NF54 and n=3 in Ddluc
10 µM 
70 
 
The stage-specific luciferase signal in NF54luc1and NF54luc3 is directly comparable to that with 
Dd2luc (Figure 3.5B). The luciferase levels peak in mature-trophozoites/early schizonts at the 
time when DNA replication commences and is linked to the upregulation of the proliferating 
cell nuclear antigen (Horrocks et al., 1996). Using the same luciferase gene expression cassette 
in NF54 has created the same luciferase expression profile. Interestingly, the stage-specific 
pattern is the same, but the level of expression of luciferase appears different, with the luciferase 
expression from the episomal plasmid(s) in NF54luc1and NF54luc3 higher than that of the 
integrated copy in Dd2luc. 
 
Both NF54luc1 and NF54luc3 were transfected with MH3 plasmid that contains an hDHFR drug 
resistance marker, a gene that confers resistance to the antifolate WR99210. Here we validated 
the transfection by determining in vitro resistance to WR99210 in NF54luc1 and NF54luc3 strains. 
The effect of WR99210 on these two transgenic parasites was determined in vitro using a 48 
hours MSF assay. Corresponding estimates of EC50 data were developed in both transfected 
NF54 parasite strains, in the untransfected NF54 and Dd2luc (which also maintains a copy of 
hDHFR on chromosome 7 (Nkrumah et al., 2006; Wong et al., 2011). The assay was carried 
out using two-fold dilution series in triplicate and as two independent biological repeats (Figure 
3.6) and the EC50 obtained from these log concentration-response curves reported in Table 3.1.  
As expected of the now WR99210 resistant strains, the EC50 in the transgenic NF54
luc1 and 
NF54luc3 is higher than untransfected NF54 parasite (Table 3.1). The mean EC50 of 
untransfected NF54 is 0.056 nM meanwhile NF54luc1 is 49 nM and NF54luc3 15nM and certainly 
similar to that of the WR99210 resistant Dd2luc (35.7nM). Unsurprisingly, the WR99210 
resistance Index (EC50 in transgenic strain/untransfected strain) is high (Table 3.1). 
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Figure 3.6 NF54 transfected with MH3 are more resistant to the antifolate WR99210. 
Log10 concentration-normalised response curves for WR99210 in the indicated parasite lines A, 
B (Dd2luc, NF54), C, D (NF54luc1, NF54luc3 ). Each data point represents the mean with standard 
deviation (n=6). 
 
 
 
 
 
                                 
                                                                                                                                                                                 
A B 
C D 
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Table 3.1: Showing mean EC50 of WR99210 in nM and resistance index (obtained by dividing 
value EC50 of NF54
luc on non-transgenic NF54 parasite). 
 
 
 
 
 
 
 
 
 
NF54luc1 and NF54luc3 both show trophozoite stage-specific luciferase expression and are 
resistant to WR99210 – as is Dd2luc. There is risk of contamination of newly transgenic strains 
with Dd2luc, that could result from the regular use of Dd2luc in most experiments, was tested by 
molecular genotyping over the polymorphic regions of  MSP1 (Merozoite surface protein 1) 
block2, MSP2 (Merozoite Surface Protein 2) block 3 and GLURP (Glutamate-Rich Protein) RII 
repeat region, based on their common use of genetic polymorphisms in malarial 
epidemiological studies (Ridzuan et al. 2016). Total gDNA from NF54 (untransfected strain), 
NF54luc1, NF54luc3 and Dd2luc were isolated using a blood Mini (QIAGEN) kit. Genomic DNA 
from an unrelated strain, HB3, was available in the laboratory. The isolated DNA was analysed 
by genotyping MSP1  block2, MSP2 block 3 and GLURP RII repeated regions using 
oligonucleotide primers (Ridzuan et al. 2016). Approximately 50 ng of DNA used in all PCR 
reactions and the sizes of the PCR products compared by performing gel electrophoresis and 
visualized of Ethidium Bromide stained gels (Figure 3.7). 
 
 
 
Strain Mean EC50 
(nM) 
95 % CI Resistance indexa 
Dd2luc 35.7 24.7-51.5 ND 
NF54 0.056 0.03-0.08 ND 
NF54luc1 49.5 31-78.1 875 
NF54luc3 18.9 17.5-20.4 321 
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Figure 3.7 Genotyping of HB3, Dd2luc, NF54, NF4luc1 and NF54luc3 Size fractionated PCR 
products following amplification over polymorphic regions in (A) MSP1 and Glurp genes and 
(B) MSP2 gene.  
 
 
For all three polymorphic genes, the size of the amplified product was the same for NF54 and 
the derived transfected strains. Whilst there were only small differences in the size of the PCR 
products for NF54 and Dd2 (MSP1) and NF54 and HB3 (MSP2), comparison across all strains 
across all genes shows that Dd2, HB3 and the three NF54 parasite genotypes can be predicted 
from each other. This confirms that the NF54luc1 and NF54luc3 are genetically distinct from 
Dd2luc, but also that they are genetically the same as each other and NF54 at these three gene 
positions. 
 
 
3.2.4 NF54luc transgenic parasites do not appear to lose the reporter plasmid following a 
period of drug-selection removal 
 
To select for potential homologous integration events, episomally transfected parasites are 
usually exposed to the loss of drug-selection (during which the episomal plasmid can become 
lost in the absence of selection) for three weeks and then drug selection reapplied (O’Donnell 
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et al., 2002). With the luciferase reporter being simple to assay, the loss of the luciferase signal 
as the plasmid is lost on the removal of WR99210 can be monitored. Sequences that may act as 
sites of homologous recombination between MH3 and the nuclear genome are Rep20, PCNA 
5’ and 3’ flanking sequences and hrp2 3’ flanking sequence (see Figure 3.3).  
WR99210 selection was removed from NF54luc1 and NF54luc3 and Dd2luc (this is control as the 
hDHFR gene is already integrated and should not be lost). Over a period of 50 days in the 
absence of WR99210, the parasite cultures were synchronised and adjusted to 2% trophozoite 
parasitaemia at 2% HCT and a luciferase assay done (Figure 3.8). 
 
 
 
Figure 3.8: Time-course of luciferase expression following removal of WR99210. 
Luciferase signals in trophozoites of NF54luc1, NF54luc3 and Dd2luc over 50 days.  
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It was expected that in NF54luc1 and NF54luc3 that the luciferase signal would decrease as the 
episomal MH3 plasmid was lost – with the luciferase signal in Dd2luc being relatively constant. 
The data shows that the Dd2luc signal is reasonably constant over the 50 days monitored (Figure 
3.8). The signal for NF54luc1 and NF54luc3 varies dramatically, with this variation probably 
resulting from changes in parasitaemia and the exact life stage selected for the luciferase assay 
– but it does not show the expected loss of luciferase signal over time as the plasmid is lost. An 
EC50 assay was repeated for WR99210 after 50 days of drug selection removal for both NF54
luc1 
and NF54luc3 to monitor WR99210 resistance in these two strains. This concentration-response 
curves (Figure 3.9) and EC50 values determined (Table 3.2) show that both NF54
luc1 and 
NF54luc3 are still WR99210 resistant even after a long period of growth in the absence of drug 
selection pressure.  
 
 
A B 
 
 
Figure 3.9 NF54luc1 andNF54luc3 are resistant to WR99210 after 50 days in the absence of 
selection. Log concentration normalised response curves for NF54luc1 (A) andNF54luc3 (B) 
maintained on WR99210 (red) or after 50 days removal from WR99210 (blue). Mean ± stdev 
(n=6) are shown. 
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Table 3.2: Showing mean and 95% confidence intervals of the EC50 to WR99210 in nM and 
resistance index (obtained by dividing value EC50 determined in these transgenic lines 
compared to non-transgenic NF54 parasite in Table 3.1) b Data from Table 3.1 
 
 
Interestingly, there is a very slight reduction in resistance in NF54luc1 (but with overlapping 
95% CI) and a larger reduction in NF54luc3, the latter EC50 reduced by three-fold (although still 
321 times more resistant than the untransfected NF54) and the 95% CI do not overlap. The 
original stage-specific luciferase expression in NF54luc3 was approximately twice that of 
NF54luc1 (Figure 3.5), suggesting that perhaps there were more episomal copies of MH3 present. 
And, in this period of no drug selection, some, but not all, of the episomal plasmid, was lost. 
 
3.2.5 NF54luc transgenic parasites appear likely to maintain episomal plasmid after 
removal of drug selection pressure 
There may be two explanations here – and they are not necessarily exclusive of each other. The 
first is that whilst the original report that plasmids bearing a Rep20 sequence are lost during 
culture in the absence of drug selection (O’Donnell et al., 2002), this has only been shown in 
this study and may not be true of all plasmids/parasite clones it is placed within. Or, the rate of 
losing the episomal plasmid with a Rep20 sequence is different in different plasmids/parasite 
Strain Mean EC50 (nM) 95% CI Resistance Indexa 
NF54luc1 b 49 31-78.1 875 
NF54luc1off 35 29.8-41.5 625 
NF54luc3 b 18 17.5-20.4 321 
NF54luc3off 62 51.5-77.9 <1000 
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strains. The alternative is that there has been a very rapid and efficient homologous integration 
of MH3 into any of Rep20, PCNA 5’ and 3’ flanking sequences or hrp2 3’ flanking sequences 
in the parasite genome. 
To explore whether there was episomal plasmid present in NF54luc parasites after 50 days of 
drug selection, total genomic DNA was isolated and 100ng of material from NF54luc1 
andNF54luc3 after 50 days drug selection free were transformed into chemically competent 
E.coli and then plated onto ampicillin selection agar plates. In the first attempt, no bacterial 
colonies were observed for either DNA sample. A repeat of the experiment, using the same 
conditions provided only one colony-forming unit using the NF54luc1 parasite DNA. Plasmid 
DNA was prepared from this colony and a restriction of the isolated plasmid done compared to 
that of the original MH3 plasmid prepared for the genetic modification of the parasites (Figure 
3.10). 
 
       
Figure 3.10 Comparative restriction mapping analysis. Gel electrophoresis of restricted (see 
enzyme over respective lane) plasmid isolated from (A) NF54luc1 off WR99210 selection and 
(B) the original MH3 plasmid. Faint bands in (A) are picked out with stars to aid comparison 
with (B). 
 
A B 
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From this restriction digest analysis, it is clear that the rescued MH3 plasmid from NF54luc1 off 
WR99210 is essentially the same as the MH3 plasmid before transfection. This suggests that 
the rescued plasmid is either (i) present episomally in the parasite after removal of the drug 
selection and/or (ii) contamination of the transformation with exogenous MH3 plasmid on 
surfaces in the laboratory. The latter conclusion resulting from the recovery of only one CFU 
after two attempts of E. coli transformation. 
In order to explore further whether NF54luc parasites have integrated MH3 into gDNA, q-PCR 
was exploited to determine the relative quantification of luciferase gene copies present before 
and after the loss of WR99210 selection pressure using the 2-ΔΔCt method. Genomic DNA was 
isolated from NF54luc1, NF54luc3, NF54luc1 off, NF54luc3 off and Dd2luc. The relative quantification 
of a luciferase gene copy number was determined using a Sybr Green I Taqman assay 
(StepOnePlus, Applied Biosystems) using internal standards of P. falciparum β-actin1, 
aldolase and seryl-tRNA synthetase genes. A no DNA template was included in the experiment 
as a negative control. The relative quantification (RQ) of luciferase using the known integrated 
luciferase reporter in Dd2luc was established as 1, with luciferase RQ values in the NF54luc1, 
NF54luc3, NF54luc1 off, NF54luc3 off samples (mean and stdev of n=3 biological repeats) reported 
in Figure 3.11. 
The Relative Quantification of luciferase expression from the different strains was analysed by 
ANOVA (Bonferroni's Multiple Comparison post-test). Here, comparing NF54luc luciferase 
copy number before and after the removal of drug selection showed a loss of luciferase copy 
number as WR99210 was removed. However, the reduction in copy number in NF54luc1 is small 
and not significant. The reduction in copy number is greater in NF54luc3 and is also significant. 
Interestingly, both NF54luc strains after WR99210 removal have a copy number that is close to 
half that of Dd2luc. In the original report for Dd2luc (Wong et al., 2011) the Southern blot analysis 
did suggest that at least two copies of the pΔ1 plasmid had integrated – suggesting that at least 
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one copy of MH3 is present after removal of drug selection, but that this is the minimal required 
to survive drug pressure. 
 
 
Figure 3.11 Quantitative analysis of luciferase copies before and after WR99210 removal 
in NF54luc parasites. Relative quantification (RQ) of luciferase gene expression in the 
parasite lines indicated. The data is the mean (±stdev) from three biological repeats, each of 
three technical repeats. Ns, not significant; ** p<0.001 (Bonferroni's Multiple Comparison 
post-test) 
 
 
To explore if MH3 plasmid has integrated into NF54luc, a Southern blot of restricted genomic 
DNA isolated from NF54luc1 before and after the removal of WR99210. and NF54luc1. As any 
integration site is unknown and MH3 plasmid might be episomal, the restriction enzymes were 
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chosen to frequently cut parasite gDNA (biased in AT content) and had at least one site in MH3 
plasmid (Figure 3.4). gDNA was restricted with  ApaI, KpnI, PstI and EcoRI and the DNA size-
fractionated and southern blotted. PCR, using the biotin-dUTP incorporation method was used 
to prepare a probe to the luciferase gene for hybridization. The assumption was that the 
restriction enzymes ApaI, PstI and EcoRI but not KpnI will hybridise to 8835bp episomal 
plasmid band – with variations from this suggesting the MH3 had integrated. Southern blot 
analysis (Figure 3.12) indicate that ApaI, PstI and KpnI give bands of the expected size (ApaI 
and PstI of 8.8Kbp and KpnI at 8Kbp) for episomes in NF54
luc1 before and after the removal of 
drug selection. The larger bands in PstI and KpnI are probably uncut plasmid. The signal from 
EcoRI is not expected. There is a single EcoRI restriction site in MH3 (Figure 3.4) that was 
confirmed again after this result (data not shown). The presence of a weak luciferase signal at 
about 2Kbp could suggest that (i) there has been an integration event but this is not observable 
using the other three restriction enzymes or (ii) that the MH3 plasmid in the parasite does 
contain a new EcoRI site introduced early after transfection. 
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Figure 3.12 Southern blot analysis of NF54luc1. (A) Ethidium bromide stained gel 
electrophoresis of restricted gDNA, M is DNA marker (B) Southern blot using a biotinylated 
probe to luciferase gene. DNA fragment sizes are indicated in kilobase pairs. 
 
 
3.2.6 Stage-specific inhibition of in vitro growth in NF54luc using heparin 
Previously, we demonstrated that the MSF assay can’t be used to investigate the growth 
inhibition activity of different glycosaminoglycans against the blood stages of P.falciparum. 
We showed that the luciferase activity in Dd2 could report concentration-dependent growth 
inhibition, and we next tested whether the same was true in the new NF54luc strain generated 
here (from this point on, NF54luc is stated – this is NF54luc3). Highly synchronized, 2% 
trophozoite stage of NF54luc and Dd2luc strains, were incubated with three concentration of 
heparin (100, 33 and 11 µg/ml), with technical triplicate and three biological repeats (n=9). 
Growth inhibition was determined over 6 and 48 hours of incubation using the standard 
luciferase-based assay. The luciferase data were normalized against untreated control and a 
mean ± SD of n=9 of normalized growth (%) plotted (Figure 3.13). As expected, there was no 
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cytocidal effect of heparin in the 6 hours of incubation of trophozoites in both strains – heparin 
does not affect maturing trophozoites. But after 48 hours of incubation, and the completion of 
one parasite life cycle, we can see a concentration-dependant effect of heparin, that suggests 
that heparin is acting at the schizont to ring-stage transition into a new host erythrocyte. 
Importantly, there appears to be no difference between the stage-specific and concentration-
specific responses between Dd2luc and NF54luc, indicating we have a luciferase-based reporter 
of glycosaminoglycan inhibitory activity in two distinct genetic backgrounds. 
 
 
Figure 3.13 Stage and concentration-dependant inhibition of parasite growth by heparin 
in Dd2luc and NF54luc.  The proportion of normalised growth (compared to untreated control) 
from a luciferase assay using the strains and heparin concentration as shown after (A) six hours 
of incubation in trophozoites and (B) after 48hrs of incubation of trophozoites. Bars show the 
mean ± stdev of n=9 data 
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3.3 Discussion 
Discovery for future drugs requires reliable, robust and simple methods that can be readily 
adapted for high-throughput screening (Burrows et al., 2014). Antimalarial action in vitro was 
for a long time determined by uptake by the parasite of the radioactive substrates, such as [3H] 
hypoxanthine, to measure parasite viability following drug treatment (Elabbadi et al., 1991). 
Whilst these radioisotope-based assays are reliable and accurate, they rely on expensive 
materials, expensive detection devices and generate radioactive waste. Other alternative growth 
inhibition assays have been developed using (inexpensive) fluorescent-based dyes that 
intercalate into parasite DNA such as  Hoechst 33258 (Smeijsters et al., 1996), 4,6-diamidino-
2-phenylindole (DAPI) ( Baniecki et al., 2007)  and SYBR Green I (Smilkstein et al., 2004; 
Johnson at el., 2007). The latest innovation in assays of parasite growth used genetic 
engineering of the parasite to enable them to express a bioluminescent, usually luciferase, 
reporter and then exploit the sensitivity of this assay is simple but robust assays (Cui et al., 
2008; Sandra Hasenkamp et al., 2013). Fluorescent-based assays have been used to explore 
growth inhibition and invasion blocking activity of heparin and related sulphated GAGs against 
P.falciparum. These assays, however, rely on flow cytometry to count the fluorescently-
labelled infected erythrocytes – a process that requires wash steps, flow on a potentially 
expensive machine. Our initial steps in exploring the production of a plate-based assay with 
heparin, Enoxaparin, Reviparin and refined GAG fractions from Crab (F4) and Prawns (F5) 
revealed issues with GAG-fluorescent dye interactions irrespective of the presence of the 
parasite DNA. The key objective here was to establish whether a simple plate-based assay for 
heparin and other sulphated GAGs could be used based on a luciferase assay – and develop a 
new parasite strain genetically modified to share the same reporter characteristics as the 
available Dd2luc  strain, although in a different genetic background with a known distinct 
invasion phenotype i.e produce NF54luc.  
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I report the generation of a transgenic P.falciparum NF54luc strain that expresses a luciferase 
reporter using the same stage-specific patterning as in Dd2luc. This assay was then validated to 
show that the effect of the heparin on inhibition of parasite growth was both concentration-
dependent and linked to the parasite reinvasion phase at the end of intraerythrocytic 
development. Interestingly, luciferase-based assays have not been previously exploited to 
explore GAGs growth inhibition activity with most studies useing microscopic or flow 
cytometry-based assays as methods to measure growth inhibition activity of GAGs (Rieckmann 
et al., 1978; Boyle.,et al., 2010; Boyle et al., 2017; Marques et al., 2016). This chapter, 
therefore, reports the first use of luciferase-expressing transgenic lines as well as the preparation 
and validation of a new NF54luc strain for this purpose.   
 
The first two approaches used to transfect P.falciparum were unsuccessful. The first approach 
used the pINT and PΔ1 plasmids in a co-transfection using DNA-loaded erythrocytes to 
transfect the NF54attb strain provided by David Fidock’s laboratory. This approach was first 
described by Nkrumah et al., (2006) with the NF54attb strain reported first in Adjalley et al., 
(2010). Use of the bxb1 integrase system to prepare Dd2luc from Dd2attp was described by Wong 
et al., (2011). Despite four repeat transfections (in pairs) no transfectants were recovered. The 
pINT and PΔ1 plasmids were from the same source as the previous study. One potential issue 
considered was that the NF54attb strain had been accidentally mixed with NF54. The Dd2attp 
strain is easy to differ from Dd2 as it is WR99210 resistant due to the hDHFR resistant marker 
cotransfected with the attB site. In the NF54attb strain, the hDHFR selection marker was 
removed after insertion of the attB site and so remains WR99201 sensitive – just like NF54 
(Adjalley et al., 2010). The second approach was to transfect NF54 (obtained from American 
Type Culture Collection ATCC) episomally with the PΔ1 plasmid alone – this plasmid having 
the luciferase gene reporter and BSD selection marker. Again, despite repeated attempts, this 
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approach was unsuccessful too, and no transfectant parasites were recovered even after six 
weeks of post-transfection follow up. This failure led to the revised subcloning of the pcna-
luciferase expression cassette into the new host plasmid strain with the more amenable hDHFR 
drug selection marker and the potential for the Rep20 repeats to support efficient plasmid 
segregation into daughter cells on parasite replication (O’Donnell et al., 2002). Plasmid MH3 
was introduced using DNA-loaded erythrocytes in four separate transfections, and all were 
successful.  
 
In the new transgenic NF54luc parasite, luciferase stage-specific expression was evaluated to be 
equivalent to that of Dd2luc, where the luciferase signal developed from early trophozoite stage 
and peaked at the trophozoite-schizont stages consistent with expression linked to a DNA 
replication protein (Hasenkamp et al., 2012). As a precursor to selecting potentially DNA-
integrated parasite populations for clonal selection, the NF54luc1 and NF54luc3 transgenic lines 
had the WR99210 drug selection removed. The luciferase signal was monitored over the next 
50 days to monitor the reduction in luciferase signal as episomal plasmid is lost in the absence 
of the WR99201 drug pressure. The evidence suggested no real loss in luciferase signal over 
this time and parasites recover at the end of the drug off period were both bioluminescent and 
resistant to WR99201 - NF54lucloff and NF54luc3off still resistance to WR99210 with EC50 of 35 
and 62 nM, respectively. Interestingly, in the only other report of plasmid curing with Rep20 
parasites by O’Donnell et al., (2002), they report a significant loss of episomal plasmid after 
only 20 days. The two Rep20 plasmid constructs are different and this may account for the 
difference in behaviour, although only two reports exist of this behaviour. Follow up with 
Professor Fidock by my supervisor did not help as the Fidock team do not use this plasmid 
construct much or have done plasmid curing experiments. However, to try to understand 
whether the MH3 plasmid DNA was either integrated (and had done so at very high efficiency) 
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or was still episomal, we attempted to recover MH3 plasmid DNA from NF54lucoff into E.coli 
by the transformation of a DNA preparation from the parasite. Two attempts were made, with 
only the second experiment providing a single colony, transformation of  E.coli with DNA 
isolated  from other episomally transfected parasite would provide an appropriate positive 
control to understand how many CFU would grow under these conditions (although this 
positive control was not available at the time of the experiment). Although this was of 
apparently unchanged MH3 plasmid. That only one colony was recovered was not considered 
as evidence of there being episomal plasmid DNA in the parasite as this could also have been 
the result of environmental contamination following the megaprep of MH3 required to give 
enough DNA for the transfection experiments. Quantitative PCR between parasites before and 
after plasmid curing show no significant loss of luciferase copy number in NF54luc1off compared 
to NF54luc1, meanwhile, NF54luc3off plasmid loss compared to NF54luc3 was significant, although 
it may be that NF54luc3 started with high levels of plasmid DNA. Interestingly, both NF54luc 
strains after WR99210 removal have a copy number that is close to half that of Dd2luc where 
Dd2luc has been reported likely by Wong et al. (2011) to have two copies of luciferase integrated 
into chromosome 7. This suggests that at least one copy of MH3 is perhaps present after 
removal of drug selection in both NF54luc1off and NF54luc3off, with this the minimal required to 
survive any following drug pressure. The expectation was that a Southern blot analysis would 
resolve this issue. Analysis of luciferase in NF54luc1 and NF54luc1off strongly suggests MH3 is 
episomal, with restriction enzymes analysis giving either the expected giving plasmid size 
8835bp or another other slower migrating signal that may due to uncut plasmid. With some 
frustration, the presence of a weak luciferase signal at about 2Kbp using EcoRI could also 
suggest that (i) there has been an integration event but this is not observable using the other 
three restriction enzymes or (ii) that the MH3 plasmid after transfection contains a new EcoRI 
site introduced by a mutation event early after transfection.  
87 
 
At this point, we acknowledged that we had generated a NF54luc transgenic parasite resistant to 
WR99210, with the correct stage-specific expression of luciferase and that the NF54luc parasite, 
when used in luciferase assay to test the growth inhibition activity of heparin, showed similar 
concentration-dependent activity to that in Dd2luc. We had therefore delivered on the key aim 
of the research to have a genetically modified strain of NF54 equivalent to Dd2 for our 
screening assays. Further efforts to determine exactly what had happened to MH3 required 
cloning of the strain and likely whole-genome sequencing, with Rep20, pcna and other P. 
falciparum sequences in MH3, there are multiple potential sites for homologous recombination 
for integration and this was not the objective of the study.    
The NF54luc transgenic parasite has, however, been taken further in other research in our 
laboratory. This strain is also chloroquine-sensitive, where Dd2luc is chloroquine-resistant 
(Ullah et al., 2017). Mrs Mufuliat Famodimu is using both NF54luc and Dd2luc in studies of the 
rate of kill of the MMV Malaria Box and TCAMs drug discovery libraries. In addition, the 
potential to re-engineer the MH3 plasmid, particularly as it has been shown to be effective in 
transfection success, to put new stage-specific control sequence around the luciferase reporter 
gene to explore kill action at other developmental stages is interesting. Or, alternatively to use 
MH3 to put the sensitive luciferase viability reporter into new genetic background, eg in 
artemisinin-resistant parasites. 
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Chapter Four: Investigating the erythrocyte invasion-blocking potential of 
Low Molecular Weight Heparins (LMWH) 
 
 
4.1 Introduction 
Low molecular weight heparins (LMWHs) are widely used anticoagulants and comprise of 
heparin fractionated by depolymerizing heparin chemically or enzymatically. LMWHs have 
different clinical applications as anticoagulants and are commonly used as prophylactics for the 
management of venous thrombosis risk that may lead to deep venous thromboembolism during 
a range of surgical procedures (Hirsh et al., 2001). Depolymerisation results in shorter heparin 
fragments with a lower molecular weight (MW), with mean MW, ranged approximately 
between 4000-7000 daltons (Hirsh, Levine MN., 1992), some one-third of the size of heparin.  
Similar to heparin, LMWHs are heterogeneous regarding molecular weight and their 
anticoagulation activity (Gray et al., 2008). Various chemical and acid depolymerization 
methods lead to different LMWHs products, by virtue of where they introduce the break in the 
polysaccharide chain, including leading commercial products such as Tinzaparin, Enoxaparin, 
Reviparin and Dalteparin.  Whilst these LMWHs are distinct from one another and heparin, 
their anticoagulant mechanism of action is similar to heparin. Heparin works as an anticoagulant 
through binding to anti-thrombin (ATIII) using a distinct pentasaccharides motif. This binding 
increases ATIII affinity for Factor Xa and thrombin, sequestering them from the coagulation 
cascade. Whilst there is no dependence of the polysaccharide unit length for Factor Xa binding 
(Figure 4.1), the sequestration of thrombin is dependent on a minimal unit length of 18 
saccharides (Pavao., 2002). For heparin, most of the polysaccharides are at least 18 saccharide 
units or more and are typically 30-50 saccharide units (Köwitsch et al., 2018). LMWHs, 
however, are typically shorter than this 18-saccharide length, which means that whilst a LMWH 
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polysaccharide may contain the pentasaccharide that binds to ATIII, it will only sequester 
Factor Xa and not thrombin (Hirsh, Levine MN., 1992) ( Figure 4.1). This results in a medicine 
that is favoured as an anticoagulant in terms of the route of administration and better-regulated 
kinetics of anticoagulation that does not need as regular a monitoring schedule as is used with 
unfractionated heparin (Warkentin et al.,1995). In addition, the shorter chain lengths of LMWH 
result in a lower affinity of interaction with Platelet Factor 4 (PF4). The formation of a PF4 
tetramer, stabilised by heparin, can lead to the development of autoantibodies to the PF4 
complex that leads to heparin-induced thrombocytopenia (HIT). Therefore, the decreased 
incidence of HIT offers another benefit in the use of LMWH (Walenga et al., 2004). 
Due to differences in how LMWHs are produced, there are differences in their inhibition of 
blood coagulation, that reflects differences in how they affect the binding capacity to factor Xa. 
For example, LMWHs with higher MW tend to inhibit factor IIa (thrombin formation) over 
Factor Xa with LMWHs with lower MW showing a more specific inhibition of Factor Xa 
binding (Thomas et al., 2015). These pharmacokinetic differences are described in the FXa/FIIa 
ratio and are shown here in Table 4.1 (Gerotziafas et al., 2007) 
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Figure 4.1 The difference between (A) heparin and (B) LMWHs mechanism of action and 
their binding ability to coagulation factors (Gerd R. Hetzel & Christoph Sucker, 2005) 
 
 
Table 4.1 Common LMWH anticoagulant, molecular weight and their anti FXa/FIIa, anti 
FXa/FIIa ration (This table reproduced from Thomas, Lybeck et al., 2015).  
 
A 
B 
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Several methods are used to depolymerise unfractionated heparin to LMWH (Gray et al., 2008). 
These include;  (i) nitrous acid and organic nitrite are used to break the heparin chain at N-
sulphated glucosamine residues, leaving a characteristic anhydromannose reducing-end residue 
which is usually reduced to anhydromannitol, (ii) chemical or enzymatic beta-elimination 
method that leaves an unsaturated uronic acid residue at the non-reducing terminus or (iii) 
oxidative depolymerisation, which produces the least specific structure in the resulting product 
(for examples see Table 4.2). 
 
Table 4.2 LMWHs preparation methods (This table reproduce from (Hirsh et al., 2001) 
 
 
An example of how differences in production methods that lead to differences in the chemical 
structure of LMWHs and thus their activity is shown between dalteparin (Fragmin®) and 
tinzaparin (innohep®). Dalteparin is produced by controlled nitrous depolymerization of 
sodium heparin sourced from porcine intestinal mucosa, and yields molecules composed of 
acidic sulphated polysaccharides chains. These polysaccharide chains contain 2,5-anhydro-D-
mannitol residues as end groups. Tinzaparin produced enzymatically by the controlled 
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depolymerization of heparin using heparinase from a bacterial source (Flavobacterium 
heparinum), results in molecules with predominantly 2-O-sulpho-4-enepyranosuronic acid 
structure at the non-reducing end and a 2-N,6-O-disulpho-D-glucosamine structure at the 
reducing end of the chain. These difference in the manufacturing process result in the 
differences in the pharmacokinetic anticoagulation profiles described for these products in 
Table 4.1. 
 
In addition to heparin being used as an anticoagulant, heparin has shown activity by inhibiting 
P.falciparum intraerythrocytic growth in vitro as well as other sulphated glycosaminoglycans 
such as dextran sulphate, which inhibit parasite growth in vitro and in vivo in a mammalian 
mouse model (Boyle et al., 2010). This inhibition is described as being mediated through 
blocking merozoite access to the erythrocyte (Kulane, A. et al., 1992). Further, heparin has also 
been shown in vitro to provide anti-cytoadhesion, rosette disrupting and merozoite invasion 
blocking activity(; (Rowe et al., 1994; Clark, Su, & Davidson, 1997; Barragan et al., 1999) 
Furthermore, heparin have been shown growth and merozoite invasion inhibition activity in 
zoonotic malaria parasite P. Knowlesi (Lyth et al., 2018) and P. berghei (L Xiao et al., 1996).  
 
Heparin possesses not only blood-stage inhibitory activities but also, that heparin and other 
sulphated GAGs have inhibited sporozoite invasion of hepatocytes (Samuel j et al., 1992).  It is 
apparent that heparin, as well as other sulphated GAGs, offer an opportunity to inhibit more 
than one point in the life cycle of more than one Plasmodium spp. These mechanism(s) of 
heparin action are not well understood. P.falciparum growth inhibition by heparin has been 
described (Boyle et al., 2010), where heparin seems to inhibit parasite growth by blocking the 
invasion of erythrocytes by merozoite by inhibiting the first essential step of erythrocyte 
invasion through the merozoite surface protein 1 (MSP1). Thus, in contrast to most other 
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antimalarial drugs, heparin apparently inhibits the extracellular stages of P.falciparum 
development (Danny W. Wilson et al., 2013). Additional research suggests that heparin target 
several merozoite proteins, including the erythrocyte binding protein 140 (EBA-140) 
(Kobayashi et al., 2013) as well as rhoptry and microneme proteins involved in reorientation 
and signalling steps of invasion (Baum et al., 2009). If it is expected that heparin and other 
GAGs inhibit parasite invasion by targeting multiple invasive proteins, this multi-site targeting 
may reduce the possibility of the parasite developing effective resistance to many processes 
simultaneously. This seems to be likely as efforts to generate parasite resistant to heparin in 
vitro were unsuccessful (Boyle et al., 2010).  
Heparin has previously been used as an adjunct therapy to treat patients with severe malaria 
(Smitskamp &Wolthuis 1971; Munir et al., 1980; Rampengan 1991) these trials, however, were 
halted due to the high anticoagulation activity of heparin that led to bleeding. Recently, a low-
anticoagulant LMWH has been developed, sevuparin, which has anti-plasmodial growth 
inhibition activity but lacked anticoagulation activity. Sevuparin is a negatively charged 
polysaccharide derived from heparin with eliminated antithrombin binding (Anna M Leitgeb et 
al., 2017). Sevuparin, like heparin and LMWHs, has an array of chain lengths, with 6-16 units 
of repeated disaccharides of 2-N-sulfo-6-O-sulfo-glucosamine and iduronic-2-O-sulfate acid 
(Figure 4.3) with an average of molecular weight of around 8000 daltons (Telen et al., 2016). 
Unlike heparin and LMWHs, Suviparin has no anticoagulation properties, as the specific 
saccharides sequences required to bind to ATIII have been removed from sevuparin, resulting 
in low levels of binding to anti-IIa and factor Xa (Telen et al., 2016).   
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Figure 4.2 The chemical structure of LMW sevuparin. The polysaccharide consists of 
repeated units of the 2-N-sulfo-6-O-sulfo-glucosamine and iduronic-2-O-sulfate acid 
disaccharide. (Sourced from Telen et al., 2016). 
 
Sevuparin’s properties have been exploited in multiples disorders and disease. In non-infectious 
disease, sevuparin has shown the ability to bind to multiple adhesive legends which are 
responsible for vascular occlusion in sickle cell disease (Telen et al., 2016). This binding leads 
to a reduced adhesion and occlusion of capillary blood flow from cytoadhesive sickle cells 
(White et al., 2019). Whilst the same anti-cytoadhesion efficacy is found using heparin (White 
et al., 2019) and the LMWH Tinzaparin (Telen et al., 2016), sevuparin is a leading  clinical trial 
Phase II drug candidate to treat vaso-occlusion crises (VOC) in sickle cell Interestingly, 
sevuparin also disrupts rosetting formation and cytoadherence of P.falciparum, in vivo studies 
in rats (Saiwaew et al., 2017). In humans, sevuparin has been evaluated in patients with 
uncomplicated malaria, where sevuparin showed a dose-dependent anti-rosetting and anti-
cytoadhesion activity (Saiwaew et al., 2017) and been evaluated recently as an adjunct therapy 
in clinical trial phase I/II (Anna M Leitgeb et al., 2017). 
 
Whilst the intraerythrocytic growth-inhibition activity of heparin and enoxaparin have been 
evaluated, a systematic exploration of this activity across a range of different LMWH has not. 
In this chapter, a systematic side-by-side comparison of the in vitro the growth inhibition and 
erythrocyte invasion-blocking effects of the commercial LMWHs tinzaparin, dalteparin, 
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enoxaparin and reviparin are explored. In addition, using the NF54luc transgenic parasite 
described in the previous chapter, these activities are explored in more than one genetic 
background of P. falciparum. 
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4.2 Results 
4.2.1 Low molecular weight heparins (LMWHs) inhibit intraerythrocytic parasite growth 
in vitro 
Whilst the invasion-blocking potential of heparin has been previously demonstrated (Boyle et 
al., 2010), a systematic and comparative demonstration of the same activity for LMWH has not. 
Four LWMH were commercially sourced; Tinzaparin, Enoxaparin, Deltaparin and Reviparin. 
Their potential in blocking intraerythrocytic growth over one 48hr cycle was determined and 
compared against unfractionated heparin and the structurally unrelated dextran sulphate. Their 
effect on blocking intraerythrocytic growth was each done at three concentrations (100, 33.3 
and 11.1 µg/ml) with their effect normalised against an untreated control (100% growth). The 
experiments were done as technical triplicates in three biological repeats (n=9) using both 
Dd2luc and NF54luc.  Using the luciferase assay, normalized growth was determined and the 
mean ± StDev of n=9 of normalized growth (%) plotted (Figure 4.3). 
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Figure 4.3 Growth inhibition activity of LMWH, dextran sulphate and heparin.  The % 
normalized growth (compared to untreated control) of the indicated compound/concentration 
(see key) against (A) (A) Dd2luc and (B) NF54luc after 48 hours incubation is shown. Bars 
represent mean ± StDev from n=9 experiments.  
 
As expected, there is a concentration-dependent response in growth inhibition for heparin. The 
same is also true for the LMWH and dextran sulphate. Comparison of the data for different 
compounds in Figure 4.3 indicates that dextran sulphate and heparin appear the most potent 
inhibitors of intraerythrocytic growth, followed by the LMWH tinzaparin and dalteparin with 
the least potent inhibition provided by enoxaparin and reviparin. This relative order appears to 
be present in both Dd2luc and NF54luc, suggesting that there is no readily strain-dependent 
difference. To analyse this further, the % normalised growth for each compound at each 
concentration were compared between Dd2luc and NF54luc in a scatterplot and a linear 
regression of the data done (Figure 4.4). 
 
 
                                                   
A B 
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Figure 4.4 Scatterplot correlation of inhibitory effects of LMWH in Dd2luc and NF54luc  
The mean % normalised growth for each compound/concentration in Dd2luc and NF54luc have 
been plotted (see key for concentration data) and a linear regression performed. 
 
The linear regression provides a slope of 1.2 ± 0.17 that suggested that there is a direct linear 
relationship between the effect of each concentration of each compound on the two distinct 
strains. The slight bias to Dd2luc is apparent in Figure 4.4 where the NF54luc normalised growth 
appears to reach a 75% growth irrespective of the concentration used. We consider this is 
unlikely to be a systematic error as we see the effect in three biological repeats, each performed 
using cultures produced on different days. The correlation (r2=0.72) and significance 
(p<0.0001) suggests that these compounds do not apparently show strain-dependent differences 
in their effect.  Of note is that whilst the 100 and 11.1µg/ml data cluster to the left and right of 
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the chart, respectively, that for 33.3 µg/ml shows greater variation. Here, the three most potent 
activities in both strains are recorded for dextran sulphate, heparin and tinzaparin. 
To provide more specific information using the provisional relative ranking of LMWH growth 
inhibition data, serial dilutions (two-fold) were used to do log concentration versus normalised 
growth plots to allow an EC50 of this growth inhibition to be measured. NF54
luc and Dd2luc at 
trophozoite stage (2% parasitaemia, 4% HCT) were collected and incubated with two-fold of 
serial dilution of either LMWHs, heparin or dextran sulphate for 48hr. using the screening data, 
initial concentrations of 300µg/ml were used for the LMWH and 100 µg/ml for heparin and 
dextran sulphate. The experiment was carried out as technical triplicates with three biological 
repeats. Parasite growth was normalized against untreated control and mean ± SD of n=9 of 
normalized growth (%) plotted (Figure 4.5). Using a non-linear regression tool, these graphs 
were used to estimate the EC50 values in both strains along with their 95% confidence intervals 
(Table 4.3). 
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Figure 4.5 Log concentration versus normalised growth plots to determine EC50. Log 
concentration normalized response curves for the indicated LMWH, heparin and dextran 
sulphate in Dd2luc (red) andNF54luc (blue) are shown. Each point represents the mean and StDev 
of n=9 data.  
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Table 4.3 EC50 values of growth inhibition effect of LMWHs in Dd2luc and NF54luc  
 
To correlate the EC50 values for each compound between the two strains, a linear regression 
analysis was performed between the NF54luc and Dd2luc data (Figure 4.6). The slope of 1.13 ± 
0.12 indicates a near 1:1 correlation between the EC50 values in NF54
luc and Dd2luc. The 
correlation is strong (r2 0.95, p=0.0008) and with the EC50 data agreeing with the screening 
data, this establishes a relative order of growth inhibition of heparin > dextran sulphate> 
dalteparin and tinzaparin > enoxaparin and reviparin in both NF54luc and Dd2luc.           
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Figure 4.6 Scatterplot correlation of LMWH, heparin and dextran sulphate EC50 in Dd2luc 
and NF54luc.  The EC50 for each compound in Dd2
luc and NF54luc have been plotted and a linear 
regression performed. 
 
 
4.2.2 Correlating the Luciferase growth assay date with flow cytometry Growth 
Inhibition Assays (GIA) 
In chapter 3 it was shown that a plate-based fluorescence assay of the inhibition of parasite 
growth using heparin or other GAGs did not provide a useful assay. The growth inhibition effect 
of heparin and GAGs has, however, been demonstrated using a flow cytometry assay using 
fluorescent DNA intercalating dyes such as Sybr Green I (Bei et al., 2010 Jin Woo Jang et al., 
2014; Boyle et al., 2017) The limitations of this flow cytometry assay are; (i) the protocol 
requires that samples are collected and washed before and after staining with the dye and is, 
therefore, a more time-consuming process and (ii) this method requires access to a flow 
cytometer and appropriate data analysis software. This equipment demand is balanced in the 
luciferase assay with a need to access to a luminometer, but also a limitation of the luciferase 
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assay is that the assay can only be done using genetically modified strains. However, in moving 
forward with a luciferase-based assay system, I decided to test whether the 48 hr luciferase 
assay data developed for Figure 4.3 for the NF54luc strain correlates with normalised growth 
inhibition data developed using the same compounds and concentrations – but measured on a 
flow cytometer. Here the cultures were set up and exposed in the same way as for the luciferase 
experiment, with three biological repeats done. The starting parasitaemia was reduced to 0.5% 
as the experiment was allowed to proceed over two cycles of parasite growth, with samples 
harvested at both 48hr and 96hr to compare against the 48hr data from the luciferase assay. This 
modification was added as flow cytometry approaches use either 1 or 2 cycles of growth and 
we wanted to evaluate both timepoints here. 
Using the forward scatter versus yellow fluorescence signal of the intact erythrocyte gated 
population, the proportion of Sybr Green I stained (i.e infected) erythrocytes can be measured. 
For each treated culture, this parasitaemia estimate was normalised against the parasitaemia of 
the untreated sample in that biological control series. Three repeats provided for a mean and 
StDev of these three repeats (Figure 4.7) for the 48hr and 96hr flow cytometry assays.  
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Figure 4.7 Growth inhibition activity of LMWH, dextran sulphate and heparin assessed 
by flow cytometry.  The % normalized growth (compared to untreated control) of the indicated 
compound/concentration (see key) at (A) 48hrs and (B) 96 hrs in NF54luc when exposed to the 
indicated concentration of the compound. Bars represent mean ± StDev from n=3 biological 
repeats.    
 
 
To compare these data against the corresponding 48hr luciferase data, regression analyses 
comparing each set of normalised growth inhibition assay (GIA) data for the different 
compounds/concentrations were done (Figure 4.8). This regression analysis shows no real 
difference between the 48hr luciferase GIA data and both of the 48 hr and 96 hr flow cytometry 
GIA data with the slopes and regression constants essentially the same. These data suggest a 
good, but not exact correlation between the growth inhibition data developed using these two 
methods. Correlation between datasets developed using the same approach was proven when 
the 48hr and 96hr flow cytometry GIA data were compared against each other (Figure 4.6C). 
Here the regression provides a tight and significant correlation between the two data sets (slope 
B A 
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of 0.97, r2 of 0.93 and p<0.0001). This is not a 1:1 ratio as the regression line is offset, reflecting 
that after 96hr the degree of growth inhibition provided by these compounds is greater than at 
48hr.  
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Figure 4.8 Exploring the correlation between luciferase and flow cytometry growth 
inhibition assays. Scatterplots correlating the mean normalised growth inhibition of (A) 
luciferase 48 hr versus flow cytometry 48hr, (B) luciferase 48 hr versus flow cytometry 96hr 
and (C) flow cytometry 48 hr versus flow cytometry 96 hr. The parameter reported is indicated 
on each axis and the results of the linear regression indicated. These data were developed only 
using the NF54luc strain. 
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4.2.3 LMWHs inhibit parasite growth by blocking erythrocyte invasion 
Heparin has been shown to inhibit P. falciparum growth by blocking merozoite invasion of a 
new host erythrocyte (Wahlin et al., 1992; Boyle et al., 2010; Recuenco et al., 2014). Following 
the demonstration that LMWH inhibits intraerythrocytic growth in two different strains of the 
parasite with a concentration-dependent effect similar to heparin and dextran sulphate (although 
with higher EC50), the next step was to establish that the inhibition effect of LMWH was 
mediated at the level of erythrocyte rupture and reinvasion. Erythrocyte rupture and invasion is 
typically assessed by exposing a synchronised schizont stage culture to the blocking agent and 
culturing for 18 hrs. The rupture/reinvasion inhibition effect is determined by a microscopic 
examination of a Giemsa stained thin smear to observe newly established ring stage infections. 
A normalized invasion inhibition is then expressed as follows; 
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝑖𝑛𝑣𝑎𝑠𝑖𝑜𝑛 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 (%) = 100 − (
𝐴
𝐵
∗ 100) 
Where A is the mean ring stage count from three biological repeats after exposure to the 
blocking agent and B is the mean from three matched controls with no blocking agent. Dd2luc 
and NF54luc schizont stage cultures were exposed to 300, 100 and 33.3µg/ml of LMWH, 
heparin or dextran sulphate, with three independent biological repeats. The higher starting 
concentrations used in this screen was based on the high EC50 of the LMWH. The mean and 
StDev of the normalised invasion inhibition from three biological repeats (n=3) for each 
concentration of each compound were plotted (Figure 4.9).   
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Figure 4.9 Invasion inhibition assessment of LMWH by microscopy. The mean±StDev 
(n=3) of the normalized invasion inhibition (compared to untreated control) for the indicated 
concentration (see key)/compound in (A) Dd2luc and (B) NF54luc. 
 
From this figure, there appears to be a similar concentration-dependent invasion blocking effect 
in the two parasite strains. To confirm this a regression analysis of the normalised invasion 
inhibition data for each concentration/compound in both NF54luc and Dd2luc were plotted and a 
linear regression done (Figure 4.10). A strong linear correlation was found (r2=0.95 and p< 
0.0001) with a slope of 1.38 ± 0.07. That the slope did not reveal a direct 1:1 comparison is 
likely based on two facts. First, that fixed concentrations of the compounds were tested in the 
two strains, rather than different fold concentrations based on the EC50 data determined, and 
there is a trend (all compounds except heparin) where these compounds have a slightly stronger 
inhibitory effect in NF54luc. Also, secondly, these data are based on manual counting 
observations – requiring a significant amount of time and subject to human error.  
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Figure 4.10: Linear regression analysis of invasion inhibition between NF54luc and Dd2luc 
strain. Each point represents the mean of (n=3). 
 
Visual confirmation that the process of invasion was blocked using the LMWH compounds was 
done by taking samples of culture prior to the preparation of thin smears for light microscopy, 
staining the samples with the fluorescent Sybr Green I dye (primarily stains nucleic acid) and 
observing wet mounts of the culture using a fluorescent microscope. This was done only using 
samples from tinzaparin, dalteparin and heparin at 300 or 100 µg/ml – these compounds and 
concentrations showing the highest invasion blocking activity described in Figure 4.9. 
Interestingly, whilst it would be expected that merozoites would not be readily visible in 
experiments where no ring-stage parasites are observed, it was difficult to observe merozoites. 
In Figure 4.11 images of merozoites adjacent to erythrocytes, and potentially blocked during 
the invasion of erythrocytes, are shown. Given the very low numbers of events observed, and 
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that these fluorescent images could not definitely be indicated as evidence of invasion blocking 
(the merozoite may be laying against the erythrocyte) a more systematic counting was not done. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 Bright field and fluorescent imaging of merozoites following heparin or 
LMWH treatment.  Dd2luc parasites exposed to 300 µg/ml of the indicated compound and 
stained with Sybr Green I fluorescent dye. 
 
 
 
 
Bright field Bright field 
+ Sybr Green 
Tinzaparin 
Dalteparin 
Heparin 
20 µM 
110 
 
4.2.4 Exploring the inhibition of erythrocytic rupture and merozoite release by LMWH 
and heparin   
Recent work by Glushakova et al. (2017) reported during this study identified a second in vitro 
effect of heparin on the inhibition of parasite growth. Their work specifically explored the 
action of heparin in the inhibition of the rupture of the infected erythrocyte membrane and/or 
release and dispersion of merozoites. Either one or both of these effects will prevent the 
invasion of new erythrocytes and establishing a new ring stage infection as shown above. To 
explore this effect, a time course morphological study was started. This time course recognised 
that by only looking at heparin or LMWH treated cultures shortly after the invasion (i.e the 18 
hrs used above) may not allow morphological differences between unruptured, but otherwise 
normal, schizont and a cluster of merozoites trapped inside an erythrocyte to be discriminated 
between. 
As assay strategy was decided that looked at exposing the treated schizont culture for 48hrs, 
with a morphological examination of Giemsa-stained thin smears by light microscopy (Figure 
4.12A). Samples were harvested from a 2% schizont (4% haematocrit) culture treated with 
100µg/ml of each LMWH, heparin or dextran sulphate with an untreated control for 
comparison. At 18hrs, 24 hrs and 48hrs, samples were removed and the proportion of each 
major intraerythrocytic stage (ring, trophozoite and schizont) as well as what are described here 
as “clustered merozoites” determined from counts of 100 infected erythrocytes (see Figure 
4.12B for examples). The merozoite cluster was defined as an erythrocyte sized stained parasite 
material, which does not appear retained in an erythrocyte membrane, which is still associated 
with a darkly stained vesicle (the parasite food vacuole presumably trapped with the clustered 
merozoite). This observation is consistent with the activity of heparin in both inhibiting infected 
erythrocyte rupture as well as the dispersal of merozoites (Glushakova et al., 2017). The 
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experiment was conducted for three independent biological repeats, with the mean and StDev 
of the proportion of these four morphological stages plotted (Figure 4.13).  
 
 
                                   
 
 
 
Figure 4.12 (A) Schematic representing the time course assay. Synchronised schizonts were 
exposed (or left untreated in a control) to 100µg/ml of the compound. The culture was examined 
at 18, 24 and 48hrs. The expected main morphological stage of an untreated culture is shown 
below the time course. Representative Giemsa-stained thin smears for each main morphological 
stage is shown below. (B) Example images representing a clustered merozoite – showing their 
size compared to an erythrocyte, that there is no clear erythrocyte membrane and that they all 
appear with pigmented centre. 
B 
 
A 
10 µM 
10 µM 
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Figure 4.13 Staging of morphological stages following treatment with LMWH, dextran 
sulphate and heparin. The mean proportion ± StDev of each of the main intraerythrocytic 
stage or clustered merozoite is represented (see key). These proportions are based on the counts 
of 100 NF54luc infected erythrocytes/clustered merozoites over (A) 18 HRS, (B) 24hrs, (C) 48 
hrs from three independent experiments. No data (*) is available for dextran sulphate as at 
100µg/ml no reinfection occurred nor were clustered merozoites observed.  
 
A B 
C 
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This experiment provided data distinct to that of the ring stage count. The latter provides an 
indication of the relative inhibition of reinfection – and allowed a ranking of heparin against 
the LMWH to be determined. This time course experiments counts up to 100 infected 
erythrocytes, irrespective of the total number. In fact, for dextran sulphate, at 100µg/ml no 
reinfection occurred in any of the three repeat experiments nor were clustered merozoites 
observed at any time. The control, untreated, cultures show the expected progression from 
predominantly rings at 18hrs to predominantly trophozoites at 24 hrs and predominantly 
schizonts at 48hr. 
As previously reported by Glushakova et al., (2017) who also used NF54 and a concentration 
of 100µg/ml of heparin, they see evidence of the inhibition of erythrocyte rupture and lack of 
merozoite dispersal, creating clustered merozoites. The same observation is observed here. At 
18 hrs, schizonts are most predominant as opposed to rings. This is probably, heparin has dely 
schizont rupture . As you move forward 6 hours, the proportion of merozoite clusters increases 
to a point where about 80% of the observed parasites appear to be merozoite clusters at 48 hrs. 
The same effect does not, however, seem to be evident from the four LMWH. Here, despite our 
observation that at 100µg/ml there is between 40% (Enoxaparin) to 95% (Dalteparin) inhibition 
of reinvasion – compared to 95% inhibition by heparin – there was not readily observed 
merozoite clusters in any treatment using a LMWH. 
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 4.3 Discussion 
Most severe malaria deaths in hospitalized children happen within the first 24 hours (A. M. 
Dondorp et al., 2008) ). In order to provide time for antimalarial therapies to work, research has 
explored the potential for adjunct therapies (eg. steroids, anticonvulsants, monoclonal 
antibodies, volume support, acidosis correction and iron chelation) to support the immediate 
first 24 hours, although these show little or no benefit  (Maitland., 2015). The effect of heparin 
in inhibiting P.falciparum growth by blocking merozoite invasion and the reversal of 
cytoadherence and rosetting as an adjunct therapy have also been explored(Smitskamp 
&Wolthuis 1971; Munir et al., 1980; Rampengan., 1991), although these studies were not 
progressed due to the risk of heparin-induced thrombocytopenia. Given that LMWH retain their 
anticoagulation activity, although with a far less reduced risk of thrombocytopaenia, we have 
explored here the growth inhibitory effect of four common LMWH here, recognising that whilst 
we know LMWH do inhibit intraerythrocytic growth (Boyle et al., 2017), these growth 
inhibition activities have not been systematically characterised, and not beyond one P. 
falciparum strain.  
The LMWHs used in this study showed a concentration-dependent reduction in parasite growth 
in two strains (NF54luc and Dd2luc) in the novel luciferase growth inhibition assay. The 
correlation of inhibitory effects between the two strains tested was good (r2 = 0.72). 
Importantly, whilst this study also provided an estimation of the EC50 for all LMWH in the two 
strains as well as a relative ranking of Dalteparin/Tinzaparin>Enoxiparin/Reviparin, and these 
data are in broad agreement with the provisional evaluation reported by Boyle et al (2017) that 
these are all weakly acting growth inhibitors (EC50 predicted to fall between 20-100µg/ml). 
Taking the EC50 data, adding that of Sevuparin (mean EC50 of 5.2 µg/ml and mean size of 8kDa 
from (Leitgeb et al., 2017), we note that there appears to be a correlation between the size of 
the low molecular weight heparins and their growth inhibitory activity (Table 4.4). 
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Table 4.4. Exploring the relationship between growth inhibition and MW of LMWH, 
heparin and dextran sulphate  
 
 
Whilst there appears a pattern of relationship growth inhibition and MW in the compounds 
reported in this table, Sevuparin sits less well in this rank order - with its growth inhibition 
effect EC50 of 5.2 µg/ml (Leitgeb et al., 2017) more similar to that of an unfractionated heparin 
and being slightly larger (mean size of 8KDa (Telen et al., 2016) from than the LMWH 
Tinzaparin. However, that a growth inhibition effect correlates with the size of a fractionated 
heparin does correlate with data on heparin and other sulphated GAGs length, in rosette 
disturbing (Rogerson et al.,1994;Barragan et al., 1999)  ,cytoadhesion (L Xiao et al.,1996)  and 
blood-stage parasite growth inhibition (Clark, Su, & Davidson, 1997; L Xiao et al., 1996). 
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The capacity of LMWH growth inhibition is not only determined by length but also by 
sulphation degree, where most of LMWH in this study are highly sulphated. Unsurprisingly, 
the correlation between the length of LMWHs and the growth inhibition is agreed with their 
main function as anticoagulants, LMWHs with higher MW are more potent to inhibit Anti-Xa 
factor (Hirsh et al., 2001)  (see table 4.5). 
 
Table 4.5 relationship between MW and anticoagulation activity of heparin fractions * 
 
*Table was adapted from (Hirsh et al., 2001)  
 
Using the ring stage counting assay the stage specificity of the LMWH inhibition was explored. 
As for heparin, the LMWH inhibits growth by interfering with the reinvasion of a new host 
erythrocyte. Our data (Figure 4.9) shows that all the LMWH, including the least potent reviparin 
and enoxaparin, completely block the formation of newly invaded rings at a 300 µg/ml 
concentration. The most potent effect using a 100 µg/ml concentration was that of tinzaparin, 
the largest of the LMWH tested. The correlation between these ring invasion inhibition studies 
in the two strains was high (r2 =0.95) suggesting that invasion blocking via these LMWH is not 
a strain-dependant phenomenon. Although an important qualification of this statement is that 
whilst the two strains tested here do have differences in their erythrocyte invasion phenotype, 
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they are still only two strains and the third strain with a different invasion phenotype would 
support this observation.   
The ring invasion inhibition rank order data correlates well with the luciferase growth inhibition 
rank order assay. That is – heparin > dextran sulphate > tinzaparin/dalteparin > 
enoxaparin/reviparin. This same rank order of effect was observed when we tested the invasion 
blocking data using the flow cytometry assay approach in the NF54luc strain. Importantly, when 
using either the luciferase or flow cytometry assays, the growth inhibition data correlates well 
(r2 =0.8) irrespective of whether the one cycle luciferase data is compared against the one or 
two-cycle flow cytometry data. A comparison between luciferase or flow cytometry growth 
inhibition assay with the ring invasion counting assay done using microscopy shows that each 
method provides relative benefits and issues in the monitoring of the growth inhibition effect 
(see also Table 4.6).   
The luciferase assay, introduced in this thesis, offers advantages in terms of the rapid, robust 
and reliable development of data in a high throughput plate-based assay. The same reliable and 
robust data can be obtained by flow cytometry, but the latter method requires sample processing 
steps and without an automatic loader for the flow device, this is a time-consuming series of 
manual steps. Both methods, however, require specialist equipment, although the luminometer 
is cheaper than most flow cytometers. The most significant issue with the luciferase assay is 
that we can only study strains genetically modified to express the luciferase reporter protein.   
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Table 4.6 Comparison of the growth inhibition assays used in the LMWH study 
 
 
In this study we report that LMWHs have no apparent effect on intraerythrocytic development 
– i.e. they are not cytocidal to trophozoites such as drugs like artemisinin and chloroquine 
(Ullah et al., 2017). The growth-inhibitory effects are apparent after 48 hrs of parasite 
incubation with the LMWHs (Figure 4.3) and more specifically after 18 hrs of incubating 
schizont stage parasite with LMWHs (Figure 4.9). However, most studies related to 
P.falciparum growth inhibition by heparin and/or GAGs have reported that inhibition of 
parasite growth through the blocking the extracellular form of parasite (merozoite) binding to 
the host erythrocyte surface(Boyle et al, 2010; Boyle et al., 2017; Burns et al., 2019; 
Glushakova et al., 2017; Recuenco et al., 2014). During this study, we did observe some free 
merozoites attached to the surface of erythrocytes, but also observed a role for heparin in the 
blocking of parasite egress. Heparin delay schizont rupture, but not LMWHs nor dextran 
sulphate (Figure 4.13) and induced the formation of aberrant, irregular shaped schizonts 
(termed in this study as clustered merozoites) (Figure 4.12.B). These clustered merozoites have 
no clearly defined erythrocyte membrane and appear as parasite-derived material collected 
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around a food vacuole (based on black pigment). This phenomenon was readily observed after 
48 hrs of heparin incubation, suggesting the delayed schizonts were converted into clustered 
merozoites and failed to establish the re-invasion process. Our observation of delay in schizonts 
rupture consistent with several reports (Boyle et al., 2010; Evans et al., 1998; Butcher et al. 
1988). Evans et al., (1998) describes that curdlan sulphate has no effect on intraerythrocytic 
development but does effect schizonts by delaying rupture that the merozoites released failed 
to invade erythrocytes. Whilst these studies describe that heparin blocks merozoite invasion 
and schizonts rupture delay, they do not describe any morphological changes in heparin treated 
parasites. Moreover, many studies exploring the inhibitory effect of heparins release merozoites 
through a mechanical shear and therefore have not explored the action of heparin or other GAGs 
on schizont rupture. Our data suggest that heparin may not only inhibit parasite growth by 
targeting merozoite invasion of erythrocytes but also by blocking schizont rupture and/or 
merozoite egress and separation.  
Notably, this schizont rupture/egress effect was not observed in parasites treated with dextran 
sulphate which showed potent growth inhibition. No aberrant schizonts were seen and suggest 
that the large MW dextran sulphate has no effect in inducing clustered merozoites but is perhaps 
solely inhibiting population growth through inhibition of merozoites invading erythrocytes. 
This suggests that there may be some difference in the mode of inhibition between heparin and 
dextran sulphate and, perhaps, that we need to study different classes of GAGs to explore 
whether there are differences in the growth invasion phenotype at schizont rupture and 
merozoite invasion. 
LMWH did not show the same schizont rupture effect as heparin. LMWH treated parasites 
developed normally, with no delay in schizont rupture observed, and as the growth inhibitory 
effect occurred between the schizont and ring stage, this suggests LMWHs inhibited parasite 
growth solely blocking merozoite invasion of erythrocytes only. This potential difference 
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between LMWHs and heparin may arise a consequence of the reduced chain length in the 
LMWH limiting their capacity to cross-link between merozoites or between merozoites and 
another structure such as the food vacuole or disrupted host erythrocyte surface. Although given 
that LMWH is less potent in inhibiting growth, their effect on blocking schizont rupture may 
only be seen when an appropriate high fold-concentration is achieved. The experiments used a 
fixed concentration of 100 µg/ml over 48 hrs. For heparin, this is 22x EC50, whilst for the 
LMWH this is only1.2-1.5x EC50. At 300 µg/ml, a 3.6 to 4.4x EC50 all LMWHs showed 
complete invasion inhibition with no ring stages observed, however no merozoite cluster was 
seen in all three biological repeats tested. So, whilst it may be that the differences between the 
growth inhibition of heparin and LMWH are affected at different stages of egress and merozoite 
invasion, it is clear that the concentration-dependant inhibitory effects of heparin and LMWH 
at these stages are different. A model for this proposal is provided in Figure 4.14. 
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A B 
C 
Figure 4.14 A proposed model contrasting the mechanism(s) of action of LMWH, 
dextran sulphate and heparin. (A) Untreated parasite schizont (i), Parasitophorus vacuole 
rupture and releases the merozoites into the host erythrocyte (ii) after parasitophorus vacuole 
rupture prior and then the erythrocyte membrane become perforated (iii), merozoites are 
released and become disassociated from the parasite food vacuole (iv)merozoites are free to 
invade a fresh erythrocyte host and establish a ring stage (v). (B) LMWH/Dextran sulphate 
exposed schizonts (concentration of 100 or 300 µg/ml, respectively) show no effect on 
schizont maturation and merozoites egress and release with these compounds apparently 
acting by blocking merozoite invasion so that a new ring stage infection is not established. 
(C) Heparin exposed schizonts (concentration of 100 or 300 µg/ml) delay schizont and 
heparin moves through membrane pores prior to merozoite egress. Heparin prevents 
merozoites separating normally, keeping them associated with the parasite food vacuole with 
a second target of heparin action by blocking merozoite invasion of the new host. 
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The observation described here of heparin blocking schizonts rupture may explained by study 
published recently by Glushakova et al., (2017) (It needs more methods such as live imaging 
microscopy to confirm it). Here they similarly describe the use of a 100 µg/ml concentration of 
heparin effectively blocking merozoite release and their clustering in three different parasite 
strains. The report describes how heparin enters an infected erythrocyte when the host 
erythrocyte plasma membrane perforates (after the rupture of the parasitophorous vacuole 
which is not affected) to block the complete erythrocyte membrane rupture and the trapping 
merozoites within the erythrocyte to prevent their dissemination and finally the formation of a 
clustered merozoites (morphologically-changed infected cell where most merozoite clustered 
within erythrocyte). The mechanism of egress blocking is likely due to heparin-binding with 
the inner aspect of erythrocyte membranes as well as targeting merozoite surface proteins 
organised onto the apical end of the merozoite. Interestingly, our Giemsa-stained heparin-
treated clustered merozoites morphologically appear to be the last stage of the merozoite cluster 
formation, after the complete rupture of the erythrocyte membrane, with the merozoite material 
associated with the remnants of the food vacuole (Glushakova et al., 2017). 
Das et al., (2017) demonstrated that P. falciparum actin-I (PfACTI) is essential and required 
for merozoite segregation during parasite egress. The absence of PfACTI, using a conditional 
knock out system, leads to the failure of merozoite separation and a defect in erythrocyte 
invasion. Interestingly, their Giesma stained images of rapamycin-treated parasites (Figure 
4.15) shows clustered merozoites attached to food vacuole and are seems similar to the heparin-
treated clustered merozoite in this study. Therefore, if we assume that heparin may have blocked 
the function of PfACTI, resulting in a delayed and/or complete loss of merozoite release, it 
would be interesting to explore if heparin interacts or inhibit ACTI protein. 
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Figure 4.15. The similarity in Giemsa-stained images of merozoite clusters in PfACT 
knockout and heparin-treated schizonts (A) PfActI deficiency induced by rapamycin-treated 
parasite with the black arrow indicating the merozoites attached to the food vacuole. (B) NF54luc 
parasite treated with 100 µg/ml of heparin for 48 hrs with the arrows indicate the merozoites 
attached to the food vacuole (image was taken using light microscopy under 100X oil emersion 
magnification). (C) Scanning electron microscopy of rapamycin-treated parasite, showing 
conjugated merozoite. Both A and C Source: (Das at el., 2017) 
 
 
 
10 µM 
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In considering the potential of LMWH as an adjunct therapy based on what we now know on 
their potency, some information on how LMWH is currently used clinically (and therefore 
considered likely to be a safe concentration to use) has been explored here to estimate the 
concentration of LMWHs and compared them to EC50 values from this study. LMWH is used, 
for example, in the treatment and prophylaxis of thromboembolic disease, a specific example 
is the use of enoxaparin in infants and children (Albisett et al., 2001) (See Table 4.7A). Using 
the information about the dose and weight to determine the mass of heparin delivered, and an 
estimating of the total blood volume from an online calculator 
(https://reference.medscape.com/calculator/estimated-blood-volume) an approximate serum 
concentration of heparin (assuming 100% of the LMWH is available to inhibit parasite growth) 
for a series of weights correlating to young children (3000ml) to adults (6000ml) (See Table 
4.7.B). From these simple predictions, it would suggest that safety guidelines for the use of 
LMWH would deliver between 5 to 20µg/ml of LMWH at best conditions. This contrasts with 
the estimated EC50 for the inhibition of parasite growth of between 39.5 to 87.5 µg/ml. 
Therefore, it would appear that we could deliver 0.06-0.5 times the 50% effective concentration 
– much less than an amount that would be expected to support a reduction in parasitaemia in a 
culture that expands logarithmically every 48 hours. Therefore, there appears to be no support 
provided here for the use of LMWH as an adjunct therapy in reducing parasite growth by 
blocking the merozoite release and reinvasion process. Whilst there is a reduced risk of heparin-
induced thrombocytopaenia associated with LMWH, these compounds would need to have an 
increase in anti-plasmodial growth by some 10 to 84-fold (to achieve a potential delivery of a 
5xEC50 dose). 
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Table 4.7 Exploring the potential therapeutic use of LMWH as an anti-plasmodial agent. (A) Treatment and prophylactic doses of enoxaparin 
used for the treatment of thromboembolic disease in infants (3.5to 5 kg (Albisetti et al., 2001). Estimates of blood volume were obtained from 
https://reference.medscape.com/calculator/estimated-blood-volume. (B) The treatment dose of enoxaparin based on weight for child (3000ml) to 
an adult (6375ml) and using a NHS summary prescription guide (2018). The two final columns in both tables provide the best estimate of the 
concentration of LMWH achieved compared to the EC50 of their anti-plasmodial action in the last column. 
A 
 
B 
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Chapter five: Investigation in vitro the growth inhibitory and invasion 
blocking effects of heparin mimetics in P.falciparum  
   
5.1 Introduction 
Resistance in P.falciparum to artemisinin-based combination therapies continue to be reported 
in Southeast Asia (Hati, Das, Roy, & Saha, 2018; Tun et al., 2015), raising concerns that the 
present antimalarial therapies will be soon ineffectual (Amaratunga, et al., 2016). There is a 
necessity to continue to discover a new class of drugs or compounds with different mechanisms 
of action, which are effective against all drug-resistant strains, can clear parasitaemia quickly 
and improve clinical outcomes (Burrows et al., 2017). In addition to these characteristics, any 
new class of compounds should target multiple lifecycle stages that could improve the 
efficiency of the drug and decrease the possibility of the parasite to develop resistance.  
Severe malaria disease symptoms from P.falciparum malaria occur throughout the blood-stage 
infection, where the extracellular form of the parasite (merozoites) invade and then multiply 
inside erythrocytes. The small window of time during which schizonts rupture and release 
merozoites offer a novel target through invasion-blocking inhibitors (Danny W Wilson et al., 
2015). This novelty arises as all current antimalarial drugs work by targeting the parasite within 
erythrocytes (Danny W. Wilson, Christine Langer, Christopher D. Goodman, Geoffrey I. 
McFadden, & James G. Beeson., 2013). The use of a compound that can block merozoite 
invasion, most likely in combination with current or future antimalarial drugs that target the 
intraerythrocytic stage, maybe valuable with this combination maximizing the efficacy of the 
drug, having cidal effects both intra and extracellular.  
During P.falciparum infection, merozoite invades erythrocyte through a multi-step complex 
process, where receptor-ligand interaction involved to mediate the invasion event. Briefly: (i) 
the merozoite makes initial contact of the erythrocyte in a process mediated by merozoites 
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surface proteins (MSPs); (ii) the parasite deform the erythrocyte plasma membrane as it starts 
to move into the new host; (iii) during which the parasite forms a tight junction with erythrocyte; 
(iv) with the parasite forming a parasitophorous vacuole bringing in erythrocyte membrane 
through the action of an actin-myosin motor; (v) with the invasive pore then bonding after the 
parasite invades and enter the erythrocyte (Weiss et al., 2015) . Heparin is known to inhibit 
parasite merozoite invasion (as reviewed in chapter 4) by blocking one of these invasion steps. 
In addition, other sulphated GAGs with invasion inhibitory activities have been identified, 
including sulphated GAGs such as dextran sulphate (Butcher et al., 1988), curdlan sulphate, 
carrageenans, fucosylated chondroitin sulphate, K5 polysaccharides, suramin, polyvinyl 
sulfonate sodium salt, sulphated cyclodextrins, inulin sulphate, xylan sulphate, tragacanth 
sulphate and scleroglucan sulphate (Table 5.1).  
Using heparin as an adjunct therapy is challenging due to its anticoagulation and heparin-
induced thrombocytopenia (HIT) activity.  Work here on LMWH (chapter 4) has shown some 
LMWH inhibit parasite growth in vitro at high concentration (100µg/ml). This low plasmodial 
growth inhibition activity requires higher concentrations to meet a useful clinical therapeutic 
dose. Sevuparin, by contrast, is a low-anticoagulation LMWH that has shown moderately potent 
in vitro invasion blocking activity and has been tested in a clinical trial (Leitgeb et al., 2017), 
although the efficacy of the inhibitors seems less potent in vivo than was perhaps hoped. 
Previous work has also explored the idea that heparin can be chemically modified to increase 
the anti-plasmodial effect and reduce its anticoagulation activity (Boyle et al., 2017). These 
chemical modifications work by modifying the degree of sulphation, or the position of sulphate 
groups, in the heparin L-iduronic acid-D glucosamine dimers and has been shown to impact on 
parasite growth inhibition activity and reduce anticoagulation activity (Boyle et al., 2017).  
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Table 5.1 Diversity of sulphated carbohydrates and heparin mimetics that inhibit parasite 
growth by blocking merozoite invasion into erythrocyte and/or inhibit parasite 
cytoadhesion 
 
Heparin and other sulphated GAGs have also been identified in several studies to disturb 
rosettes and inhibit parasite cytoadherence, including; carrageenans (Adams et al., 2005), 
curdlan sulphate (Havlik et al., 2005; Helen M. Kyriacou et al., 2007), fucosylated chondroitin 
sulphate (Bastos et al., 2014), a synthetic heparin mimetic PI-88 (Yvonne Adams et al., 2006) 
as well as the LMWH sevuparin (Saiwaew et al., 2017). The low anticoagulant heparin DFX232 
also shows rosette disrupting activity in infected erythrocytes isolated from clinical samples 
(Leitgeb et al., 2011). Modified heparin, or their mimetics, offer an opportunity to improve 
chemical inhibition of invasion of erythrocytes – with this anti-plasmodial activity being 
carefully balanced against any anticoagulant or HIT activity. Modifications of heparin and 
sulphated GAGs have been reported to inhibit HIV1 and HIV2 virus invasion (Yoshida et al., 
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1995) and parallels with this antiviral activity and erythrocyte invasion activity has been 
recently reviewed (Burns et al, 2019). Chemically modified heparins and depolymerized 
LMWH derivatives have also been identified to disrupt P.falciparum rosette formation as well 
as having a reduced anti-coagulation activity (Skidmore et al., 2008). The potential for 
chemically modified heparins is of particular interest as they are already known to inhibit and 
reverse cytoadhesion to endothelial cells in vitro and they have reduced anticoagulation activity 
as determined in aPTT and PT assays (Mark A Skidmore et al., 2017). Similarly, chemical 
modification of heparin (although different to those used in the Skidmore et al., 2017 study 
reported above) as well as a panel of sulphated GAGs were also recently shown to inhibit 
merozoite invasion into erythrocyte as well as show a reduced anticoagulant activity compared 
to unfractionated heparin  (Boyle et al., 2017).  
Due to its anticoagulation/HIT risk, as well as concerns of contamination of this animal (porcine 
and bovine) material with prions or viruses, heparin has not been taken further in testing for 
their use as an adjunct therapy. Moreover, contamination of heparin with other sulphated GAGs 
(chondroitin sulphate) and the resulting adverse clinical effects (hypotension, swelling of the 
larynx) have been reported and have been identified as a further limitation of the use of heparin 
(Kishimoto et al., 2008,Viswanathan et al., 2008). An interesting alternative for chemically 
modified heparin is naturally sulphated GAGs isolated from marine sources (termed here as 
marine GAGs) these are often isolated from aquatic invertebrate species and provide a unique 
source of unexploited compounds. Marine GAGs have previously been assessed for their anti-
plasmodial and other medicinal activities. For example, fucosylated chondroitin sulphate, 
isolated from the sea cucumber Acaudina molpadioides has anti-inflammatory effects (Hu et 
al., 2015), a shrimp heparin-like compound isolated from Litopenaeus vannamei also has 
demonstrated anti-inflammatory properties (Brito et al., 2008). Depolymerized fucosylated 
chondroitin also has a virus invasion blocking effect (Huang et al., 2013), as well as a P. 
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falciparum erythrocyte invasion blocking effect, with similar effects noted for GAGs isolated 
from other sea cucumber species Ludwigothurea grisea and Isostichopus badionotus, from the 
red algae Botryocladia occidentalis and from the marine sponge Desmapsamma anchorata 
(Marques et al,. 2016; Bastos et al., 2014). The different sulphation levels in carrageenan 
isolated from seaweeds showed different growth inhibition activities against P.falciparum. 
They consist of three major types kappa (k), lambda (l), and iota (i). These carrageenans inhibit 
merozoite invasion as well as cytoadhesion of P.falciparum in vitro (Adams, Smith, Schwartz-
Albiez, & Andrews, 2005), and reduced parasitaemia in mice infected with Plasmodium 
berghei in vivo, although the treatment with carrageenans did not result in the recovery and 
survival of infected mice (James & Alger., 1981).  
Whilst a range of sulphated GAGs from non-mammalian sources have been identified to inhibit 
parasite growth (see Table 5.1 for examples), a systematic evaluation – particularly when 
compared to other chemically modified or low molecular weight heparin sources has not. One 
related study by Boyle et al., (2017), primarily looking at sulphated GAGs (the materials also 
available for this study) did carry out an evaluation of their effects on growth inhibition, 
although no differentiation between a merozoite clustering or merozoite invasion phenotype 
was assessed in that study. Here we take a range of potential heparin mimetics – chemically 
modified GAGs (including a novel over-sulphated heparin), GAGs from a variety of sources 
that have been sulphated (sulphated GAG) as well as several naturally sulphated GAGs (and 
their fractions) isolated from six marine species. This study sets out to provide a systematic 
evaluation of a range of activities (growth inhibition, anticoagulation, merozoite 
clustering/invasion) in two distinct parasites NF54luc and Dd2luc strains. The objective being a 
recommendation of compounds that would warrant further consideration based on their high 
anti-plasmodial action and low potential anticoagulation risk. Moreover, given that the 
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merozoite clustering phenotype has only been established for heparin, identification of other 
GAGs that elicit this phenotype is another objective of this research. 
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5.2 Results 
5.2.1 Sulphated polysaccharides and chemically modified heparin inhibit P.falciparum 
growth in vitro 
A panel of sulphated glycosaminoglycans, as well as chemically modified heparins, were made 
available by Dr Mark Skidmore of Keele University. The sulphated glycosaminoglycans 
available have been provisionally characterised for their P. falciparum in vitro growth 
inhibition effects (Boyle et al., 2017). In this study here the method for analysis 
(bioluminescence v original flow cytometry), concentrations evaluated (multiple 
concentrations tested here) and different parasites strains were tested. The same Boyle et al. 
(2017) study also explored the P. falciparum in vitro growth inhibition effects for a range of 
chemically modified and size-fractionated heparins – here we report a systemic characterisation 
of sulphation patterns on heparin as well as the inclusion of a novel “over sulphated” chemically 
modified heparin (CMH9). Therefore, a library of sulphated polysaccharides and chemically 
modified heparins have been tested for their growth inhibitory against two parasite strains 
(Dd2luc and NF54luc) over one cycle (48hrs) of growth. Heparin and dextran sulphate were 
included in each experiment for comparison with compounds as both are potent in vitro 
inhibitors of P. falciparum growth. Their effect on growth inhibition was each done at three 
concentrations (100, 33.3 and 11.1 µg/ml) with their effect normalised against an untreated 
control (100% growth). The experiments were done as technical triplicates in three biological 
repeats (n=9). The growth inhibition was determined using a luciferase assay, normalized 
growth was determined and the mean ± StDev of n=9 of normalized growth (%) plotted (Figure 
5.1 and 5.2). 
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Figure 5.1 Growth inhibition activity of chemically modified heparins and other GAGs. 
The % normalized growth (compared to untreated control) of the indicated 
compound/concentration against (see key). (A, C) were done using Dd2luc and (B, D) with 
NF54luc for a 48 hours incubation. Bars represent mean ± StDev from n=9 experiments.  
chemically modified heparin with the following modification: CMH1. Porcine mucosal 
heparin, CMH2. NAc heparin, CMH3. 2-de-O-S heparin, CMH4. 6-de-O-S heparin, CMH5. 2-
de-O-sulfated and N-acetylated, CMH6. 6-de-O-sulfated and N-acetylated, CMH7. 2 and 6 de-
O-sulphated and N-sulphated, CMH8. 2 and 6 de-O-sulphated and N-acetylated, CMH9 over 
sulphated heparin (also I-3 and A-3 sulphated as well as the usual I2S, A6S, NS) 
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Figure 5.2 Growth inhibition activity of different glycosaminoglycans. The % normalized growth (compared to untreated control) of the 
indicated compound/concentration against (see key). (A) using Dd2luc and (B) with NF54luc for a 48 hours incubation. Bars represent mean ± 
StDev from n=9 experiments.
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Some GAGs clearly show a concentration-dependant inhibition in both Dd2luc and NF54luc 
strains; for example, CMH9, as well as sulphated agarose and gellan sulphate, appear to 
demonstrate strong inhibition of in vitro growth. Comparing the different concentration-effect 
for these compounds in Dd2luc and NF54luc provides evidence of similarity of action in both 
strains but also there is a rank order of action for the 37 different compounds tested. In order to 
compare the action of the same compounds in the two strains as well as construct a rank order 
of effect, the growth inhibition effect for all compounds at all concentrations in both strains was 
projected (Figure 5.3) and a Singular Value Decomposition used to provide a principle 
components analysis of this data. Data for the growth inhibitory effect of LMWHs from the 
previous chapter were also included in this analysis to compare their activity. This Singular 
Value Decomposition analysis was performed in Matlab by Professor Peter Andras of Keele 
University. In this analysis, the first principle component (PC1) accounts for 88.8% of all 
variation in the data (PC2 accounts for 8.5% of the data and PC3 the final 2.7% of variance) 
and is taken here as a single value (high values inhibit the strongest) of the concentration-
dependant inhibition of growth to provide for a ranking process for the effect of the compounds 
in the two different strains (Table 5.2) (full table appendix I). Taking the PC1 data for each 
compound in the two strains tested allows for a linear correlation to be explored to test whether 
they show an equivalent effect in the two different strains (Figure 5.4). This correlation shows 
a significant correlation (r2=0.78 and p<0.001) with a slope that suggests a 1:1 correlation 
between the PC1 data for the different compounds in the two strains (slope=1.03 ± 0.09) 
suggesting that their activity in inhibiting growth is not strain-specific.   
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Figure 5.3 Three-dimensional projection of the growth inhibition data for modified 
heparins and sulphated GAGs. Projection show % normalized growth inhibition for each 
concentration of compound used. Blue circled compounds/concentrations are inhibition most 
effectively, whilst those in red are inhibiting less effectively. 
 
Table 5.2 Ranking inhibition activity of compounds according to their PC1 values in Dd2luc and 
NF54luc.  
Rank Strain Compound PC1 Strain Compound PC1 
1 Dd2Luc CMH9 73.2 NF54Luc CMH9 88.9 
2 Dd2Luc Gellan sulphate 63.9 NF54Luc Propylene glycol alginic 
sulphate  
84.9 
3 Dd2Luc Agarose sulphate 62.3 NF54Luc Gellan sulphate 83.9 
4 Dd2Luc K-carrageenan 
sulphate 
55.3 NF54Luc K-carrageenan 
sulphate 
77.5 
5 Dd2Luc Dextran sulphate 51.4 NF54Luc Agarose sulphate 73.2 
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6 Dd2Luc Arabic sulphate 49.8 NF54Luc Arabic sulphate 68.04 
7 Dd2Luc CMH7 48.9 NF54Luc Levan sulphate 63.7 
8 Dd2Luc Propylene glycol alginic 
sulphate  
45.7 NF54Luc Dextran sulphate 60.6 
9 Dd2Luc Heparin 45.07 NF54Luc Tinzaparin 58.9 
10 Dd2Luc Levan sulphate 35.8 NF54Luc Welan sulphate 55.6 
11 Dd2Luc CMH1 35.8 NF54Luc Pullulan sulphate 52.6 
12 Dd2Luc Tinzaparin 33.1 NF54Luc Tara sulphate 52.5 
13 Dd2Luc Welan sulphate 30.5 NF54Luc CMH1 40.3 
14 Dd2Luc Fucogalactan sulphate 26.0 F54Luc Amylose sulphate 40.2 
15 Dd2Luc Gum Mastic 25.9 NF54Luc Heparin 39.8 
16 Dd2Luc CMH4 22.3 NF54Luc Ghatti sulphate 37.6 
17 Dd2Luc Ghatti sulphate 21.06 NF54Luc Dalteparin 33.8 
18 Dd2Luc Pullulan sulphate 20.7 NF54Luc CMH7 30.6 
19 Dd2Luc Amylose sulphate 10.2 NF54Luc Fucogalactan sulphate 29.9 
20 Dd2Luc Xanthan sulphate 9.8 NF54Luc Reviparin 28.3 
21 Dd2Luc CMH2 9.1 NF54Luc Xanthan sulphate 16.6 
22 Dd2Luc Dalteparin -13.6 NF54Luc Enoxaparin 12.7 
23 Dd2Luc (Hydroxypropyl)methyl 
cellulose sulphate 
-20.5 NF54Luc CMH4 0.2 
24 Dd2Luc Arixtra -22.9 NF54Luc Arixtra -10.5 
25 Dd2Luc Pectin sulphate -23.08 NF54Luc Gum Mastic -15.1 
26 Dd2Luc Tara sulphate -24.4 NF54Luc CMH2 -29.4 
27 Dd2Luc Reviparin -31.05 NF54Luc Hypromellose sulphate -33.1 
28 Dd2Luc Hypromellose sulphate -48.08 NF54Luc Pectin sulphate -43.5 
29 Dd2Luc Chondroitin Sulphate A -54.4 NF54Luc CMH3 -45.6 
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30 Dd2Luc Enoxaparin -54.4 NF54Luc Glycogen Type II 
sulphate 
-54.6 
31 Dd2Luc CMH8 -56.8 NF54Luc Locust Bean gum 
sulphate 
-57.8 
32 Dd2Luc Locust Bean gum 
sulphate 
-64.4 NF54Luc Paramylon sulphate -60.1 
33 Dd2Luc CMH3 -64.4 NF54Luc CMH8 -70.8 
34 Dd2Luc Glycogen Type II 
sulphate 
-67.6 NF54Luc Chondroitin Sulphate A -71.3 
35 Dd2Luc Paramylon sulphate -73.8 NF54Luc CMH6 -75.9 
36 Dd2Luc CMH6 -75.7 NF54Luc CMH5 -76.2 
37 Dd2Luc Hyaluronic acid -78.5 NF54Luc (Hydroxypropyl)methyl 
cellulose sulphate 
-76.7 
38 Dd2Luc Chondroitin Sulphate C -81.8 NF54Luc Carboxymethyl 
cellulose sulphate 
-90.2 
39 Dd2Luc Carboxymethyl 
cellulose sulphate 
-96.7 NF54Luc Chondroitin Sulphate C -92.8 
40 Dd2Luc CMH5 -100.5 NF54Luc Hyaluronic acid -103.7 
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Figure 5.4 Correlation in growth inhibition in Dd2luc and NF54luc.  PC1 values for all 
compounds listed in Table 5.2 are plotted for their effect on the two strains tested. A linear 
regression of these data is shown. The red symbols show the data for heparin in the different 
studies performed (heparin is control in all experiments used).
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5.2.2 Determination of EC50 for the most potent inhibitors of growth 
Analysis of the initial screening data using principal component analysis provides for a ranking 
of the most potent inhibitory compounds, ie those with the highest PC1 value. Comparing the 
lists in NF54luc and Dd2luc identifies six compounds that fall in the top eight for both strains. 
These are the over sulphated heparin CMH9 as well as five sulphated GAGs; gellan sulphate, 
agarose sulphate, κ-carrageenan sulphate, Arabic sulphate and propylene glycol alginic 
sulphate. Using serial dilutions (two-fold), a log concentration versus normalised growth plots 
to allow an EC50 of this growth inhibition were done. NF54
luc and Dd2luc at trophozoite stage 
(2% parasitaemia, 4% HCT) were collected and treated with these six compounds for 48hr. The 
experiment was performed as technical triplicates with three biological repeats. Parasite growth 
was normalized against untreated control and mean ± SD of n=9 of normalized growth (%) 
plotted (Figure 5.5). Using non-linear regression analyses, the EC50 values in both parasite 
strains along with their 95% confidence intervals were determined (Table 5.3). 
To explore the correlation between the EC50 values for each inhibitor in the two strains, a linear 
regression analysis was applied between the NF54luc and Dd2luc EC50 data (Figure 5.6). The 
slope of 0.76 ± 0.09 indicates a near 1:1 correlation between the EC50 values in NF54
luc and 
Dd2luc, again supporting that this inhibitory effect is not strain-dependent. The correlation is 
strong and significant (r2=0.94, p<0.0001). The ranking of these EC50 data agree broadly with 
the same ranking order determined from the screening data (Figures 5.1 and 5.2) and creates a 
relative order of growth inhibition of agarose sulphate and CMH9 > κ-carrageenan sulphate and 
propylene glycol alginic sulphate > gellan sulphate and Arabic sulphate in both NF54luc and 
Dd2luc.   
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Figure 5.5 Log concentration versus normalised growth plots to determine EC50. Log 
concentration normalized response curves for the chemically modified heparin (CMH9) and 
sulphated GAGs were determined in Dd2luc (red) andNF54luc (blue). Each point represents the 
mean and StDev of n=9 data 
 
Table 5.3 EC50 of the growth inhibition effect of CMH9 and the sulphated GAGs in 
Dd2luc and NF54luc
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Figure 5.6 Scatterplot exploring the correlation between EC50 of sulphated GAGs and 
CMH9 EC50 in Dd2luc and NF54luc.  The mean EC50 for each compound in Dd2
luc and NF54luc 
are plotted and a linear regression performed. 
 
 
 
5.2.3 Exploring the stage-specificity of growth inhibition by CMH9 and sulphated GAGs 
We have previously demonstrated in chapter 4 that growth inhibition by LMWH was mediated 
at the point of merozoite egress and erythrocyte invasion and, like unfractionated heparin, there 
is no apparent cytocidal effect during the intraerythrocytic growth. The luciferase growth 
inhibition assay, done over 6 hours in trophozoites, offers the opportunity to assess cidality 
during parasite intraerythrocytic development (Ullah et al., 2017). To monitor this for the 
library of chemically modified heparins and sulphated GAGs, fourteen compounds were 
selected (see Figure 5.7) that reflected both highly potent and low potent effect during 48 hrs 
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of parasite growth and any concentration dependant cidality in the trophozoite stage tested. 
Compounds were incubated with trophozoite stage parasite (Dd2luc or NF54luc ) in a three-fold 
series dilution of inhibitors (100, 33.3 and 11.1µg/ml) and incubated with the parasite for 6hr. 
Growth inhibition using luciferase-based assay was determined for three technical and 
biological repeats (n=9). The rapidly acting chloroquine was added at a super-lethal 
concentration (10 µM) to demonstrate trophozoite cidality. Parasite growth was normalized 
against an untreated control and mean ± SD of n=9 of normalized growth (%) plotted (Figure 
5.7). 
 
 
Figure 5.7 Demonstrating the apparent absence of a cytocidal effect of chemically 
modified heparins and sulphated GAGs against the trophozoite intraerythrocytic stage. 
Bars represent mean ± StDev from n=9 determinations of luciferase activity compared to 
untreated control. The key shows the three different concentrations used. CQ is chloroquine at 
10µM concentration. 
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As expected, all the sulphated GAGs and chemically modified heparins, irrespective of whether 
they have potent or lack anti-plasmodial growth inhibition activity all show no apparent 
cytocidal activity against trophozoite stage parasites over 6 hrs. The next step was to establish 
whether the inhibitory effect is mediated at the level of erythrocyte rupture, merozoite release 
and reinvasion. Inhibition at this stage is typically assessed by exposing a synchronised schizont 
stage culture to the inhibitors and culturing for 18 hrs. The rupture/reinvasion inhibition effect 
is determined by a microscopic examination of a Giemsa stained thin smear to observee newly 
established ring stage infections. The same approach used in chapter 4 to assess the percentage 
of invasion inhibition was used here. Dd2luc and NF54luc schizont stage cultures were exposed 
to 100 or 11.1µg/ml of heparin (known control), CMH9, the sulphated GAGs as well as 
(hydroxypropyl) methylcellulose. The latter compound having been shown earlier to have no 
growth inhibitory effect at 100µg/ml (Figure 5.2). The mean and StDev of the normalised 
invasion inhibition from three biological repeats (n=3) for each concentration of each 
compound were plotted (Figure 5.8).   
Comparison of the data from NF54luc and Dd2luc appears to show a similar concentration-
dependent invasion blocking effect in these two parasite strains. As we expect, heparin shows 
an almost complete blocking of invasion at 100µg/ml, with high levels of inhibition still 
apparent at 11.1µg/ml – an observation that agrees with the same control when used in chapter 
4. Similarly, we see no inhibitory effect from (hydroxypropyl) methyl cellulose with ring-stage 
cultures comparable to untreated controls. CMH9 and the sulphated GAGs all showed a 
complete 100% blocking effect at 100µg/ml with some variation in this effect apparent at 
11.1µg/ml. These variations in effect suggest a rank order of invasion inhibition of agarose 
sulphate and CMH9 > propylene glycol alginic sulphate> κ-carrageenan sulphate > gellan sulphate 
and Arabic sulphate in both NF54luc and Dd2luc – a rank order almost identical to their 48hr growth 
inhibitory effect (Section 5.2.2).  
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Figure 5.8 Assessing the effect of CMH9 and sulphated GAGs in blocking the reinvasion 
of erythrocytes. The mean ± StDev (n=3) of the normalized invasion inhibition (compared to 
untreated control) for the indicated concentration (see key)/compound in (A) NF54luc and (B) 
Dd2luc. 
 
To explore the similarity in compound activity in the two strains, a linear regression analysis of 
the normalised invasion inhibition data for 11.1µg/ml in both NF54luc and Dd2luc were plotted 
and a linear regression done (Figure 5.9). Only the 11.1µg/ml data was used as the data for 
100µg/ml was typically 100% and showed little useful variance for this analysis. A strong linear 
correlation was found (r2=0.99 and p< 0.0001) with a slope of 0.99 ± 0.02, again indicating that 
the invasion blocking effect appears non-strain independent. 
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Figure 5.9 Scatterplot correlations of inhibition of erythrocyte reinvasion by CMH9 and 
sulphated GAGs in Dd2luc and NF54luc. The inhibition of erythrocyte reinvasion for each 
compound at 11.1µg/ml in Dd2luc and NF54luc have been plotted and a linear regression 
performed.  
 
 
In chapter four, we investigated the effect of LMWH, dextran sulphate and heparin on schizont 
rupture – showing that only heparin has an effect on schizont rupture and described the 
formation of the clustered merozoite phenotype (Glushakova et al., 2017). Here we investigated 
if the highly potent inhibitors of 48hr growth and erythrocyte reinvasion (CMH9 and the 5 
sulphated GAGs) were similarly capable of forming the clustered merozoites like heparin or if 
there was an absence of these clustered merozoites as seen with dextran sulphate. Agarose 
sulphate, gellan sulphate, propylene glycol alginic sulphate, κ-carrageenan, Arabic sulphate and 
147 
 
CMH9 were tested. In addition, two compounds that show no apparent growth inhibitory effect, 
CMH6 and chondroitin sulphate C (CSC) were tested here. As with the protocol described in 
chapter 4, the count of parasite phenotypes observed over three times points was done – and it 
is important to note that this data represents the proportion of the different stages (ring, 
trophozoites, schizonts and clustered merozoites) observed and not their absolute frequency 
(this being determined using the ring stage assay). Samples were harvested from a 2% schizont 
(4% haematocrit) culture treated with 100µg/ml of each inhibitor with an untreated control for 
comparison. At 18hrs, 24 hrs and 48hrs, samples were removed and the proportion of each 
major intraerythrocytic stage (ring, trophozoite and schizont) as well as what are described here 
as “clustered merozoites” determined from counts of 100 infected erythrocytes. As before, the 
merozoite cluster was defined as an erythrocyte sized stained parasite material, which does not 
appear retained within an erythrocyte membrane, which is still associated with a darkly stained 
vesicle (the parasite food vacuole presumably trapped with the clustered merozoite) (Figure 
5.10 and 5.11). This observation is consistent with the activity of heparin and other strong 
GAGs inhibitors in both inhibiting infected erythrocyte rupture as well as the dispersal of 
merozoites The experiment was conducted as three independent biological repeats, with the 
mean and StDev of the proportion of these four morphological stages plotted (Figure 5.12). 
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Figure 5.10. Example images representing the clustered merozoite phenotype. The 
photograph of a gellan sulphate (100µg/ml) treated NF54luc culture as a Giemsa-stained thin 
smear observed by light microscopy under 100x magnification. A B and C represent close-up 
images of an erythrocyte sized stained parasite material, which does not appear retained within 
an erythrocyte membrane, which is still associated with a darkly stained vesicle – defined here 
as a merozoite cluster. 
 
Figure 5.11 (next two pages) Representative examples of clustered merozoites from 
NF54luc exposed to CMH9 and sulphated GAGs. Photographs of Giemsa-stained thin smears 
taken by light microscope under 100x magnification. (A-H) represent clustered merozoites 
observed on treatment with agarose sulphate, gellan sulphate, propylene glycol alginic sulphate, 
κ-carrageenan, Arabic sulphate, CMH9, unfractionated heparin and a mature schizont from 
untreated control.   
10 µM 
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Figure 5.12 Morphological staging following treatment with CMH9 and sulphated GAGs. 
The mean proportion ± StDev of each of the main intraerythrocytic stage or clustered merozoite 
is represented (see key). These proportions are based on the counts of 100 NF54luc infected 
erythrocytes/clustered merozoites from three independent experiments. Morphological changes 
were monitored over (A) 18 hr, (B) 24 hr and (C) 48 hr. 
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All the potent inhibitors were taken forward show a time-dependent effect in the development 
of the clustered merozoite phenotype – suggesting that their growth inhibition and erythrocyte 
reinvasion blocking effect is most likely a result of the inhibition of the dispersal of free 
merozoites for reinvasion. This phenotype was described previously for heparin by Glushakova 
et al., (2017), and is now shown here for over sulphated heparin and five sulphated GAGs. In 
Figure 5.12, the effect of heparin, as previously reported in chapter 4, was repeated here. there 
is a delay in schizont rupture, with the relative frequency of observed merozoite clusters 
increasing over the next 30 hrs. The untreated control shows the expected progression in 
morphological staging over time, with compounds that show little effect in growth inhibition 
(CMH6 and CSC) showing no apparent effect on parasite morphology (ie appear the same as 
the untreated control). All six of the potent inhibitors taken show an inhibitory effect greater 
than that of heparin – more merozoite clusters are observed and they are observed at higher 
levels than earlier (Figure 5.12) 
After showing that all six compounds apparently inhibit parasite growth by blocking merozoite 
release, we next set out to demonstrate if there is a concentration dependence to this effect. The 
same method described above was used to test the effect of these compound, highly 
synchronized NF54luc and Dd2luc parasites of schizont stage treated with three different 
concentrations (100, 50, and 25 µg/ml) of agarose sulphate, gellan sulphate, propylene glycol 
alginic sulphate, κ-carrageenan, Arabic sulphate and CMH9. The same unfractionated heparin, 
CMH6 and CSC controls were also tested. The effect of these inhibitors was monitored after 
48 hr of incubation, a thin smear being Giemsa stained for treated and a count of the different 
morphological changes (clustered merozoites) and schizonts parasite stages for 100 infected 
cells done. An untreated parasite was also included, with the experiment done as three 
independent biological repeats (n=3), with the mean and StDev of the proportion of these four 
morphological stages plotted (Figure 5.13). 
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Figure 5.13 Concentration-dependent clustered merozoite formation by CMH9 and sulphated GAGs. The mean proportion ± StDev of 
each of the main intraerythrocytic stage or clustered merozoite is represented (see key). These proportions are based on the counts of 100 of 
Dd2luc (A-B) and NF4luc (C-D) infected erythrocytes/clustered merozoites from three independent experiments. CSC, chondroitin sulphate C.
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The control experiments worked as expected. Untreated samples consist entirely of schizont 
stages after 48hr of growth. CMH6 and CSC show no apparent effect on growth and share the 
same exclusive schizont morphology. Heparin shows a concentration-dependent effect, this had 
been suggested from the work in chapter 4 (100 and 300 µg/ml) but is clearly shown here in 
both NF54luc and Dd2luc parasite cultures. The relative proportion of clustered merozoites show 
that there is a similar concentration-dependent effect for agarose sulphate, gellan sulphate, 
propylene glycol alginic sulphate, κ-carrageenan, Arabic sulphate and CMH9 in both NF54luc 
and Dd2luc parasites. Interestingly, the relative proportions suggest the more potent inhibitors 
such as agarose sulphate, propylene glycol alginic sulphate, κ-carrageenan and CMH9 have a 
more potent concentration-dependent effect than do Arabic sulphate and gellan sulphate. These 
latter two compounds have a growth inhibitory EC50 similar to, or greater than, that of the 
unfractionated heparin, with all the other four compounds having a growth inhibitory EC50 less 
than heparin. 
 
5.2.4 Assessing the anticoagulation activity of CMH9 and sulphated GAGs 
Given the known issues associated with heparin’s anticoagulant activity, an evaluation of the 
anticoagulant activity in these six leading candidates was determined. The clotting time of these 
compounds was measured using activated partial thromboplastin time (aPTT) and prothrombin 
time (PT). Briefly, PT is used to evaluate the effect the extrinsic clotting pathway, whereas the 
aPTT instead reports on the effect on the intrinsic clotting pathway. In these assays, human 
plasma was incubated at 37°C with two-fold dilation (starting with100µg/ml) of the compound 
being tested as well as the appropriate aPTT and PT assay substrate. All anticoagulation activity 
in both tests were compared to heparin (with a known anticoagulant activity) and dextran 
sulphate (no known anticoagulant activity). The experiment was conducted as three biological 
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repeats (n=3) with the mean ±stdev of the clotting times being plotted against the concentration 
of the compound tested (Figure 5.14). Separate aPTT and PT data (appendix ii) 
 
 
Figure 5.14 Assessing the anticoagulation activity of CMH9 and sulphated GAGs. Each 
data point represents mean (n=3) biological repeats. All anticoagulation activity of inhibitors 
(see key) was compared to heparin (blue) and dextran sulphate (red). (A and B) PT determined 
up to 60 seconds of incubation and (C and D) aPPT for up to 120 seconds.  
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The normal clotting time of untreated human plasma in a PT assay is 14-18 second and for an 
aPTT it is 40-60 seconds, depending on temperature, source of human serum/reagents. In the 
absence of an anticoagulant activity for an added compound, this clotting time for human serum 
remains unchanged. This is clearly seen for dextran sulphate which has no anticoagulant 
activity. The anticoagulant activity of heparin is evident in the PT assay at or about 25µg/ml as 
the sample does not clot within 60 sec. Similarly, for the aPPT assay, the anticoagulant activity 
at or about 3µg/ml prevents clotting within 120 sec. Analysis of the anticoagulation activity of 
all six inhibitors was reduced compared to heparin in both the PT and aPTT assays. The 
compounds with the highest anticoagulation activity were CMH9 (four-fold reduction 
compared to heparin in PT assay and 8-fold reduction in aPTT) and agarose sulphate (four-fold 
reduction compared to heparin in both aPTT and PT assays). With regards to the extrinsic 
pathway tested in the PT assay, all the remaining compounds showed at least an 8 fold reduction 
in anticoagulation activity compared to heparin, and in the case of Arabic sulphate, propylene 
glycol alginic sulphate and κ-carrageenan, these compounds are much more similar to dextran 
sulphate in the concentrations tested here. Similarly, for the aPTT assay of the intrinsic 
pathway, all the remaining compounds showed at least 8-16 fold reduction in activity compared 
to heparin. Of note, propylene glycol alginic sulphate was again more similar to dextran 
sulphate. What is of particular note here is that whilst for the majority of compounds tested 
here, they would show some anticoagulation activity within 2-4 fold of their EC50 values, 
propylene glycol alginic sulphate would not with assays here showing that addition of 25 times 
their EC50 concentration does not result in any appreciable detection of anticoagulation activity.  
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5.2.5 Initial evaluation of the anti-plasmodial activity of marine-derived 
glycosaminoglycans  
Several opportunities to develop new sources of antimalarial drugs to tackle emerging 
P.flaciparum antimalarial resistance are underway (Klein., 2013). Whilst this chapter has so far 
explored chemically modified heparins and sulphated GAGs, the following section explores the 
potential anti-plasmodial activity of GAGs isolated from a range of marine sources outlined in 
Table 5.4. These materials were isolated and provided for this work by a PhD student Courtney 
Mycroft-West from Dr Skidmore’s team at Keele University. Their potential activity was tested 
here as (i) they represent a potentially valuable waste product from these easily available 
foodstuff marine species, (ii) are novel as whilst some marine GAGs have been tested 
previously for their anti-plasmodial activity (Marques et al., 2016), these have not and (iii) are 
already sulphated and do not need to be chemically modified prior to their testing in P. 
falciparum.  
 
Table 5.4 Marine GAGs tested in this study  
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Crude (non-fractionated) GAGs from each of the six species were provided as an aqueous 
solution at a concentration of 10 mg/ml, incubated with NF43luc parasite at three concentrations 
(100, 33.3 and 11.1 µg/ml) with unfractionated heparin at same concentration included as a 
known control for growth inhibition over 48hr. Growth inhibition was determined and 
normalised against an untreated control (100% growth). The experiments were done as 
technical triplicates in three biological repeats (n=9) with the mean ± StDev of n=9 of 
normalized growth (%) plotted (Figure 5.15). 
 
 
Figure 5.15 Growth inhibition of crude GAGs isolated from marine sources. The % 
normalized growth (compared to an untreated control) of the indicated compound/concentration 
(see key) against NF54luc strain after 48 hours incubation is shown. Bars represent errors of 
mean ± StDev from n=9 experiments.  
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Whilst none of the marine GAG crude extracts were as active as heparin, three of them (Crab, 
Prawn and Squid) showed some concentration-dependent activity, with the remaining not 
showing any activity below 100µg/ml. The three crude marine GAGs samples were fractionated 
by a charge on an ion-exchange column by Courtney Mycroft-West and three to four fractions 
of each provided for the second round of anti-plasmodial action testing. These fractionated 
marine GAGs were tested for their growth inhibition following the same method used above, 
tested at three concentrations (100, 33.3 and 11.1 µg/ml), in NF54luc parasite and for 48 hrs. 
Growth inhibition determined and normalised against an untreated control (100% growth). The 
experiments were conducted as technical triplicates in three biological repeats (n=9) with the 
mean ± StDev of n=9 of normalized growth (%) plotted (Figure 5.15). 
Most of the fractions (F) showed no improvement in activity when compared to the crude 
samples (Figure 5.15). Only Prawn F5, Crab F3 and Crab F4 showed an apparent increase in 
anti-plasmodial activity compared to the original samples – and in all cases, there is >80% of 
growth inhibition at 100 µg/ml. To confirm this initial screening data, and provide an EC50 
concentration of this effect, these three fractions were taken forward for a full concentration-
inhibition assay. NF54luc strain parasites at trophozoite stage (2% parasitaemia, 4% HCT) were 
collected and incubated with two-fold of serial dilution of fractionated mGAGs of (prawn F5, 
crab F3 and crab F4) for 48hr. Based on the screening data, initial concentrations of 100µg/ml 
were used for the marine GAG fractions. The experiment was carried out as technical triplicates 
with three biological repeats. Parasite growth was normalized against untreated control and the 
mean ± SD of n=9 of normalized growth (%) plotted (Figure 5.17). Using a non-linear 
regression tool, these graphs were used to determine the EC50 values along with their 95% 
confidence intervals (Table 5.5). 
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Figure 5.16 Growth inhibition activities of marine GAG fractions. The % normalized 
growth (compared to untreated control) of the indicated compound/concentration (see key) at 
48hrs in NF54luc when exposed to the indicated concentration of compound. Bars represent 
mean ± StDev from n=3 biological repeats.  F is referring to the fraction number 
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 Figure 5.17 Log concentration versus normalised growth plots to determine EC50 of most 
potent marine GAG fractions. Log concentration normalized response curves for the 
indicated marine GAG fractions from(C) prawn and (A, B) crab. Each point represents the 
mean and StDev of n=9 data.  
 
 
Figure 5.5 EC50 growth inhibition values of most potent marine GAG fractions.                                                 
 
A B 
C 
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To explore if these inhibitors inhibit parasite growth in the same way as heparin and other 
sulphated GAGs by blocking merozoite invasion or egress, changes in morphological progress 
on exposure to these fractions was monitored by light microscopy. NF54luc was synchronized 
and collected at schizont stage and incubated in presence or absence (control) with 100 µg/ml 
of prawn F5, Crab F3 and Crab F4 (a concentration known to inhibit parasite growth by at least 
80%) and incubated for 48 hrs. A thin smear of the treated parasite was then stained with 
Giemsa and examined by light microscopy. For all three compounds, and in at least two 
biological repeats, no clustered merozoites were observed. Wet mounts of the treated cultures 
were incubated with the fluorescent Sybr Green I dye and observing using a fluorescent 
microscope. For all three marine GAG fractions, free merozoites or merozoites adjacent to 
erythrocytes, and therefore potentially blocked during the invasion of erythrocytes, were 
observed (Figure 5.18). This would suggest that, at 100 µg/ml, the growth inhibition effect of 
these naturally sulphated marine GAGs is only mediated through merozoite invasion of 
erythrocytes. 
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Figure 5.18 Bright field and fluorescent imaging of merozoites following Prawn F5, Crab 
F3 and Crab F4 treatment.  NF54luc parasite exposed to 100µg/ml of the indicated compounds 
and stained with Sybr Green I fluorescent dye. This example of treated parasite with Prawn F5 
inhibitor and other inhibitors of Crab F3 and Crab F4 showing similar action of blocked 
merozoites. 
 
 
 
10 µM 
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5.3 Discussion 
Blood stage P.falciparum infection is the symptomatic stage of a parasite infection that offers 
a series of advantages for targeting by drugs. The targets for these drugs are either free 
merozoite or merozoites within a permeable erythrocyte with easy access for drugs. The process 
of erythrocyte release and reinvasion of merozoites involves several coordinated processes that 
offer targets in protein-protein interactions, organelle relocation and release, protein 
phosphorylation or processing by protease cleavage as well as the action of an actin-myosin 
motor (Burns et al., 2019). These processes are all essential for continued replication and are 
unique to the parasite offering some potential drug selectivity when compared to the human 
host. Sulphated GAGs have been shown to have a merozoite invasion blocking activity (Boyle 
et al., 2017, Havlik et al., 1994, Bastos et al., 2014). This study extends and develops this 
research by; 
(i) reporting the novel over-sulphated CMH9 has potent anti-plasmodial activities 
(ii) reporting a systematic analysis of the activity of a large panel of chemically 
modified heparins and sulphated GAGs- particularly exploring their stage of activity 
in merozoite release and/or merozoite invasion 
(iii) validating the assay approach devised in chapter 4 using two different genetically 
modified parasite strains 
The effect of chemically modified heparin on erythrocyte invasion has previously been reported 
(Clark et al., 1997; Boyle et al., 2017). This study here includes some of the same chemically 
modified heparins, but uniquely includes over-sulphated heparin where all O- and N- linked 
positions in the L-iduronic acid-D-glucosamine dimer have been sulphated. The data reported 
in this chapter (and summarised in Figure 5.19) indicates that sulphation of the nitrogen in the 
D-glucosamine appears important for the invasion blocking activity of the CMH. This position 
is sulphated in the potent blockers (>80% blocking at 100µg/ml) CMH4, CMH7 and CMH9 – 
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and is, by comparison, acetylated in the least potent blockers CMH3, CMH5, CMH6 and CMH8 
(<20% activity at 100µg/ml). Interestingly, CMH2 lacks the N-sulphation but is O-sulphated at 
position 2 in L-iduronic acid and position 6 of D-glucosamine. All other CMH lacking the N-
sulphation, also have one or both O-positions lacking sulphation. Together these data would 
suggest that, in the invasion assay system used here for Dd2 and NF54, that the degree of 
sulphation, as well as position of sulphate groups, is important in the invasion blocking 
antiplasmodial activity. 
These data broadly agree with the observations of Clark et al., (1997) and Boyle et al., (2017) 
– with both reports using different sources of CMH to those used in this study. Clark et al. 
(1997) reports (i) that LMWH is less potent blockers of erythrocyte invasion and (ii) that de-
sulphation at either N or O-linked (but particularly N-linked) positions reduce the invasion 
blocking activity. Similarly, Boyle et al. (2017) report that low N-sulphation or absent N-
sulphation in several chemically modified heparins reduces their invasion blocking activity. 
This latter report also suggests that de-6-sulphation in D-glucosamine is perhaps the second 
most potent effect in blocking invasion. This would not agree with our data for CMH3 and 
CMH4 – both are N-sulphated, with the 2-sulphation on L-iduronic acid in CMH4 associated 
with more potent blocking activity than the 6-sulphation on Dglucosamine in CMH3. Also, of 
note is the range of strains used in these studies that report the similarity in action of these 
CMH; NF54 and Dd2 (in this study), FCR3 (Clark et al., 1997) and 3D7 and D10 (Boyle et al., 
2017). This would agree with early reports of strain-independent blocking of erythrocyte 
invasion by unfractionated and heparin fractions (Kulane et al., 1992). 
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Figure 5.19 Chemical modification of heparin and their effect on P.falciparum growth 
inhibition and disruption of rosetting. Schematic representing a chemical modification of 
heparin, illustrating the position of sulphate groups on the L-iduronic acid 1-4 D-glucosamine 
dimer. CMH1 Porcine mucosal heparin, CMH2. NAc heparin, CMH3. 2-de-O-S heparin, 
CMH4. 6-de-O-S heparin, CMH5. 2-de-O-sulfated and N-acetylated, CMH6. 6-de-O-sulfated 
and N-acetylated, CMH7. 2 and 6 de-O-sulphated and N-sulphated, CMH8. 2 and 6 de-O-
sulphated and N-acetylated, CMH9. Over sulphated heparin (also I-3 and A-3 sulphated as well 
as the usual I2S, A6S, NS). Invasion blocking here reported as >80% inhibition at 100µg/ml. 
Invasion-blocking 
(this study) 
 
 
 
 
Rosette disruption 
(Barragan et al., 1999)   (Skidmore et al., 2008) 
  
 
 
 
 
 
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The Rosette disruption data are from Barragan et al. (1999) and represent >50% disruption at 
100µg/ml and from Skidmore et al. (2008) and represent >50% disruption at 400µg/ml.  
The same range of CMH has been tested for their effect on rosette disruption (Barragan et al., 
1999; Skidmore et al., 2008). The Barragan study used FCR3S1 and Skidmore et al. used the 
R29 rosetting strain. Their rosette disrupting activity is plotted against the structures of the 
CMH dimers in Figure 5.19.  Interestingly, the absolute requirement for the N-sulphation in D-
glucosamine seen for erythrocyte adhesion is not seen for the rosette disrupting activity, with 
the Skidmore et al., (2008) study suggesting a role for 2-sulphation in L-iduronic acid. Further, 
there seems to be a limited agreement in the strain-dependent activity between these studies, 
with the Barragan et al., (1999) study suggesting that CMH rosette disrupting activity is not 
strain-dependant based on screening of 32 different isolates. This strain-dependency may result 
from the range of PfEMP1 on the IE surface in the different strains tested and the different 
uninfected RBC receptors being used for the rosette formation – distinct to the more restricted 
cell-cell interactions for erythrocyte invasion. 
In this study, we identified a novel modification of over-sulphated CMH9 with modifications 
to I-3 and A-3 as well as the usual I2S, A6S, NS positions. CMH9 shows potent growth 
inhibition in both parasite strains with EC50 in Dd2
luc of 3.8 µg/ml and in NF43luc of 2.4 µg/ml, 
which is better comparing with unmodified heparin. This same over sulphated CMH9 also 
shows a significant potency in disrupting H1N1 virus entry (Skidmore et al., 2015), suggesting 
that an aspect of its activity must reside in the highly negatively charged polymeric structure. 
That being said, charge and size both seem to be important aspects of heparin’s blocking 
activity, although the CMH series investigated here also does suggest that the position of the 
charge is important as well.  
 Because of the concern of heparin causing bleeding due to its high anticoagulation activity, 
some consideration of the anticoagulation activity must be made. This is considered in this 
study here where we show a reduction in CMH anticoagulation activity in both aPTT and PT 
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assays. Using the aPTT data from the Skidmore et al. (2015) study of H1N1 virus blocking 
activity, the PC1 invasion blocking activity for all chemically modified heparins including 
CMH9 in this study are plotted against a fold-change reduction in anticoagulation activity 
(Figure 5.20). 
 
Figure 5.20 Reduced anticoagulation activity of CMH. The fold-change reduction in aPTT 
activity for the CMH (Skidmore et al., 2015) compared to porcine heparin (CMH1) is shown. 
The anti-plasmodial potency of CMH9 and CMH7 (high PC1 value) and reduced 
anticoagulation activity (>150 fold less anticoagulation activity). 
 
An evaluation of the rosette disruption activity and reversal of endothelial adhesion by the over-
sulphated CMH9 should be explored – with the opportunity to identify a compound with 
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reduced anticoagulation activity as well as a range of anti-plasmodial activities. Based on the 
identification that 2-sulphation of L-iduronic acid and 6-sulphation of D glucosamine both 
support rosette disruption and blocking of endothelial adhesion (both occur in unfractionated 
heparin), this would seem to be likely. In addition, however, consideration of activity in platelet 
factor 4 complex formation (ie the start of HIT activity) should be determined using synchrotron 
radiation circular dichroism (Skidmore et al., 2008) will be required to explore conformational 
changes with platelet factor 4. 
In addition, this study determined the activity of a panel of sulphated GAGs from non-
mammalian sources have been tested for their growth and invasion inhibition activity. We 
identified from 22 initial compounds, 5 additional compounds with high invasion-blocking 
activity; gellan sulphate, agarose sulphate, κ-carrageenan, Arabic sulphate and propylene glycol 
alginic sulphate. These chemically sulphated GAGs highlighted their growth inhibition 
performance and agree with previous observations where the sulphation is crucial for GAGs 
inhibition activity. Importantly, all the five tested GAGs were reduced in their anticoagulation 
activity (using the same aPTT data from Skidmore et al., 2015) when compared with 
unmodified heparin (Figure 5.21) – although by only 8 to 10-fold. Interestingly this portrayal 
of the anticoagulation and anti-plasmodial data revealed that there are no compounds in the 
optimal upper right quadrant (high blocking, low anticoagulation). Compounds such as 
carboxymethyl cellulose sulphate or locust bean gum sulphate display excellent reductions in 
anticoagulant activity – although display only minimal invasion blocking activity. 
The inhibitory activity of these five sulphated GAGs was determined to be in the range of 2.5-
10.4 µg/ml. Importantly, these same sulphated GAGs have been reported previously to have 
strong growth inhibition activity against P.falciparum (Boyle et al., 2017). This study, however, 
validated this observation in two additional strains and using a new invasion-blocking assay 
system – and extends the observation that GAGs, when used in invasion blocking assays, appear 
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to act in a strain independent manner. The same range of sulphated GAGs have been tested in 
HUVEC endothelial cell adhesion blocking studies against two IT strains (ItG and A4) and 
shown to have some differences in their blocking activities in both static and flow adhesion 
studies (Skidmore et al., 2017) – again where the cell to cell interactions require the parasite 
PfEMP1 ligand in the interaction.   
 
Figure 5.21 Reduction of the anticoagulation activity of sulphated  GAGs compared to unmodified 
heparin (PMH).  The fold-change reduction in aPTT activity for the CMH (Skidmore et al., 2015) 
compared to heparin (dotted line) is shown. The anti-plasmodial potency of the sulphated GAGs 
tested in this study are shown in Dd2luc and NF54luc (see key). 
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In addition to the reports in Boyle et al. (2017), gellan sulphate, κ-carrageenan, Arabic sulphate, 
and propylene glycol alginic sulphate have been tested elsewhere for their invasion blocking 
activity (Recuenco et al., 2014; Adams et al., 2005). Interestingly, the activity of these inhibitors 
varied in these studies. The sulphated κ-carrageenan in this study exhibited growth inhibition 
activity similar to that by Boyle et al., (2017), both studies used the same source, but previous 
work reported by Recuenco et al., (2014) describes that over-sulphated κ -carrageenan does not 
inhibit erythrocyte invasion and in  another study by  Adams et al. (2005), κ -carrageenan 
inhibits Dd2 invasion but not that of 3D7. It seems these variations may relate to the degree of 
sulphation of the GAG. However this is not as simple as increasing the overall sulphation level, 
the κ –carrageenan in Recuenco et al., (2014) was sulphated at 70% of all possible positions, 
meanwhile, gellan sulphate in the same study did block erythrocyte invasion and was sulphated 
at  37% of all positions by comparison. This seems to suggest that there may be different effects 
in different GAGs tested here that may correlate to optimal sulphation levels – rather than just 
high sulphation levels. It would, therefore, be of interest to further explore the effect of 
sulphation levels in the five GAGs tested here – particularly to see if this changes their 
anticoagulation activity – or, take the compounds like carboxymethylcellulose sulphate with 
low anticoagulation activity and explore whether the invasion blocking activity can be altered 
with different levels of sulphation.  
Of note, given the earlier observations that some CMH act to disrupt rosettes, but do not block 
invasion, some of the sulphated GAGs tested in this study (Glycogen sulphate type II, Arabic 
sulphate, hydroxypropyl methylcellulose and paramylon sulphate) have been  identified as 
blocking infected erythrocyte cytodhesion to HUVEC endothelial have been shown here ( 
except Arabic sulphate) to have weak (>20% inhibition at 100 µg/ml) or no inhibitory activity 
against the two parasite strains tested here. This again raises the issue of whether a single 
sulphated GAGs may be suitable to block or reverse the invasion, rosetting and cytoadhesion 
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phenotypes of infected erythrocytes in any potential adjunct therapy, or whether mixes need to 
be considered.   
Of note is variation in the structures (and sources) of the sulphated compounds tested in this 
study (Table 5.6). The variety of sources of the most active sulphated GAGs (seaweed, algae, 
bacteria and plant) reflect the full diversity of the sources for all the compounds selected in this 
study. Moreover, the structures of the most active compounds reflect simpler repeating 
disaccharide units (eg. propylene glycol alginate) to very complex branched and variably 
modified scaffolds (eg. gum Arabic) – reinforcing a developing message that how sulphate units 
are organised on these scaffolds is likely important in the activity of the sulphated GAGs over 
their non-sulphated starting material. 
 
Table 5.6 Structural composition and sources of sulphated GAGs in this study 
Compound  Structural composition Source  
-Carrageenan (1-3)-β-D-galactose (G unit) - (1-4)-- 
3,6-anhydroD-galactose (A unit) 
Seaweed 
Gellan sulphate Glc residues, one glucuronic 
acid (GlcA), and one rhamnose (Rha) 
residue: [3-β-D-Glcp-(1- 
4)-β-D-GlcpA-(1-4)-β-D-Glcp-(1-4)-
-L-Rhap-(1-] 
Bacterial 
Propylene glycol alginic 
sulphate 
β-D-mannuronic acid and α-L-
guluronic acid 
Marine algae  
Agarose 1,3-linked β-D-galactose 
and 1,4-linked 3,6-anhydro-α-L-
galactose. 
Chemical 
synthesis  
Gum arabic Gum arabic is a complex and variable 
mixture of arabinogalactan 
oligosaccharides, polysaccharides, and 
glycoproteins. They are mainly 
formed by chains of 3,6-linked β-D-
Galactopyranose substituted in 
position 6 by side chains of 3-linked 
α-L-arabinofuranose 
Plant 
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Dextran sulphate  -1,6-D-glucose with two OSO3Na 
moieties on each glucose ring  
Bacterial 
Pullulan α-(1 → 6)-linked (1 → 4)-α-D-
triglucosides 
Fungal 
Welan A variably modified tetrasaccharide 
repeating unit of β-D-Glcp(1-4)-β-D-
GlcA-(1-4)-β-D-Glcp-(1-4)--L-
Rhap-(1) 
Bacterial 
Locust bean gum (14)-linked β-D-mannopyranose 
backbone with branch points from 
their 6-positions linked to α-D-
galactose (that is, 16-linked α-D-
galactopyranose) 
Plant 
Gum ghatti Complex and variably substituted structure that 
consists of L-arabinose, D-galactose, D-
mannose, 
D-xylose, and D-glucuronic acid in a 
48:29:10:5:10 molar ratio  
Plant 
Levan Fructan polymer composed of 𝛽(2→6)-linked 
fructose residues 
Bacterial 
Tara gum Galactomannan polysaccharides, consisting 
of a linear main chain of (1-4)-β-D-
mannopyranose units attached by (1–6) 
linkage with -D-galactopyranose units 
Plant 
Amylose Monosaccharide of D-glucose molecules 
joined together with a D-(1–4) or a D-(1–6) 
linkage 
Plant 
Hyaluronic acid Repeating disaccharide structure [(1→3)-β-
dGlcNAc-(1→4)-β-d-GlcA-] 
Animal 
Carboxymethyl 
cellulose 
Carboxymethyl substituted β (1→4)-linked 
glucopyranose residues 
Chemical 
modified  
Paramylon β-1,3 polymer of glucose Algal 
Pectin Complex polysaccharides that contain 1,4-
linked α-Dgalactosyluronic residues 
Plant 
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We show here that all of the potent invasion inhibitors (CMH9, gellan sulphate, agarose 
sulphate, κ-carrageenan, Arabic sulphate, propylene glycol alginic sulphate) are not cytocidal 
to intraerythrocytic stages of the life cycle – such as the effect of drugs like artemisinin and 
chloroquine to trophozoites (Ullah et al., 2017). The invasion blocking data indicated that the 
inhibition occurred within 18 hrs of incubation of trophozoites with inhibitors – with the 
blocking of invasion apparent with the decrease in new ring-stage parasites. Like for heparin 
(Glushakova et al., 2017), we report here the first description of other sulphated GAGs capable 
of producing the clustered merozoite phenotype indicating that at least some part of their action 
is in blocking the release of free merozoites. Here we define clustered merozoites as having no 
clearly defined erythrocyte membrane and appear as parasite-derived material collected around 
a food vacuole. The inhibition phenotype with these six compounds starts 18 hrs post-treatment, 
notably with a delay in schizonts rupture and is consistent with other descriptions of the 
inhibition using some of these compounds (Boyle et al., 2010; Evans et al., 1998; Butcher et al. 
1988). Of note is that whilst these studies note the invasion inhibition (often defined as no 
reinvasion by merozoites), these and other studies (Recuenco et al.,2014;  Adams et al., 2005; 
Boyle et al., 2017) do not describe merozoite clusters as defined here or by Glushakova et al., 
(2017). Our data based on the morphological similarity of the merozoite clusters produced by 
all these compounds is that they would work in the same way as heparin – that being primarily 
in blocking merozoite dispersal and then in blocking the invasion of merozoites into new 
Xanthan gum Variably modified β-(1-4)-D-glucopyranose 
glucan (as cellulose) backbone with side chains 
of -(31)-α-linked D-mannopyranose-(21)-β-D-
glucuronic acid-(41)-β-D-mannopyranose on 
alternating residues.  
Bacterial 
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erythrocytes. Infected erythrocyte schizonts stage become leaky prior to egress (Lyon et al., 
1997), presumably allowing the sulphated GAGs to penetrate through parasite-derived pores. 
When inside the erythrocyte, these compounds likely interact with the inner aspect of 
erythrocyte membrane and merozoite surface proteins resulting prevent merozoite dispersal. 
Glushakova et el.,(2017), reported that heparin has a high affinity to egress proteins such as 
MSP-1, where MSP-1 is suggested to interact with erythrocyte cytoskeleton component of 
spectrin in acting to disturb the cell membrane integrity and release from erythrocyte (Das at 
el., 2015). The clustered merozoites induced by the sulphated GAGs are also morphologically 
similar to those produced when antibodies that inhibit merozoite surface proteins and induce 
immune clusters merozoites (ICM) are added (Lyon et al., 1989, 1997). Corresponding with an 
evolving hypothesis of heparin acting to induce merozoite cluster formation (discussed in 
chapter 4 discussion) we may also assume that these sulphated GAGs may block the function 
of PfACTI, resulting in merozoite dispersal prevention. 
The formation of the clustered merozoites is seen here using the most potent sulphated GAG 
and CMH9. It is also shown here for the first time that the formation of the clustered merozoite 
phenotype is concentration-dependant. What has yet to be worked out is whether these 
compounds are potent because they form merozoite clusters as part of their mechanism of action 
or whether all sulphated GAGs can form the merozoite cluster when enough of the compound 
is available. Looking for merozoite clusters across a wider range of the compounds tested in 
this study may help – we only did the morphological assessment of the most active compounds 
and a small number of low potency controls (CMH6 and chondroitin sulphate C). Of note, 
however, is that whilst dextran sulphate has reasonable anti-plasmodial potency, no merozoite 
clusters are observed. The potential for these compounds to explore the merozoite clustered 
phenotype is discussed further in chapter 6. 
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Naturally sulphated GAGs from marine sources have become increasingly popular for 
investigations of their anti-pathogenic activity and for their medical applications. For example, 
fucosylated chondroitin sulphate extracted from sea cucumber (Adams et al., 2005) has shown 
anti-plasmodial activity. That these compounds could be made available as a product of the 
food industry (high-value waste product) and that they are naturally sulphated and therefore no 
additional (and expensive) chemical modifications would be required to sulphate them, we 
initiated a pilot study to test these GAGs from animal marine source for their potential anti-
plasmodial activity. Prawn F5, Crab F5 and Crab F4 fractions proved to have moderate to low 
anti-plasmodial activity, with EC50 ranging between 16.3-58.7 µg/ml, all being less potent than 
heparin (9.5µg/ml). The anticoagulation activity of these mGAGs (Table 5.7) were made 
available by Courtney Mycroft-West of the Skidmore research group. 
 
Table 5.7 aPTT EC50 values for best marine GAG fractions (Data provided by Courtney 
Mycroft-West ) 
 
Whilst the marine GAG fractions have reduced (18.5-30 fold) anticoagulation activity 
compared to heparin in the aPTT assays – the absolute aPTT EC50 values are in the same range 
as the anti-plasmodial activity – suggesting that some anticoagulation activity would be 
observed when the required anti-plasmodial concentrations of >60 µg/ml would be used in any 
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therapy approach. Whilst there are some opportunities from naturally sulphated GAGs, the data 
offered in this pilot study suggest that they are unlikely to be available from these materials. 
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Chapter Six:  Overall discussion and perspectives 
 
In this study, we have reported the screening and characterization of the P.falciparum 
erythrocytic stage invasion-blocking phenotype of a range of naturally occurring and synthetic 
sulphated GAGS. This work has identified six sulphated GAGs with greater antiplasmodial 
activity and reduced anticoagulation to unfractionated heparin. Further, with structural 
variations and changes to the sulphation patterns of CMH9 compared to heparin, all will 
unlikely cause heparin-induced thrombocytopenia. As discussed in chapters four and five 
though is that whilst these properties are promising, they do need to be improved. For example, 
sevuparin was shown in Phase I trials to be tolerated well by adult males and can be given as 
360mg every 6 hours (Leitgeb et al., 2017). This is noted to be similar to similar doses using 
LMWH for adults, and would therefore necessarily be of the order of 40-80mg in young 
children (1.5mg/kg; see chapter 4). This would, for all the six compounds described, provide a 
maximum of a 2 to 8-fold EC50 concentration assuming a 100% distribution. With evidence 
that sevuparin at 3mg/kg, and having an in vitro erythrocyte invasion inhibition effect in the 
same range at 5.2µg/ml, has only a minimal effect on the clinical trial – and little beyond that 
of the control arm of the study – this would suggest that none of these six compounds are likely 
useful hits to take to in vivo or clinical studies. Moreover, malaria infection induced 
thrombocytopaenia in the face of high concentrations of inhibitors may increase the risk of 
haemorrhage.  
These six compounds did, however, show an interesting invasion blocking phenotype. 
Glushakova et al., (2017) have recently described the effect of unfractionated heparin on 
merozoite egress using a range of imaging methodology. Heparin appears to gain access to the 
infected erythrocyte during a multistep egress process following parasitophorous vacuole 
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rupture but before rupture of the erythrocyte plasma membrane – likely through pores created 
as an early step in this process. The access of heparin at this point is likely at the final step of 
the 48hr life cycle. Fluorescently labelled heparin binds to targets on the inside of the infected 
erythrocytes and on the surface of merozoites (likely MSP1) (Glushakova et al., 2017) and this 
appears to delay the plasma membrane rupture. In addition, heparin also interferes with the 
release of free merozoites – resulting in the merozoite cluster (Figure 6.1) – preventing 
reinvasion by preventing free merozoites being available to bind to the surface of new 
uninfected erythrocytes.  
 
 
 
 
 
 
Figure 6.1 Confocal light microscopy of P.falciparum NF54 strain exposed to with heparin 
illustrating the merozoite cluster (Source: Glushakova et al.,2017) 
 
Except for this study, no additional reports describing the merozoite cluster have been made. 
This study extensively describes this phenotype based on the multiple timepoint imaging 
studies and does so for a range of new compounds – all that have invasion blocking potency 
greater than heparin. The absence of previous descriptions may be due to most studies reporting 
the blocking effect after one time point (L Xiao et al.,1996; Clark, Su, & Davidsonl., 1997;  
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Boyle et al., 2010; Recuenco et al., 2014 Boyle et al., 2017) or that in studies of heparin blocking 
invasion they typically mechanically rupture the merozoites from mature schizonts (Holder et 
al., 1992; Blackman and Holder, 1992). These studies indicate that heparin or mimetics of 
heparin block the initial contact and apical reorientation of the merozoite (Boyle et al., 2010, 
reviewed in Burns et al., 2017) and therefore likely interact with several targets. These, along 
with the multiple intraerythrocytic targets for heparin described by Glushakova et al. (2017) is 
interesting as it suggests that resistance to heparin (or heparin mimetic) invasion-blocking effect 
would be less likely to develop resistance. 
The six compounds identified here offer a range of chemical probes to further study the cell 
biology of merozoite egress. Much like imadazopyridazines (inhibitors of protein kinase G, 
PfPKG;( Dvorin et al., 2010, Baker et al., 2017) have shown the importance of release of the 
protease subtilisin in priming merozoite release, these compounds could be used in imaging 
studies (fluorescently labelled compounds, real-time imaging studies etc) to explore the final 
stages of merozoite release. Given the recent demonstration for a role in actin I in merozoite 
dispersal (Das et al., 2017) and the availability of inducible-knockdown lines, these provide the 
second source of parasites to study with these compounds. Interesting, previous studies (from 
2012) in our laboratory, using three sulphated GAGs (including Arabic sulphate) explored their 
effect on erythrocyte invasion in enzyme-treated erythrocytes (neuraminidase, trypsin or 
chymotrypsin) using a two-colour flow cytometry assay (Theron et al., 2010). These studies 
provided some preliminary evidence that Arabic sulphate inhibition of invasion was not 
affected by any treatment, but that by sulphated glycogen was mediated through a 
chymotrypsin-sensitive invasion process. This research offers another interesting route in using 
the six sulphated GAGs as research tools in the investigation of erythrocyte invasion. 
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To develop the next generation of heparin mimetics either to study merozoite invasion and 
egress or as an adjunct therapy, key lessons were learnt as part of this study. First, the size 
(MW) of the mimetic is important. Work described here for the LMWH is an example of this 
effect in erythrocyte invasion – with this work correlating generally with previous work 
reported by Boyle et al. (2010 and 2017). Size is not everything however, chondroitin sulphate 
C is a large sulphated GAG and has low invasion blocking activity – but this does lead on to 
the next lesson, sulphation is important and where it is sulphated appears important.  
Chondroitin sulphate C lacks N-sulphation, shown in this study and in data in Boyle et al. (2017) 
when looking at different CMH to be important in blocking invasion. Variations for some of 
the sulphated GAGs, and the apparent absence of merozoite clusters using the highly sulphated 
dextran sulphate, in our study and previous reports also suggests that the optimum level of 
sulphation may be different for different GAG structures. Investigating this will be hard. It will 
require varied sulphating of a range of GAGs, with each then having its anti-plasmodial activity 
recorded (luciferase assay and potentially imaging study). An opportunity to simplify this 
approach is available based on work by a PhD colleague, Anthony Devlin, in the Skidmore 
laboratory. His research is exploring how Attenuated Total Reflectance Fourier Transformed 
Infrared Spectroscopy (ATR-FTIR) can be used to detect and quantify different types of bond 
vibrations which allows for the description of structures such as N and O-sulphation (Devlin et 
al., deposited in BioRxiv). By generating ATR-FTIR spectra for a large number of GAGs 
(Figure 6.2A) the information about the peaks (vibrations of different bonds within the 
molecule) position and height can be captured and analysed by principal components analysis 
(Figure 6.2B). In this figure – the first two PC separate out common GAGs by their structural 
component (types of glycosidic bonds) as well as the presence of 2-O-sulphated, 6-O-sulphated 
and N-sulphated components. This same approach has been used to analyse many of the CMH 
and sulphated GAGs libraries used in chapter five. Plotting the first three PC in a 3D plot 
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distributes the compounds (Figure 6.3). This data provides an interesting start. First, three very 
low potent compounds cluster in a space together (MS5; Hydroxypropyl methyl cellulose 
sulphate; MS14; pectin sulphate; MS15, gum mastic sulphate). If this ATR-FTIR library were 
expanded, and the method is designed for high throughput screening and other compounds   
 
Figure 6.2 ATR-FTIR of sulphated GAGs. (A) FTIR spectra of porcine (PMH) and ovine 
(OMH) mucosal heparin compared to dermatan sulphate (DS). (B) PCA of transformed spectra 
with PC1 and PC2 providing a 2D separation of common GAG structures by glycosidic bond 
and sulphation pattern (Source: Devlin et al., 2019 submitted to bioRxiv). 
 
fell into this space – then these may not be of interest as they share spectral features typical of 
low potency compounds. Using mass spectroscopy or nuclear magnetic resonance, the 
structures within these low potency compounds could be identified and excluded in future 
searches. The data for the more potent compounds is less clear.  CMH9, agarose sulphate,  
Arabic sulphate and propylene glycol alginic sulphate are distributed across space – and while 
it may be that being positioned higher in the space is important, CMH7 clusters more closely 
A B 
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with low potency CMH. Larger libraries and exploring other PC (there are 16 of them) may 
provide a screen for potential compounds to test as well as a means to look for common 
substructures in potent heparin mimetics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Principle components analysis of ATR-FITR of CMH and sulphated GAGs. 3D 
plot of compounds PC1 to PC3 data. Compounds highlighted in orange arrows are potent 
inhibitors (CMH7 and 9; MS 27, agarose sulphate; MS29, Arabic sulphate; MS60 propylene 
glycol alginic sulphate). Compounds with a blue arrow are not potent (MS5, Hydroxypropyl 
methyl cellulose sulphate; MS14; pectin sulphate; MS15, gum mastic sulphate). 
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The Sevuparin phase I/IIa trial showed how a low anticoagulation low molecular weight heparin 
could be employed in a trial to demonstrate safety and initial efficacy. Sevuparin was tolerated 
well in adult males and also showed a significant but short-lived blocking of reinvasion and de-
sequestration, when compared to the control arm of the trial (Leitgeb et al., 2017) Sevuparin in 
the phase IIa trail, was used in combination with atovaquone and proguanil (Malanil) and 
compared to atovaquone and proguanil alone. This was done as the rapid onset of artemisinin 
combination therapy was considered likely to obscure the reinvasion phenotype being 
measured. There was no significant difference in the trail arms on blocking of reinvasion and 
de-sequestration after 8 hours - where parasite clearance time in both groups were similar (53 
hrs in sevuparin/drug and 51 hrs in drug), the parasitaemia reduction over 24 or 48 hrs were 
similar, with sevuparin/drug (24 hrs - 87.44%, 48hrs -99.96%) and drug alone (24hrs -84.64%, 
48 hrs -99.78%). It would seem that even the slower acting atovaquone and proguanil would 
mask any additional protective effect of the Sevuparin. This is important when we think about 
how clinical trials for heparin mimetic adjunct therapies would be designed. Any adjunct 
therapy would have to be as safe as and more clinically effective than the current treatment for 
it to be considered for future use – and the current frontline treatment for malaria are the 
artemisinin combination therapies. In addition, the adjunct therapy would be of real value for 
severe malaria, where it is needed to offset the immediate life-threatening pathology to allow 
the drug time to reduce the parasite burden and reduce the development of additional pathology. 
Severe malaria is mainly associated with young children and understanding how to do a trial of 
heparin mimetic in children with severe malaria would be very difficult. The previous trials of 
heparin did so at a time when the leading antimalarials (aminoquinolines and antifolates) were 
failing and thus the standard of care was low – this is not true currently with the artemisinin 
combination therapies.  
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Perhaps one route forward for heparin mimetics as an adjunct therapy is if they are not first 
considered to be used as a drug that blocks erythrocyte invasion or disrupting resetting or de-
sequestering infected erythrocytes. Instead, the potential for heparin or a heparin mimetic in 
reducing histone-mediated coagulation and vascular leakage in cerebral malaria could be where 
new opportunities arise. Cerebral malaria is linked to infected erythrocytes sequestering in the 
microvessels of the brain (Taylor et al., 2014), with localised coagulopathy and leak of fluid 
from the blood into the brain that can lead to brain swelling. A recent report (Moxon et al, 
prerelease in bioRxiv) links these effects to the presence of histones (Figure 6.4) released either 
from sequestered parasites or from damaged endothelium.  
 
Figure 6.4 Histone staining of brain microvessel endothelium. (A) Histone staining (red) of 
a cerebral malaria case. The black arrows show staining of the internal face of the blood vessel. 
The large red puncta are human cells, with the white arrows showing the multiple small red 
puncta of infected erythrocytes sequestered within the brain micro blood vessel. (B) Sample 
from a non cerebral malaria case does not show staining of the epithelium of the blood vessel 
or sequestered infected erythrocytes (Source: Moxon et al. 
www.biorxiv.org/content/biorxiv/early/2019/03/20/563551.full.pdf). 
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Histones have previously been linked with other inflammatory conditions, eg. sepsis 
(Wildhagen et al., 2014), where treatment with an antithrombin affinity-depleted heparin (low 
anticoagulation) offers protection from more serious complications (and death). This principle 
was also shown in the Moxon et al. study, where a non-anticoagulant heparin (N-acetylated to 
remove the key N-sulphation on D Glucosamine used at 200 µg/ml) prevented histone-mediated 
toxicity of a cultured human brain microvascular endothelial cell line and protected it from 
leakage (Moxon et al., prerelease in bioRxiv). Whilst this demonstrates the potential for non-
anticoagulant heparin as a potential therapy – the current concentration evaluated for human 
brain microvascular endothelial cell lines is likely a 10-fold higher concentration that could 
likely be safely delivered to a child. Demonstrating that there is a concentration-dependent 
effect and that the concentration of the heparin/heparin mimetic could be greatly reduced and 
still be effective would be useful. This suggests further research to gain a greater understanding 
of what aspects of heparin, chemically modified heparin or sulphated GAGs could contribute 
to binding plasma histones away so that they do not cause endothelial pathology. Testing 
sulphated GAG binding to histones could be rapidly screened in surface plasmon resonance 
assays, with this screening supported by the ATR-FTIR to look for important structural features, 
with the potency of the sequestering effect tested in vitro using human brain microvascular 
endothelial cell lines to monitor cell death and their barrier function against leakage. There is a 
mouse model for cerebral malaria – using P. berghei infection of certain mouse lines (White et 
al., 2010), although its use would have to be initially tested as the pathology of this cerebral 
model doesn’t require infected erythrocyte sequestration in the brain. Importantly, moving into 
a human trial would need to consider how to safely and effectively evaluate a potent histone-
binding mimetic in conjunction with a rapid-acting combination therapy drug. 
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GAG Strain % Mean normalized growth 
when exposed to the following 
concentration of GAG (ug/ml) 
  PC1   Strain % Mean normalized growth 
when exposed to the following 
concentration of GAG (ug/ml) 
  PC1 
    100.0 33.3 11.1         100.0 33.3 11.1     
Ghatti sulphate Dd2luc 8.9 61.7 84.3 
 
21.1 
 
NF54luc 1.8 45.4 79.9 
 
37.6 
(Hydroxypropyl)methyl cellulose sulphate Dd2luc 66.1 69.2 73.1   -20.5   NF54luc 98.5 106.5 103.1   -76.7 
Gellan sulphate Dd2luc 0.7 8.3 72.1 
 
63.9 
 
NF54luc 1.2 1.3 24.3 
 
83.9 
Xanthan sulphate Dd2luc 20.0 67.4 83.6   9.9   NF54luc 14.7 64.9 79.5   16.6 
Locust Bean Gum sulphate Dd2luc 98.4 91.9 93.7 
 
-64.4 
 
NF54luc 84.6 95.1 97.5 
 
-57.9 
Pectin sulphate Dd2luc 39.1 85.3 108.5   -23.1   NF54luc 75.2 84.8 93.8   -43.6 
Gum Mastic Dd2luc 17.0 53.9 67.0 
 
26.0 
 
NF54luc 33.3 82.2 102.9 
 
-15.1 
Carboxymethyl cellulose sulphate Dd2luc 115.0 115.8 110.9   -96.8   NF54luc 112.8 111.1 104.9   -90.3 
Agarose sulphate Dd2luc 0.3 11.3 72.1 
 
62.4 
 
NF54luc 1.2 3.4 52.1 
 
73.3 
Arabic sulphate Dd2luc 0.7 22.0 88.9   49.9   NF54luc 1.0 7.1 61.3   68.0 
Amylose sulphate Dd2luc 10.3 73.9 91.2 
 
10.3 
 
NF54luc 1.4 47.3 69.6 
 
40.2 
Hypromellose sulphate Dd2luc 70.4 95.0 98.8   -48.1   NF54luc 64.9 79.3 94.7   -33.1 
Glycogen Type II sulphate Dd2luc 95.0 98.0 99.2 
 
-67.6 
 
NF54luc 82.9 94.2 93.2 
 
-54.6 
Pullulan sulphate Dd2luc 17.1 48.9 91.5   20.7   NF54luc 1.7 28.8 66.0   52.7 
Levan sulphate Dd2luc 2.7 35.6 101.5 
 
35.9 
 
NF54luc 1.5 11.6 64.7 
 
63.8 
Paramylon sulphate Dd2luc 101.0 100.0 101.3   -73.8   NF54luc 82.8 97.2 104.4   -60.2 
Fucogalactan sulphate Dd2luc 17.8 43.6 83.9 
 
26.0 
 
NF54luc 2.2 57.0 80.8 
 
30.0 
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K-carrageenan Dd2luc 11.9 18.0 56.1   55.3   NF54luc 1.2 2.8 40.6   77.5 
Welan sulphate Dd2luc 1.2 55.3 84.1 
 
30.5 
 
NF54luc 1.0 29.3 57.5 
 
55.7 
Propylene glycol alginic sulphate Dd2luc 14.0 19.9 76.6   45.8   NF54luc 0.8 1.4 21.9   84.9 
Tara sulphate Dd2luc 30.2 92.8 117.9 
 
-24.5 
 
NF54luc 1.1 37.4 51.6 
 
52.6 
DEXTRAN sulphate Dd2luc 11.4 30.4 46.0   51.4   NF54luc 0.5 14.2 71.4   60.7 
Chondroitin Sulphate A Dd2luc 86.8 89.9 92.2 
 
-54.4 
 
NF54luc 98.3 91.3 115.7 
 
-71.3 
Chondroitin Sulphate C Dd2luc 108.0 100.3 109.7   -81.8   NF54luc 119.3 103.7 112.4   -92.9 
Hyaluronic acid Dd2luc 97.2 110.3 104.5 
 
-78.6 
 
NF54luc 110.8 126.9 120.2 
 
-103.7 
Heparin Dd2luc 4.9 37.4 87.3   37.9   NF54luc 7.9 42.6 67.9   39.1 
CMH1 Dd2luc 16.0 34.2 75.8 
 
35.9 
 
NF54luc 8.8 39.1 68.6 
 
40.4 
CMH2 Dd2luc 27.0 60.2 84.3   9.2   NF54luc 58.2 84.3 88.8   -29.5 
CMH3 Dd2luc 89.0 100.6 97.7 
 
-64.5 
 
NF54luc 76.3 86.3 94.8 
 
-45.6 
CMH4 Dd2luc 8.2 45.4 112.0   22.4   NF54luc 36.4 65.4 81.2   0.2 
CMH5 Dd2luc 117.5 116.0 116.4 
 
-100.5 
 
NF54luc 100.0 104.7 101.8 
 
-76.2 
CMH6 Dd2luc 102.6 103.0 98.2   -75.7   NF54luc 101.6 102.5 101.6   -75.9 
CMH7 Dd2luc 12.3 30.6 51.1 
 
48.9 
 
NF54luc 12.2 53.0 64.8 
 
30.7 
CMH8 Dd2luc 81.9 95.7 99.0   -56.8   NF54luc 91.8 105.8 101.1   -70.8 
CMH9 Dd2luc 0.3 2.5 55.9 
 
73.3 
 
NF54luc 0.2 0.2 13.3 
 
88.9 
Heparin Dd2luc 3.6 32.5 77.8   45.1   NF54luc 7.9 42.6 67.9   39.1 
ARIXTRA Dd2luc 18.3 110.5 106.2 
 
-23.0 
 
NF54luc 26.4 87.3 94.5 
 
-10.6 
218 
 
REVAPARIN Dd2luc 52.9 93.4 88.1   -31.1   NF54luc 11.5 56.2 67.2   28.4 
ENOXAPARIN Dd2luc 65.1 108.8 103.7 
 
-54.5 
 
NF54luc 21.3 67.3 72.5 
 
12.7 
TINZAPARIN Dd2luc 1.3 50.3 85.4   33.2   NF54luc 0.3 24.8 57.5   58.9 
DALTEPARIN Dd2luc 23.1 89.8 106.0 
 
-13.6 
 
NF54luc 7.5 51.9 67.4 
 
33.8 
Heparin Dd2luc 4.9 37.4 87.3   37.9   NF54luc 7.9 42.6 67.9   39.1 
219 
 
 PT 
 
  
220 
 
 
aPTT
 221 
 
 
